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ABSTRACT 
Mumps virus (MuV) is a paramyxovirus which causes mumps, a communicable disease in humans 
characterised by pain and swelling of the parotid gland(s). Suspected mumps cases are confirmed by 
PCR detection of MuV nucleotide sequences followed by virus isolation using Vero cells. Veros are 
the “gold-standard” for MuV isolation however they may select for attenuated or adapted virus 
variants and produce genetically altered viruses unsuitable for research, although this has never 
been confirmed. A cell line investigation was performed to assess genetic stability, viral fitness and 
plaque phenotype of MuV through serial passage in a panel of cell lines including Veros. Primary ex-
vivo human airway epithelial cultures were infected with different MuV strains to investigate their 
susceptibility to MuV. The data presented here shows mutations in MuV introduced during passage 
through Vero and other continuous cell lines for the first time and suggests alternative cell lines for 
MuV propagation. HAE cells are demonstrated to be capable of isolating MuV from a clinical sample 
and producing progeny virus with superior genetic similarity to the parent virus when compared 
with Vero’s.  
No animal model exists for MuV therefore in vivo knowledge of the virus is limited. Ferrets are 
established as a successful model for influenza virus. MuV and influenza share certain biological 
features such as utilisation of sialic acid as the cellular receptor and both are negative-sense single-
stranded RNA viruses. This suggests that ferrets may be useful as a MuV model. Ferrets were 
assessed as an in vivo mumps model by investigation of clinical signs, virus shedding and recovery 
from tissues, serum antibody response and detectable immune response in PBMCs. The data 
presented here demonstrate that ferrets elicit a mumps-specific neutralising antibody response and 
mount a cytokine response consistent with viral infection, however due to lack of clinical symptoms, 
virus shedding and virus recovery from tissues, the ferret model is very limited in its usefulness for 
MuV research.  
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CHAPTER 1 – INTRODUCTION 
 
 
1.1 A Brief History of Mumps 
Mumps is one of the oldest human illnesses known, and is thought to have been first recorded by 
Hippocrates in the 5th century B.C in his Book of Epidemics. He described a painful epidemic illness 
with swelling of the testes in male patients, and around the neck and jaw, which is likely to be a 
description of the most characteristic symptom of mumps that we know today, swelling of the 
parotid gland(s). During the late 18th century, a physician named Robert Hamilton made the first 
association between mumps and its implication in central nervous system (CNS) disease during 
documentation of a fatal case (Hamilton, 1790). In 1908, a causative agent for mumps was suggested 
by Granata (first cited in (Wollstein, 1916)), who reported that the illness may be caused by a 
filterable pathogen after experiments using rabbits resulted in swelling of the parotid glands 
following direct inoculation with filtrate from a patient. In 1933, Johnson and Goodpasture carried 
out a series of experiments showing that mumps is caused by a virus (Johnson & Goodpasture, 
1934). Briefly, they inoculated Rhesus Macaques via the Stenson’s duct with saliva collected from a 
patient, and the animals were sacrificed upon development of swelling of the parotid glands. 
Homogenates were prepared from the parotid glands for passage through more animals. To fulfil 
Koch’s Postulates, bacteria free material from the infected parotid glands of the macaques was 
inoculated into groups of volunteer children via intranasal and oral routes. Saliva samples were 
taken from children demonstrating clinical symptoms and parotid swelling, and these were 
inoculated into healthy Rhesus Macaques who then once again, demonstrated the symptoms of 
mumps (Johnson & Goodpasture, 1935).  These findings and the development of using embryonated 
eggs (Habel, 1945) and tissue culture systems (Henle & Deinhardt, 1955) for isolation of the virus 
increased knowledge and understanding of mumps infection, and led to the development of the live 
attenuated mumps vaccine strain in 1967, and thus a steady worldwide decline in the number of 
cases of mumps. 
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1.2 Mumps Pathogenesis and Disease 
Mumps is traditionally known as a childhood illness and is characterised primarily by pain and 
swelling of the parotid gland(s) which may be unilateral or bilateral. Although this is by no means the 
only symptom, it is the most common characteristic in terms of diagnosis. Approximately one third 
of mumps cases are asymptomatic, however in those cases presenting symptoms, parotitis is evident 
in approximately 95% of these (Philip et al., 1959). It is generally a mild, self-limiting illness however 
in a small number of cases, more severe complications such as meningitis or encephalitis can occur 
due to CNS involvement, and it has been known to be a major cause of childhood deafness. Orchitis 
occurs in approximately 15-30% of male patients and oophoritis in 5% of female patients (Hviid et 
al., 2008). The virus is also capable of infecting a multitude of other tissues including the brain, 
heart, liver, pancreas, spleen, and kidneys.  Humans are the only reservoir for the virus.  
Mumps virus (MuV) is transmitted via droplet spread or from direct contact with an infectious 
patient therefore large groups of people living closely together are required for an outbreak of the 
disease to occur. The primary site of virus replication is the upper respiratory epithelium such as 
those found in the nasal epithelia or salivary glands. After initial replication, the virus spreads to local 
lymphoid tissues and then disseminates via a transient primary viraemia, which most likely occurs in 
T cells (Fleischer & Kreth, 1982). This allows MuV to spread to other organs resulting in a systemic 
illness, frequently being associated with localisation to the kidneys, pancreas, heart, testes, CNS and 
of course the parotid glands, however the virus is capable of infecting almost all tissue and organ 
types. The infection has also been shown to remain localised to the respiratory tract in some cases 
(Foy et al., 1971).  
The incubation period ranges from 15-24 days with virus being shed in saliva from approximately 
five days prior to the onset of clinical symptoms and five days after symptoms have subsided (Chiba 
et al., 1973). MuV can also be detected in the urine of patients up to 14 days after the onset of 
clinical symptoms (Utz et al., 1958) and has been detected in breast milk (Kilham, 1951).  
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1.3 Diagnosis of Mumps  
With regards to clinical diagnosis, acute uni- or bilateral parotitis is the most common symptom of 
mumps disease. However, infection by other viruses such as Epstein-Barr (Lee et al., 1997), human 
immunodeficiency virus (HIV) (Santra, 2009) and influenza A virus (Krilov & Swenson, 1985) has also 
been associated with parotitis, but these viruses are easily distinguishable from MuV by virus culture 
or serological techniques. Mumps is a reportable disease and by UK law, samples must be collected 
from suspect patients by health professionals to be sent for confirmatory diagnosis by laboratory 
methods.  
Worldwide, suspected mumps cases are currently confirmed by RT-PCR detection of MuV nucleotide 
sequences, serological methods using patient sera or virus isolation from clinical samples (the most 
commonly used is saliva). Serological assays such as complement fixation, haemagglutinin-inhibition 
and virus neutralisation can be used, but mumps-specific IgG and IgM immune responses are 
commonly measured using ELISA methodology (Ukkonen et al., 1981). However these are only easily 
performed when using patient sera taken at the acute phase of infection.  
 Vero cells are currently the “gold-standard” for MuV isolation and propagation. These cells are 
known to be deficient in the production of interferon (Desmyter et al., 1968) and it is likely that this 
feature makes them so permissive for MuV infection.  
 
1.4 Epidemiology of Mumps 
Mumps is endemic worldwide with cases peaking in winter and spring months, however it is 
reported throughout the entire year. Historically, the disease was most commonly reported amongst 
children between the ages of 5 and 9 years old but in recent years there has been a resurgence in 
the number of reported mumps cases and with it, a change in the most commonly affected age 
group from 5 – 9 to 15 – 24. This is likely to be due to the fact that individuals in this age group were 
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too old to receive the two-dose schedule of vaccine when it was introduced in 1988, or only received 
one dose. The question of whether or not the mumps comeback is actually due to waning immunity 
has been raised many times in the last decade. Waning immunity is defined as the loss of protective 
antibodies over time and has been blamed for several recent mumps outbreaks (Cohen et al., 2007) 
(Dayan et al., 2008) however, a study in which cellular and humoral immunity were measured in a 
group of individuals 21 years after receiving a first vaccination demonstrated reduced humoral 
immunity but persistence of highly protective anti-mumps cellular immune responses (Jokinen et al., 
2007).  Mumps is rarely seen in infants under the age of 1 year old, which is thought to be as a result 
of the presence of maternal antibodies (Plotkin & Rubin, 2008). The most recent figures from the 
Health Protection Agency (HPA) UK advise that in England and Wales for the quarter April to June 
2012, there were 930 laboratory-confirmed cases of mumps from a total of 1564 reported and 
tested (HPA, 2012).  
 
1.5 Mumps Vaccines 
Mumps is a vaccine-preventable disease and when used appropriately, the scheduled two doses of 
the current trivalent MMR (Measles-Mumps-Rubella) vaccines are a highly effective means of 
keeping disease outbreaks at bay.  
Formalin-inactivated killed vaccines were used during the 1950’s and 1960’s and this was the first 
documented means of protection against MuV by vaccination (Plotkin & Wharton, 1999). The use of 
these kinds of MuV vaccines did not last long however, with the development of live attenuated 
vaccines by serial passage of wild-type isolates in embryonated hens eggs or tissue culture during 
the late 1960’s. The Jeryl Lynn (JL) strain was the first live MuV to be used as a mumps vaccine. It 
was derived from a throat culture isolate taken from the daughter of the scientist responsible for 
development of the vaccine at Merck and Co. and was attenuated by serial passage through chicken 
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embryo fibroblasts (CEFs) after initial isolation in embryonated hens eggs (Buynak & Hilleman, 1966). 
Sequence analysis of JL MuV revealed that the virus is actually a mixed population of two very 
distinct isolates which have been designated Jeryl Lynn 2 (JL-2) and Jeryl Lynn 5 (JL-5) (Afzal et al., 
1993) (Chambers et al., 2009). The JL strain of MuV is the most commonly used worldwide in 
trivalent MMR vaccines at the time of writing, manufactured by Merck and Co as M-M-R II (Merck & 
Co, 2004). GlaxoSmithKline (GSK) Biologicals also manufacture a trivalent MMR vaccine, Priorix®, 
which has been used in the UK and throughout Europe since the late 1990’s. The MuV strain used in 
Priorix® is designated RIT 4385 and is a pure population of JL-5 obtained by selective dilution of the 
mixed population JL virus and passage through CEFs (Tillieux et al., 2009). Although these two are 
the most commonly used, there have been many other live attenuated MuV vaccines used in recent 
years and these are summarised in Table 2.  
 
Table 2 – Live attenuated MuV vaccines in recent use 
Virus strain  Growth/passage history Genotype Reference 
Hoshino Isolation in embryonated hens 
eggs, serial passage in CEFs 
B (Makino et al., 1976) 
Jeryl Lynn Isolation in embryonated hens 
eggs, serial passage in CEFs 
A (Buynak & Hilleman, 1966) 
Leningrad-3 (L-3) Isolation and passage in primary 
guinea pig kidney cells, further 
serial passage in Japanese quail 
embryo fibroblasts  
Distinct (Smorodintsev, 1960) 
(WHO, 2007) 
Leningrad-Zagreb 
(L-Zagreb) 
Further serial passage of 
Leningrad-3 strain in CEFs 
Distinct (Beck et al., 1989) 
S79 Three further serial passages of JL 
in CEFs 
A (Fu et al., 2009) 
RIT 4385 Selective dilution and passage in 
CEFs of Jeryl Lynn 
A (Tillieux et al., 2009)  
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Rubini Isolation in WI-38 cells followed 
by serial passage in embryonated 
hens eggs and MRC-5 cells 
A (Gluck et al., 1986) 
Urabe AM9 Isolation and serial passage in  
embryonated hens eggs and CEFs 
B (Yamanishi et al., 1970) 
 
The genotypes for L-3 and L-Zagreb vaccine strains have been described as distinct in Table 2 as they 
form a phylogenetically separate group and a genotype has yet to be designated. Although the 
genotypes of MuV attenuated vaccine strains are varied, the virus is said to be serologically 
monotypic, therefore protection against one strain or genotype will infer immunity to all MuVs 
(Rubin et al., 2006).  
Some of these vaccine viruses have been associated with adverse events and as a result their use has 
either been restricted or withdrawn in many countries. The L-Zagreb and parental L-3 strains have 
been associated with vaccine-related aseptic meningitis (Cizman et al., 1989) and mumps disease 
(Bakker & Mathias, 2001), as well as horizontal transmission of the vaccine viruses (Atrasheuskaya et 
al., 2006) (Kaic et al., 2008). Data linking L-Zagreb with vaccine-related meningitis (da Cunha et al., 
2002) was later shown to be inconclusive, however the virus was still found to cause mumps-like 
illness (Kulkarni et al., 2005). These vaccines are still manufactured for use by the Serum Institute of 
India. The Rubini strain of MuV has also been associated with mumps outbreaks in previously 
vaccinated populations (Strohle et al., 1997) (Goh, 1999) (Pons et al., 2000) and this virus is rarely 
used now in vaccines. The Urabe AM9 live attenuated vaccine virus was shown to be a mixture of 
MuVs varying at one amino acid residue in the haemagglutinin-neuraminidase protein (Brown & 
Wright, 1998) and has been associated with neurovirulence and vaccine-related meningitis (Furesz & 
Contreras, 1990) (Ueda et al., 1995) (Miller et al., 1993). Vaccines containing Urabe AM9 were 
withdrawn from use in the UK, Canada and many other countries (Schmitt et al., 1993). The JL and 
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RIT 4385 strains have not been associated with vaccination-related illness or complications (Hviid et 
al., 2008). 
The molecular basis of attenuation of MuVs from wild-type to vaccine strain is not fully understood 
other than serial passage in various types of tissue culture or embryonated hens eggs results in a loss 
of cytopathic effects (Plotkin & Rubin, 2008).  
 
1.6 Mumps Virus Taxonomy and Physical Properties 
1.6.1 Taxonomy  
Mumps virus is a non-segmented, negative-sense, single-stranded RNA (ssRNA) virus belonging to 
the order Mononegavirales, family Paramyxoviridae, sub-family Paramyxovirinae, and genus 
Rubulavirus. Other members of this genus include human parainfluenza virus 5 (hPIV5), human 
parainfluenza virus types 2 (hPIV2), 4a (hPIV4a) and 4b (hPIV4b) and Porcine rubulavirus. Antigenic 
cross-reactivity and the presence of neuraminidase activity are the biological features necessary for 
classification in the Rubulavirus  genus (Lamb & Parks, 2007). The family Paramyxoviridae contains 
many other important pathogenic viruses of humans and animals including measles virus (MV), 
human respiratory syncytial virus (RSV), human parainfluenza virus type 3 (hPIV3), Sendai virus 
(SeV), Newcastle disease virus (NDV) and the recently eradicated Rinderpest virus.  
1.6.2 Viral Genome  
The MuV genome is 15,384 nucleotides in length and encodes proteins in the following order: 
nucleocapsid (interchangeable with nucleoprotein throughout this thesis) (N), V, phospho- (P) and I 
proteins, membrane (M), fusion (F), small hydrophobic (SH), haemagglutinin-neuraminidase (HN) 
and large (L) proteins (Figure 1).  
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Figure 1 -  Schematic representation of MuV genome organisation. Viral genome proceeds from 3’ 
to 5’ end in the order: nucleoprotein, V/P/I, matrix, fusion, small hydrophobic, haemagglutinin-
neuraminidase and large genes. 
 
Each gene is separated by untranslated regions (UTRs) of varying lengths consisting of gene end (GE) 
sequences containing transcriptional and translational stop signals. These stop signals are followed 
by gene start (GS) sequences containing transcriptional and translational start signals for the next 
gene (Elango et al., 1988).  
There are currently 13 different reported mumps genotypes designated A-M, however only 11 of 
these are actually different as a result of duplicative reporting from different research groups (Jin et 
al., 2005; Santos et al., 2008). The SH protein demonstrates the most genomic variation and is 
therefore commonly used for genotyping MuV strains (Yeo et al., 1993).  
1.6.3 Virus Structure 
MuV forms spherical or pleomorphic virions ranging in size from approximately 100 to 600 nm. The 
virus consists of a helical ribonucleoprotein (RNP) core and a host-cell derived lipid membrane. The 
RNP core consists of the RNA genome associated with the N, P and L proteins. The viral envelope is 
studded with F and HN glycoprotein projections which extend approximately 12 to 15 nm from the 
virus surface and can be visualised by electron microscopy (Lamb & Parks, 2007). The SH protein is 
incorporated into the lipid envelope (Elliot et al., 1989) (Elango et al., 1988), while the matrix protein 
is situated between the RNP core and lipid envelope. A schematic diagram of a representative MuV 
virion demonstrating the locations of the major viral proteins is shown in Figure 2. 
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Figure 2 – Schematic representation of a MuV virion. A typical mumps virus virion consisting of 
helical RNP core comprising N, P, and L proteins, structural matrix protein underneath surface of 
viral envelope, and the surface fusion and HN glycoproteins.  
 
1.7 Mumps Virus Proteins 
The protein products from each of the MuV genes play essential roles in the survival and life cycle of 
the virus.  
1.7.1 Nucleoprotein  
The N gene encodes a 549 amino acid nucleoprotein of approximately 61-73 kilo Daltons (kDa) 
(Tanabayashi et al., 1990) and is the first unit of the MuV genome to be transcribed. The primary 
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function of the nucleoprotein is to form a complex with the P and L proteins and the viral RNA 
genome, which results in the formation of the biologically active helical capsid structure which is 
required for RNA synthesis. “Naked” viral RNA, so-called because of a lack of nucleocapsid, is unable 
to replicate and cause infection in a host cell which indicates the importance of the N protein in the 
life cycle of MuV. The protein also has a protective role in preventing the action of host cell 
proteases upon the virus (Carbone & Rubin, 2007).  
1.7.2 V/P/I Proteins 
The three distinct V, P and I proteins are transcribed from the V/P/I gene by a process known as RNA 
editing, which differs from the transcription method of all of the other MuV proteins. The V protein 
is produced from a faithful V/P/I gene transcript, however co-transcriptional addition of two non-
template guanine (G) nucleotides is necessary for production of the P protein, and addition of four 
non-template G nucleotides produces the I protein. (Takeuchi et al., 1988) (Paterson & Lamb, 1990). 
The accuracy of these insertions has previously been demonstrated to differ between MuV strains 
(Elliott et al., 1990). RNA editing results in the V, P and I proteins having the same amino-termini but 
different carboxy-termini.  
The V protein is 224 amino acids in length and approximately 25-28 kDa (Takeuchi et al., 1990). It 
plays a major role in the circumvention of the host cell interferon (IFN) response and has been 
demonstrated to interfere with the activities of signal transducers and activators of transcription 1 
(STAT-1) (Horvath, 2004a; Kubota et al., 2002; Nishio et al., 2002) as well as interacting with 
melanoma differentiation associated protein 5 (mda-5)  to inhibit interferon production via the IFN-β 
promoter (Andrejeva et al., 2004). It has also been suggested that the MuV V protein plays a role in 
altering the activities of caspase-9 in the apoptosis pathway (Rosas-Murrieta et al., 2011) and in 
suppressing interleukin-6 (IL-6) production (Xu et al., 2012).  
26 
 
The P protein is 391 amino acids in length and approximately 41-47 kDa (Takeuchi et al., 1988). Its 
main function is as part of the transcriptase complex, in association with the MuV L protein (section 
1.6.7).  
The I protein is 171 amino acids long and has a molecular weight of 19 kDa. Studies investigating the 
role of the I protein are lacking, and currently its function is unknown.  
1.7.3 Matrix Protein 
The M gene of MuV encodes the structural matrix protein which  is 375 amino acids in length and 
has an approximate molecular weight of 41-47 kDa (Elliot et al., 1989). The M protein plays a crucial 
role in virion assembly and structure, and it has been inferred from studies on the related 
paramyxoviruses NDV (Nagai et al., 1976) and SeV (Sanderson et al., 1994)  that it serves to connect 
the viral genetic information and associated proteins (N, P and L) with the cytoplasmic tails of the 
envelope surface glycoproteins (F and HN). This interaction between the F and HN cytoplasmic tails 
and the viral genome has also been demonstrated for hPIV5 (Schmitt et al., 1999).  The M protein of 
MuV has also been shown to be essential for virus-like particle (VLP) formation (Li et al., 2009) and 
due to its importance in virion assembly, is likely to play an important role in mediating virus 
budding (Takimoto & Portner, 2004).  
1.7.4 Fusion Protein 
The F protein is one of two MuV envelope surface glycoproteins and exists in a pre-cursor form 
designated as F0 which is 538 amino acids in length and approximately 64-74 kDa (Elliot et al., 1989) 
with a membrane anchor region of 30 hydrophobic residues in the C terminus (Waxham et al., 
1987). F0 is biologically inactive until it is cleaved between amino acids 102 and 103 at the R-R-H-K-R 
motif sequence by host cell proteases after transport from the endoplasmic reticulum through to 
the trans-Golgi network (Gardner et al., 2007) to form two smaller proteins designated F1 and F2 
(Herrler & Compans, 1982) (Merz et al., 1983).  
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The protease(s) responsible for this cleavage step in the MuV life cycle is furin or furin-like proteases 
(Nakayama, 1997). Furin is an ubiquitous subtilisin-like endoprotease that specifically recognises and 
acts upon the R-R-K-K-R motif, and is responsible for F0 cleavage  in other paramyxoviruses such as 
hPIV5V (Klenk & Garten, 1994), hPIV3 (Ortmann et al., 1994) and MV (Watanabe et al., 1995). The 
protease-dependent cleavage event transforms the F protein into its active state by an irreversible 
conformational change which causes the amino terminus of the F1 sub-protein containing the highly 
conserved hydrophobic fusion peptide to become exposed (Scheid & Choppin, 1974) (Hsu et al., 
1981) (Novick & Hoekstra, 1988).  
The crystal structure of the MuV F protein core has been solved, and  was shown to comprise a 
complex of a six-helix bundle with a central hydrophobic coiled-coil formed of three heptad repeat 
(HR)  peptides,  with another three HR peptides situated against the hydrophobic grooves on the 
surface of the coiled-coil (Liu et al., 2006).  F1 and F2 are linked by disulphide bonds and drive cell to 
cell and virus to cell fusion, which results in entry of the viral genomic information, and are therefore 
essential for virus spread (Morrison, 2003).  
Different MuV strains demonstrate varying extents of cytopathic effect (CPE) by cell fusion, and the 
amino acid residue serine at position 195 of the F protein has been linked with the amount of 
fusogenicity shown during infection of host cells (Tanabayashi et al., 1993). This finding may be 
strain or host-cell specific though, as a leucine residue at position 383 of the F protein of a wild-type 
MuV strain was shown to be essential for fusion in B95a cells (Yoshida & Nakayama, 2010).  
1.7.5 Haemagglutinin-neuraminidase Protein 
The HN protein is the second envelope glycoprotein located on the surface of MuV and is 582 amino 
acids in length with an approximate molecular weight of 74-80 kDa (Waxham et al., 1988). The H 
(haemagglutinin) portion of the protein is responsible for viral attachment and entry to the host cell 
by recognition of the sialic acid cellular receptor, so therefore plays a major role in infection. The N 
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portion (neuraminidase) cleaves sialic acid residues and prevents self-agglutination of released 
viruses. The N terminus of the HN protein contains a hydrophobic sequence of 19 amino acids 
responsible for the anchoring of the protein in the virus envelope (Waxham et al., 1988) and 
potential glycosylation sites of the HN protein have  been identified (Kovamees et al., 1989). 
Monomers of HN have a membrane proximal stalk consisting of a 4-helix bundle, a straight N 
terminus region and a super-coiled C terminus (Bose et al., 2011) (Yuan et al., 2011) linked to a 
globular head with a six-blade propeller structure that is characteristic of all paramyxovirus HN 
proteins (Crennell et al., 2000) (Lawrence et al., 2004) (Yuan et al., 2005).  
The MuV HN protein is the major antigenic determinant of the virus, with antibodies directed 
against this target being entirely capable of neutralising MuV (Orvell, 1978) (Orvell, 1984) (Server et 
al., 1982). Genetic markers of neurovirulence and neuroattenuation have been frequently associated 
with alterations in the HN protein sequence of wild-type MuV (Cusi et al., 1998) (Malik et al., 2009) 
and the attenuated vaccine Urabe AM9  strain (Malik et al., 2009) (Shah et al., 2009).   
The HN protein also has fusion promoter activity, and it was previously inferred from studies on 
related paramyxoviruses that F and HN proteins associate prior to fusion and the F protein is only 
released upon the binding of HN to the sialic acid receptor (Connaris et al., 2002; Gravel & Morrison, 
2003). In recent years it has been demonstrated that viruses related to MuV such as hPIV3 and NDV 
may rely on activity at a second receptor binding site on the globular head of the HN protein to 
initiate activation of the F protein (Porotto et al., 2007) (Porotto et al., 2012).  
1.7.6 Small Hydrophobic Protein 
The SH protein is the smallest MuV gene product, being just 57 amino acids long and with an 
approximate molecular weight of 6 kDa (Elliot et al., 1989). As previously mentioned, the SH protein 
demonstrates the most genomic variability and is most commonly used for genotyping MuV strains. 
Although this protein is membrane associated, it is non-structural and has been shown to be non-
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essential for virus growth (Takeuchi et al., 1996). However, the MuV SH protein has recently been 
discovered to play a role in the prevention of apoptosis of infected host cells by targeting ataxin-1 
ubiquitin-like interacting protein 4 (Woznik et al., 2010) and was identified as having a role as a 
virulence factor, when it was discovered that deleting this gene in a molecular clone of MuV resulted 
in the virus becoming attenuated (Malik et al., 2011). In the paramyxovirus RSV, it has been 
suggested that the SH protein plays a role in membrane permeabilisation as a viroporin (Carter et al., 
2010).     
1.7.7 Large Protein  
The largest gene of the MuV genome encodes the L protein, which is 2261 amino acids in length and 
approximately 180-200 kDa (Okazaki et al., 1992). The primary function of this protein is as part of 
the viral transcription machinery, whereby P and L proteins bind to one another to form the RNA 
dependant RNA polymerase (RdRp) transcriptase complex and associate with the N protein and 
genomic material to form the helical RNP virus core. This has been inferred from research carried 
out on the related paramyxoviruses SeV (Gotoh et al., 1989) and NDV, in which functional P and L 
proteins were both required in order to initiate transcription of the N gene (Hamaguchi et al., 1983).  
 
1.8 Virus Infection of Host Cells 
1.8.1 Virus Attachment and Entry 
Entry of MuV into a host cell consists of two main events, which are binding to the host cell and 
membrane fusion. The cellular receptor for MuV is sialic acid (SA), based on the observation that the 
sialidase (neuraminidase) of Vibrio cholerae acted as a “receptor-destroying” enzyme and protected 
the host cell from infection (Markwell, 1991). SA is expressed on the surface of most cells which 
reflects on the ability of MuV to be able to infect almost all cell and tissue types. Sialic acid-
containing molecules exist in varying analogues with different linkages, including sialylα2,3 lactose 
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and sialylα2,6 lactose (Villar & Barroso, 2006), and it is currently unknown as to which type of 
linkage, if either, MuV has a greater affinity for. SA is the cellular receptor for paramyxoviruses 
containing an HN protein such as hPIV5, hPIV3 and NDV, however for the rest that contain only an H 
(haemagglutinin only) protein such as MV, a specific protein is required for binding to a host cell 
(Iorio & Mahon, 2008). Both wild-type and attenuated vaccine MVs utilises signal-lymphocyte 
activating molecule (SLAM) (Tatsuo et al., 2000) and vaccine viruses also use human membrane 
cofactor 46 (CD46) as a cellular receptor (Naniche et al., 1993). The human protein EphrinB2 has 
been shown to act as the receptor for Nipah virus infection of micro vascular endothelial cells 
(Negrete et al., 2005).  
Receptor binding affinity of human and avian influenza viruses has been well characterised, and it is 
now understood that human viruses exhibit preferential binding to α2,6-linked sialic acid residues 
while avian viruses bind to α2,3-linked molecules (Rogers & Paulson, 1983) (Connor et al., 1994). In 
recent years, this has been further confirmed and investigated by infecting ex-vivo models of the 
human airway epithelium with different human and avian influenza viruses, and using lectin staining 
to determine the localisation of the differing SA moieties. These studies found that ciliated cells 
express mainly α2,3-linked and non-ciliated cells express primarily α2,6-linked SA residues 
(Matrosovich et al., 2004) (Thompson et al., 2006).  The fact that these types of cell models are 
highly similar to the in vivo situation, allows for the results from studies such as these to be 
translated directly to influenza infection in the human host. Human airway epithelial (HAE) cell 
models have also been used for experimental infection and pathogenesis studies of MuV-related 
paramyxoviruses including RSV (Zhang et al., 2002), hPIV3 (Zhang et al., 2005) (Palermo et al., 2009) 
and hPIV5 (Zhang et al., 2011), and therefore may be suitable for MuV research.  
Alterations to the amino acid sequence of the MuV HN protein have been well-documented with 
regards to their effects on receptor-binding. Amino acid change S466D was shown to reduce 
receptor binding affinity and neuraminidase activity in a wild-type MuV (Malik et al., 2007) and 
31 
 
amino acid change E335K in the HN protein has also been demonstrated to alter receptor binding 
specificity of the Urabe strain of MuV (Reyes-Leyva et al., 2007). Two variants of the MuV Urabe 
AM9 strain differing by a single amino acid in the HN glycoprotein were shown to exhibit different 
affinities for the α2,3 and α2,6 linked molecules (Reyes-Leyva et al., 2007).  
The HN glycoprotein serves as the attachment protein, recognising the SA receptor and binding to it. 
Once binding has occurred and the fusion of the viral and host cell membranes has been mediated, 
RNPs enter into the cytoplasm. The exact mechanism of fusion mediation by the MuV F protein is 
unclear, however studies on CDV, MV and MuV F protein-expressing Vero cells have suggested that 
the F1 subunit is proteolytically further to F1A and F1B and that this action may aid in the formation of 
F protein “pores” in the host cell membrane, allowing entry of the viral genomic information (von 
Messling et al., 2004).  
Once the MuV RNPs have entered the host cell, virus replication and transcription can take place.  
1.8.2 Virus Transcription and Replication 
Virus replication occurs in the cell cytoplasm where the RdRp transcriptase complex uses the MuV 
nucleocapsid (complex of N, P and L proteins) as the template molecule to synthesis complementary 
positive-sense mRNAs and full length RNA from the negative-sense genome. The viral RdRp initially 
acts on a single promoter at the 3’ end of the genomic RNA, synthesises the positive-sense leader 
RNA and terminates at the end of the leader region before acting upon the GS sequence at the start 
of the N gene. The positive-sense full length RNA (anti-genome) is used as the template for the new 
negative-sense MuV genomic RNA. The leader sequence and N mRNA are the first to be transcribed, 
with the L gene mRNA being last. Transcription of MuV and all other non-segmented –ssRNA viruses 
occurs by what is called a stop-start mechanism. This means that the RdRp does not disengage from 
the template upon release of the mature mRNA, and instead remains bound to the template and 
scans for the next GS site in the untranslated region (Cordey & Roux, 2006). Since the RdRp can only 
32 
 
initiate at the 3’ end of the genome, decreasing quantities of monocistronic mRNAs are synthesised 
for genes located further from the 3’ end. This results in the formation of a transcription gradient in 
which the concentration of N mRNA is greatest and the subsequent mRNA transcripts are reduced in 
relation to their distance from the 3’ end promoter (Rassa & Parks, 1998) (Hausmann et al., 1999).  
Replication cannot take place until the primary transcription has taken place and a critical amount of 
N and P proteins are present (Conzelmann, 1998). Synthesis of the genomic RNA requires the RdRp 
to effectively “ignore” the GS and GE signal sites and continue along the template producing a full-
length complementary RNA (Lamb & Parks, 2007). This occurs by the encapsidation of the 5’ end of 
the positive-sense leader RNA, which results in the RdRp being unable to recognise GS and GE sites 
and instead reads through the whole template producing an full-length RNA transcript (Lamb & 
Parks, 2007).   
It was first discovered using SeV that paramyxoviruses replicate under a phenomenon referred to as 
the Rule of Six (Calain & Roux, 1993) in which the number of nucleotides in the viral genome must be 
divisible by six in order for efficient replication to take place. Therefore, if during the RNA editing 
process to produce the V/P/I gene (section 1.7.2) six nucleotides exactly are not introduced, the 
virus may be incapable of efficient replication (Kolakofsky et al., 1998).  
1.8.3 The Host Cell Anti-Viral Response to Infection   
Upon infection by a virus, cells initiate an antiviral response by producing interferons (IFN) and 
cytokines or chemokines. These are protein or glycoprotein molecules secreted by the cell in order 
to limit or inhibit viral replication and exist as type I (α/β), type II (γ) or type III (λ) IFNs.  RNA viruses, 
including the paramyxoviruses, are recognised by the host cell by melanoma-differentiation-
associated gene 5 (mda-5) and retinoic acid inducible gene I (RIG-I) like receptors (RLRs) which then 
initiate a signalling cascade involving a number of molecules to induce IFN responses, which is 
reviewed in (Yoneyama et al., 2004) (Takeuchi & Akira, 2008) and (Jensen & Thomsen, 2012). RIG-I 
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and mda-5 recognise structures or molecules known as pathogen-associated molecular patterns 
(PAMPs) on or produced by double-stranded RNA (dsRNA) viruses. Specifically, 5’ triphosphate single 
stranded RNA produced by viral polymerases has been demonstrated to act as the ligand for RIG-I 
sensing of RNA viruses (Hornung et al., 2006) (Pichlmair et al., 2006). Pattern recognition receptors 
(PRRs) are molecules expressed on the surface of innate immune cells and are equally important in 
innate immunity as they are also responsible for sensing PAMPs. One example of a PRR is toll-like 
receptor 3 (TLR3), which is expressed on cell surfaces and is capable of sensing PAMPs upon virus 
infection (Dunlevy et al., 2010). However it is RIG-I that is essential for recognition of MuV and the 
paramyxoviruses. Upon recognition of PAMPs, RIG-I and mda-5 are both recruited to the IFN-β 
promoter stimulator (IPS-1) which in turn activates several transcription factors including interferon 
regulatory factor3 (IRF-3) and nuclear factor (NF)-κB. IRF-3 and NF-κB regulate type I IFN expression 
and cytokine production respectively (Kawai et al., 2005). IFN and cytokine molecules bind to their 
specific receptors which in turn results in stimulation of the Janus kinase (JAK)-signal transducer and 
activator of transcription (STAT) signalling pathway which is reviewed in (Darnell et al., 1994) and 
(Shuai & Liu, 2003). Briefly, binding of a cytokine or IFN to a specific cellular receptor causes 
dimerization and activation of JAK tyrosine kinases. Once activated, the JAKs phosphorylate tyrosine 
residues on the receptor and this creates sites for the localisation of the STAT proteins, which are a 
family of latent cytoplasmic transcription factors. The next stage in the JAK-STAT pathway is the 
phosphorylation and resultant dimerization of the STATs causing them to move into the nucleus and 
activate gene transcription.    
Many viruses have the ability to circumvent the IFN response to some extent, usually by means of a 
protein(s) which can interfere with the host cell’s antiviral response. The roles that the V protein of 
paramyxoviruses play in these processes has been well documented (Gotoh et al., 2002) (Horvath, 
2004a) (Horvath, 2004b) (Ramachandran & Horvath, 2009). The MuV V protein acts to interfere with 
the IFN response by targeting STAT proteins for degradation  (Kubota et al., 2001) (Kubota et al., 
2005b) (Nishio et al., 2002) and the association of MuV-V with the protein RACK1 (Kubota et al., 
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2002) results in antiviral signalling disruption by interfering with the formation of the STAT-1, RACK1 
and IFN receptor complex. More specifically, the V protein of MuV has been demonstrated to 
suppress transcription of IL-6 by targeting STAT-3 for degradation by ubiquitylation (Ulane et al., 
2003). MuV V also targets STAT-1 for proteasome-mediated degradation by interaction of the CYS-
rich C-terminus (Kubota et al., 2001) however it does not fully degrade STAT-1 but only decreases 
the levels of the protein (Kubota et al., 2005a). Paramyxovirus V proteins have recently been found 
to bind to a helicase demonstrating homology to RIG-I and mda-5 called laboratory of physiology 
and genetics 2 (LPG2) which resulted in the inhibition of RIG-I-dependent IFN signalling (Childs et al., 
2012). The V protein can also bind to, and thus prevent mda-5 from activating the IFN-β promoter 
(Andrejeva et al., 2004). However, the MuV Enders strain which is known to encode a V protein that 
inhibits IFN action was demonstrated to be sensitive to IFN despite the functional V protein (Young 
et al., 2009) and more recently, MuV V has been revealed not to inhibit the activities of IRF-3 (Irie et 
al., 2012). This indicates that other antiviral factors are also involved in the host cell response. 
Analysis of cytokine levels in cases of mumps meningitis showed elevated levels of IFN-γ, interleukin 
(IL)-2, IL-6, IL-8, IL-10, IL-12 and IL-13 in CSF (Ichiyama et al., 2005) (Martin et al., 1991) (Asano et al., 
2011) indicating that the cytokine response cannot be entirely avoided. For example, the cytidine 
deaminase apolipoprotein B mRNA-editing enzyme-catalytic polypeptide 3G (APOBEC3G) exerts an 
antiviral effect on MuV with a fully functional V protein and inhibits transcription and protein 
expression (Fehrholz et al., 2012).  
Viral proteins involved in circumvention of the host cell antiviral response are not restricted to 
paramyxoviruses. Another example of a protein such as this is the N-terminal protease fragment 
(NPro) of Bovine viral diarrhoeal virus (BVDV) which is known for its ability to block signalling of IFN-
α and IFN-β (Gil et al., 2006) and has been demonstrated to specifically inhibit DNA-binding of IRF-3 
and by doing so, causes it to be targeted for enzymatic degradation (Hilton et al., 2006).  
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1.8.4 Host Range Determination  
In very simple terms, the host range of a virus is determined by proteins of the both the virus and 
the host. These factors can provide restrictions to, or act in favour of the virus and include the 
presence of a suitable receptor(s), the antiviral response of the host to infection and properties at 
the gene level of the virus or host. These are important due to their role in maintaining species-
specificity of viruses and can prevent viruses from “jumping” from one species host to another (E.g. 
animal to human).  
The first stage in the infection of a host cell by any virus is binding to the suitable receptor upon the 
cell surface, and if this is not available then infection will not occur. Sialic acid, the MuV and 
influenza virus receptor is ubiquitously expressed and in abundance, however in the case of 
influenza A, if a specific type of sialic acid linkage is not available then infection of the host cell 
becomes more difficult. Human influenza viruses preferentially bind α2,6 whereas avian and equine 
viruses bind α2,3 linkages, and recognition of α2,3 sialic acid has been demonstrated to be critical 
for virus replication in horses (Suzuki et al., 2000) which makes this factor a host range determinant. 
The human poliovirus receptor (PVR) acts as the host range determinant for polio, which can only 
naturally infect humans and primates. However, introduction of the PVR into the mouse genome 
results in mice becoming susceptible to polio infection (Ren et al., 1990).  
Host restriction factors are inhibitory to viral replication and are most commonly associated with 
components of the innate, anti-viral immune system. Section 1.8.3 discusses the host cell anti-viral 
response in greater detail with emphasis on MuV and its evasion of certain aspects of the innate 
pathway by the V protein. The V protein of NDV acts in a similar manner to MuV V as an IFN 
antagonist, and has previously been reported to act as a host range determinant as the activities of V 
are restricted to avian cells (Park et al., 2003). The host range of hPIV5 has also been demonstrated 
to be restricted by the action of the V protein. STAT1 is efficiently targeted by the V protein and 
degraded in human cells, however due to the differences between human and murine STAT2, STATs 
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are unable to be fully degraded by hPIV5 in murine cells which has an inhibitory effect on virus 
replication, thus effectively restricting its host range (Parisien et al., 2002).  
Specific amino acids in viral proteins can also be associated with determination of host range, one 
example of this being the amino acid at position 627 of the PB2 polymerase protein of influenza A. It 
was observed by the authors that all avian influenza viruses contain a glutamic acid at this position 
and all human influenza viruses contain a lysine at position 627 (Subbarao et al., 1993).  
 
1.9 In Vitro Mumps Research 
1.9.1 Studies of MuV in Cell Substrates 
As mentioned in section 1.3, Vero cells are currently the “gold-standard” for isolation and cultivation 
of MuV from clinical samples, and they are also the standard cell line used for growth of MuVs in the 
laboratory. Their permissiveness for infection is likely due to their defectiveness in IFN production 
(Emeny & Morgan, 1979). Although Vero cells are commonly used, it has been suggested that they 
may be selective, insensitive and unsuitable for the production of virus isolates to be used in 
research (Afzal et al., 2005). A previous study also demonstrated that Vero cells produce virus 
populations that are different from the original parent virus when serially passaged (Yates, 1995) 
and passage of a wild-type MV through Vero cells was reported to cause a functional change in the 
viral haemagglutinin protein (Bankamp et al., 2008). These suggestions about the effect that Vero 
cells may have on MuV during passage have not been confirmed.  
The study in which concerns were raised over the use of Vero cells (Afzal et al., 2005) was carried 
out in order to assess alternative cell lines for MuV propagation including CaCO2 (human colorectal 
adenocarcinoma), PLC/PRF/5 (human liver hepatoma) and NCI-H292 (human lung carcinoma) using 
techniques such as plaque assays, immunofluorescence staining and electron microscopy. The 
authors suggested that due to the small number of cell lines investigated and the limited 
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experiments carried out, a much larger scale study would be required to obtain more conclusive 
results however this has not yet been carried out. Studies investigating the genetic stability of MuV 
during serial passage are extremely limited. MuV protein synthesis has been analysed in Vero cells 
(Herrler & Compans, 1982) (Rima et al., 1980) and CEFs (Naruse et al., 1981) and was shown to be 
highly similar in both cells with very slight differences in the electrophoretic mobilities of proteins 
between MuV strains and not cell lines. A later study in which MuVs were adapted to either Vero 
cells or embryonated hen eggs, reported differences in RNA production during culture in Vero cells 
(Afzal et al., 1990), however the results were inconclusive and did not provide definitive answers 
about the interaction of MuV with these cells. Genetic characterisation of a wild-type MuV grown on 
MRC-5 (human lung) cells after four passages through the amniotic cavity of embryonated hens eggs 
suggested that by passage four there were two virus variants present, however whether this was 
due to natural heterogeneous variations or an early laboratory contamination was inconclusive 
(Ivancic et al., 2004).  
Several other cell lines have been assessed for their suitability of wild-type MuV isolation, and Vero 
and LLC-MK2 (Rhesus monkey kidney) cells were shown to be equally efficient using the shell vial 
method (Reina et al., 2001) which is an indirect immunofluorescence method that requires acetone 
fixation of cells and so no live virus is recovered using this technique. The cell line NCI-H292  was 
shown to be permissive for culture of different strains and serotypes of paramyxoviruses (Castells et 
al., 1990), and  the marmoset lymphoblastic cell line B95a has also been used for MuV isolation from 
clinical samples during an outbreak of the disease (Knowles & Cohen, 2001). HeLa (human cervical 
carcinoma) cells have been successfully manipulated to stably express the HN and F proteins of MuV 
(Hishiyama et al., 1996) and several different strains of MuV were demonstrated to propagate 
successfully in continuous human stomach carcinoma cell lines (Kato, 1981). These studies all 
indicate that there are cell substrates available that may be suitable for MuV isolation and culture 
other than Vero or CEFs. As mumps is a solely human illness, MuV may replicate more efficiently and 
stably when grown in cell lines of human origin.  
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A highly sensitive cell culture system for MuV would be of great use. The factors which make a cell 
line capable of supporting MuV growth and replication are currently unknown.  
1.9.2 Defective Interfering Particles 
Defective interfering (DI) particles are viral genomes that are incomplete, and missing some of the 
genetic information of the parent virus due to polymerase errors causing internal deletions during 
the replication process. DI particles are an unavoidable product of virus replication and have been 
implicated in the establishment and maintenance of persistent viral infections (Huang & Baltimore, 
1970). In non-segmented negative-sense ssRNA viruses, DI particles are known to exist as either 
copy-back or internal deletion genomes, reviewed in (Lazzarini et al., 1981). Copy-back DI genomes 
lack the 3’ end of the genomic RNA, and instead have a complementary 5’ sequence in its place, 
whereas internal deletion DI genomes retain the correct 5’ and 3’ sequence ends. DI virus particles 
cannot successfully infect cells by themselves, and they require co-infection with the parent virus for 
replication.   
As discussed in section 1.7.2, RIG-I is heavily involved in the host cell IFN response, and DI genomes 
of RNA viruses have been shown  to induce the activities of RIG-I and increase IFN activation and 
production (Johnston, 1981) (Strahle et al., 2006) (Chen et al., 2010).  
DI particles generated from SeV replication have been well-characterised (Re et al., 1983) (Hsu et al., 
1985) (Engelhorn et al., 1993) and DI genomes of hPIV5 have been previously studied to show that 
the adherence of the nucleotide lengths of the viral genome to the Rule of Six enhances DI 
replication efficiency (Murphy & Parks, 1997). MuV has also been demonstrated to generate DI 
particles during persistent infection of continuous human cell lines with the vaccine strain L-3 
(Andzhaparidze et al., 1982). The presence of large populations of DI particles can result in the 
production of lower infectious progeny virus titres and the von Magnus phenomenon describes how 
high MOIs results in the generation of large quantities of DI particles in tissue culture (Von Magnus, 
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1954). Therefore, virus infection in vitro using a low MOI can reduce the likelihood of DI genomes 
being produced.  
 
1.10 In Vivo Mumps Research 
Humans are the only known natural reservoir of MuV. No animal model has been developed for 
MuV (Carbone & Rubin, 2007), and conclusive in vivo experimental data and knowledge of the virus 
and infection is therefore limited. The search for an animal model has been on-going for a long time 
and although experimental data on mumps has been obtained from in vivo studies in the past, 
results have been inconclusive or the studies were not designed to investigate in such a way that the 
data could be translated into human disease.  Studies have been carried out using Rhesus Macaque, 
cat, guinea pig, hamster, rat and mouse models. 
1.10.1 Experimental Animal Models 
In 1915, Wollstein demonstrated that it was possible to cause a pathological condition in cats similar 
to that found in humans with parotitis that was suspected to be caused by MuV, by inoculating the 
animals with patient material via the parotid gland and the testes (Wollstein, 1916). After seven days 
the animals demonstrated tenderness and swelling of the parotid gland and testes and an increased 
white blood cell count which was taken to be indicative of an immune response. The authors were 
unable to show that MuV was the causal agent of the parotitis. Other viruses have been found to 
cause swelling of the parotid glands such as influenza (Bastien et al., 2009) (Krilov & Swenson, 1985) 
and Epstein Barr (Lee et al., 1997) therefore the data obtained from cats was inconclusive. This was 
substantiated by a later study in which kittens were injected with MuV into the parotid gland and 
were found to demonstrate no signs of illness, no virus was recovered and no serum antibody 
response was detected (Enders et al., 1945).  
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Both suckling and pregnant hamsters have been experimentally infected with MuV. Several different 
egg-adapted MuV strains have been demonstrated to be neurovirulent in new born hamsters 
(McCarthy et al., 1980), infecting neurons and choroid plexus cells, and upon intravenous inoculation 
of pregnant hamsters with MuV isolated from human breast milk, the uterus and placenta of all test 
animals became infected but no virus was recovered from the foetus or other tissues (Ferm & 
Kilham, 1963). 
MuV has been shown to replicate in guinea pig primary cells (Gavitt & Bird, 1967) and the animals 
have also demonstrated an antibody response to MuV (Enders et al., 1945) (van der Veen & 
Sonderkamp, 1965) (Tokuda, 1957). In addition to this, MuV has also been recovered from the brains 
and testes of guinea pigs after intracerebral and intra-testicular inoculation with an egg-adapted 
strain of the virus, and neutralising antibodies were detected at day eight post-infection after the 
intracerebral route of administration  (Tokuda, 1957). 
Suckling mice were shown to exhibit a serum antibody response when infected with mumps 
(Overman, 1954), and the virus has been shown to replicate in the lungs, salivary glands, heart, liver, 
testes and spleen of infected mice (Tsurudome et al., 1987), however, the MuV strains used in both 
of these studies were selectively replicated by several passages of the virus through mouse brains or 
in the murine cell line L929. Other studies using a murine experimental model also required to adapt 
virus strains by passaging through mouse and hamster brains (Kilham & Murphy, 1952). In many 
studies carried out to experimentally inoculate mice with MuV the infection has been shown to be 
abortive (Tsurudome et al., 1987) (Yamada et al., 1984).  
 Mumps vaccine viruses such as the Urabe AM9 and L-3 strains, have been linked to cases of 
meningitis in vaccine recipients (Balraj & Miller, 1995), and the in vivo neurovirulence test is one of 
the pre-clinical safety requirements for new or candidate live attenuated mumps vaccines (WHO, 
1994). Because of the neurovirulent potential of wild-type MuV and its association with meningitis, it 
is important that we have an in-depth understanding of this phenotype. The MuV neurovirulence 
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test has traditionally been performed using non-human primates such as Rhesus Macaques however 
results obtained have in some instances not correlated with the actual outcome in human vaccine 
recipients (Afzal et al., 1999) or the difference in data obtained for wild-type and vaccine strains has 
not been statistically significant (Rubin et al., 1999). In recent years neonatal rats have been studied 
as an alternative model. An international collaborative study between the Centre for Biologics 
Evaluation and Research at the Food and Drug Administration (FDA) and the National Centre for 
Biological Standards and Control (NIBSC) used a panel of wild-type and live attenuated vaccine MuV 
strains to inoculate neonatal rats intra-cranially before analysing the brains at 25 days post infection 
for severity of hydrocephalus. The results demonstrated that the rat neurovirulence test was 
reproducible and gave correct correlations between the MuV strain and neurovirulent potential 
(Rubin et al., 2005). Neonatal rats have also been used to screen a panel of recombinant MuVs in 
order to investigate genetic markers of neurovirulence (Sauder et al., 2011).  
1.10.2 Mumps and Ferrets 
Ferrets (Mustela furo) have been used successfully as an experimental model for several pathogenic 
bacteria and viruses. Experimental infection with the bacterium Campylobacter jejuni was 
demonstrated to reproduce similar disease to that observed in humans (Fox et al., 1987) and ferrets 
have also been used to investigate immunity to this organism (Bell & Manning, 1990). Aerosolised 
Mycobacterium bovis has been used to vaccinate ferrets to demonstrate their suitability as an 
animal model for assessing tuberculosis vaccines in wildlife species (McCallan et al., 2011). Ferrets 
are also susceptible to infection with SARS coronavirus and have been used in transmission studies 
(Martina et al., 2003) and vaccine efficacy studies (Kobinger et al., 2007).   
The ferret model is frequently used to investigate Morbillivirus infection, immunity and host-
interactions (Pillet et al., 2009). Although these animals are not susceptible to measles, they are a 
natural host for CDV, which is a canine virus closely related to MV. CDV infection of ferrets produces 
the same clinical symptoms as measles in humans. Because of this, ferrets have been suggested as a 
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model for testing candidate vaccines for MV and other paramyxoviruses. Vaccination of ferrets with 
recombinant vaccinia and canarypox viruses expressing fusion and haemagglutinin (HA) proteins of 
CDV was shown to result in a 100% survival rate, as well as no viraemia and high titres of neutralising 
antibodies when challenged with CDV (Stephensen et al., 1997).  More recently, this in vivo model 
has been used to demonstrate that infection-enhancing lipopeptides Pam3CSK4 and PHCSK4 can be 
employed as adjuvants to increase the immune response to a CDV vaccination with a view to using 
ferrets to assess other live attenuated paramyxovirus vaccines (Nguyen et al., 2012).   Ferrets can 
also be successfully infected with Nipah virus (NiV), another member of the family Paramyxoviridae, 
and have been used to assess prevention of NiV infection and disease using Chloroquine (Pallister et 
al., 2009). 
Ferrets are established in the field of virology as a successful animal model for studying influenza 
virus infection, pathogenesis and transmission (Maher & DeStefano, 2004) and (Matsuoka et al., 
2009). This in vivo model is thought to be the most accurate in terms of an animal representing 
human influenza infection. The ferret respiratory tract has been characterised and shown to have 
similar patterns of α2,3 and α2,6 SA expression to those found in the human respiratory tract (Piazza 
et al., 1991; van Riel et al., 2007).  MuV and influenza are known to have similar biological 
properties, and until the 1950’s, both were considered to be members of the same virus family and 
MuV was referred to as Myxovirus parotidis (Andrewes et al., 1955). Both are negative-sense, single 
stranded RNA viruses which utilise sialic acid as the host cell receptor, and have proteins with 
haemagglutinin and neuraminidase activities.  
In early experiments, ferrets inoculated with MuV by injection into the testicles were reported to 
show no signs of illness or serum antibody response (Enders et al., 1945). However, ferrets that were 
infected intranasally with an egg-adapted MuV Enders strain were shown to illicit a serum antibody 
response and infection resulted in a type of bronchiolitis similar to that caused by some strains of 
influenza. Infectious virus was also recovered from nasal washings, turbinates and lung samples at 
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days 3 and 4 post infection (Gordon et al., 1956). These differences in results may have been due to 
differing routes of infection. Cultured ferret cell lines from the brain and lungs have shown 
susceptibility to infection by paramyxoviruses (Trowbridge et al., 1985), and preliminary data from 
our laboratory suggests that ferrets mount an immune response to MuV (unpublished data).   Based 
on all of this, ferrets have the potential to be an effective animal model for MuV infection.  
An effective animal model would be of great use for studying pathogenesis, virulence, tissue tropism 
and persistence of MuV. It could also be useful for assessing attenuated vaccines. 
 
1.11 Fundamental Mumps Research 
Although mumps cases have been documented for hundreds of years, and vaccines have been 
available for over 60 years, specific virological data on MuV is somewhat lacking. Much of the 
knowledge available from the literature is inferred from research carried out on other 
paramyxoviruses, in particular the closely related hPIV5 which is often referred to as a prototypical 
rubulavirus and paramyxovirus. The lack of a sensitive cell culture model and an effective animal 
model are two reasons contributing to this lack of knowledge in the field of mumps research and the 
availability of effective in vitro and in vivo models would allow fundamental virological research to 
be carried out.  
For example, although a MuV vaccine is available with a high uptake rate and demonstrated efficacy, 
the mechanism of how live MuVs become attenuated enough to become vaccine viruses and how 
these vaccines work are questions that are currently unanswered. Specific data on basic aspects of 
the life cycle of the virus such as fusion and budding processes are only inferred from data on other 
paramyxoviruses, and as useful as this information has been, we cannot know for certain that MuV 
operates in precisely the same manner. One recent example of how MuV has been demonstrated to 
differ from related paramyxoviruses is in its ability to avoid restriction in release of VLPs by tetherin, 
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whereas Sendai and Nipah viruses were both shown to be sensitive to tetherin action (Kong et al., 
2012). MuV pathogenesis data availability is also sparse, and an effective animal model would allow 
conclusive studies to be carried out on sites of viral replication, transmission, and viral spread within 
the host to name but a few. In vivo studies could also be employed to investigate immune responses 
to mumps, another area about which little is known.   
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1.12 Project Aims 
The aims of this project are:  
 To investigate a panel of cell lines and identify those which are suitable for supporting MuV 
growth and replication, and are capable of producing high titre progeny virus from clinical 
isolates which have very similar genotypic and phenotypic properties to the parent virus. 
 To identify a cell line(s) that could be used as an alternative to Vero cells in diagnostic 
laboratories.  
 To determine what changes are made to MuV at the genome level upon serial passage in Vero 
cells 
 To determine some of the molecular reasons for a cell line being suitable for MuV propagation 
(for example: preferences for different types of sialic acid linkage) 
 To assess ferrets as an animal model for MuV infection.   
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CHAPTER 2 – MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Eukaryotic Cell Lines 
The cell lines used are detailed in Table 3.  
Table 3 – Eukaryotic Cell Lines  
Origin Cell Line Source Reference 
Human A549; Lung carcinoma Professor Rick Randall,  
University of St Andrews 
(Foster et al., 1998) 
A549 (expressing NPro protein of 
BVDV); Lung carcinoma 
Professor Rick Randall,  
University of St Andrews 
(Young et al., 2003) 
A549 (expressing V protein of  
hPIV-5); Lung carcinoma 
Professor Rick Randall,  
University of St Andrews 
(Young et al., 2003) 
IMR-90; Lung (foetal) NIBSC, Ref No 770501* (Nichols et al., 
1977) 
MRC-5; Lung (foetal) NIBSC, Ref No 660902* (Jacobs et al., 1970) 
NCI-H292; Lung carcinoma NIBSC, Ref No 000724* (Carney et al., 1985) 
(Banks-Schlegel et 
al., 1985) 
Ca Ski; Cervical carcinoma NIBSC, Ref No 920702* (Pattillo et al., 1977) 
Hep 2C; Cervical carcinoma NIBSC, Ref No 740502* (Moore et al., 1955) 
MucilAir™ Human Airway Epithelial 
(HAE) cells 
Epithelix Sarl, Switzerland (Huang et al., 2011) 
MCF-7; Breast carcinoma NIBSC, Ref No 000410* (Soule et al., 1973) 
Detroit 562; Pharyngeal carcinoma ECACC, Cat No 87042205 (Peterson et al., 
1971) 
PANC-1; Pancreatic carcinoma ECACC, Cat No 87092802 (Lieber et al., 1975) 
293T; Kidney (SV-40 transformed) NIBSC, Ref No 000617* (Graham et al., 
1977) 
CaCO2; Colorectal adenocarcinoma NIBSC,  Ref No 010310* (Fogh et al., 1977a) 
(Fogh et al., 1977b) 
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HGT-1; Stomach carcinoma NIBSC, Ref No 890101* (Laboisse et al., 
1982) 
NT2/D1; Testes carcinoma NIBSC, Ref No 030211* (Andrews et al., 
1984) 
RD; Muscle rhabdomyosarcoma NIBSC, Ref No 990825* (McAllister et al., 
1969) 
Non-
Human 
Primate 
 
 
 
 
 
 
 
 
 
 
BSC-1;  African Green Monkey 
kidney 
NIBSC, Ref No 890602* (Hopps et al., 1963) 
COS-7; African Green Monkey 
kidney (SV-40 transformed) 
Professor Salvador 
Moncada,  
UCL Cancer Institute 
(Gluzman, 1981) 
CV-1;  African Green Monkey 
kidney 
Professor Geoff Smith, 
Imperial College London 
(Jensen et al., 1964) 
DBS-FcL2;  African Green Monkey 
lung 
ECACC, Cat No 90112815 (Wallace et al., 
1973b) (Wallace et 
al., 1973a) 
Vero; African Green Monkey kidney NIBSC, Ref No 880101* (Yasumura & 
Kawakita, 1963) 
 DBS-FrhL2; Rhesus Monkey  lung ECACC, Cat No 89101303 (Wallace et al., 
1973b) (Wallace et 
al., 1973a) 
LLC-MK2; Rhesus Monkey kidney ECACC, Cat No 85062804 (Hull et al., 1956) 
(Hull et al., 1962) 
MA-104; Rhesus Monkey kidney 
(foetal) 
NIBSC, Ref No 820402* (Whitaker & 
Hayward, 1985) 
B95a; Marmoset lymphoblast NIBSC, Ref No 001026* (Miller et al., 1972) 
Other 2° Ferret Lung NIBSC, Ref No 860401* N/A 
Mpf; Ferret brain ATCC, Cat No ATCC-CRL-
1656 
(Trowbridge et al., 
1982) 
L20B; Mouse L cell (expressing 
polio virus receptor) 
NIBSC, Ref No 910705* (Pipkin et al., 1993) 
(Mendelsohn et al., 
1986)  
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L929; Mouse L cell NIBSC, Ref No 810101* (Sanford et al., 
1948) 
LtK-; Mouse L cell NIBSC, Ref No 920501* (Kit et al., 1963) 
TM3; BALB/C mouse testis Leydig 
cell 
ECACC, Cat No 91060526 (Mather, 1980) 
 
BHK-21; Syrian Hamster kidney ECACC, Cat No 85011433 (MacPherson, 1963) 
CHO-K1; Chinese Hamster ovary ECACC, Cat No 85051005 (Kao & Puck, 1968; 
Puck et al., 1958) 
JH4 Clone 1; Guinea Pig lung ECACC, Cat No 86070201 (Hoying, 1975) 
MDCK; Canine kidney NIBSC, Ref No 821104* (Madin & Darby, 
1958) 
MDCK-SIAT1; Canine kidney over-
expressing α2,6 sialyltransferase  
Carolyn Nicholson, NIBSC (Matrosovich et al., 
2003) 
RK-13;  Rabbit kidney NIBSC, Ref No 750402* (Beale et al., 1963) 
Primary CEF; Chicken embryo fibroblast  Institute for Animal 
Health, Compton via Dr 
Marc Davies, Imperial 
College London 
N/A 
Kidney; Cynomolgus Macaque Prepared at NIBSC 
(Lauren Parker) 
N/A 
Testes; Cynomolgus Macaque Prepared at NIBSC 
(Lauren Parker) 
N/A 
Ex-Vivo MucilAir™ Human Airway Epithelial 
(HAE) cells 
Epithelix Sarl, Switzerland N/A 
* NIBSC Ref No refers to in-house cell bank number 
N/A - not applicable 
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2.1.2 Cell Culture Media 
Cell culture and maintenance media are detailed in Table 4. 
Table 4 – Cell Culture and Maintenance Media  
Media used in cell culture/routine maintenance Cell Line 
Minimum Essential Medium (MEM)  
(Sigma Aldrich, UK) 
10% (v/v) Foetal Calf Serum (FCS) (Sigma Aldrich, UK) 
2% (w/v) 200 mM L-Glutamine (Sigma Aldrich, UK) 
2° Ferret Lung 
293T 
BHK-21 
BSC-1 
Ca Ski 
CaCO2 
CV-1 
DBS FcL2 
DBS FrhL2 
Detroit 562 
HGT-1 
Hep 2 
Hep 2 C 
IMR-90 
JH4 Clone 1 
L20B 
LLC-MK2 
MA-104 
MCF-7 
MDCK 
MRC-5 
RD 
Vero 
Dulbecco’s Minimum Essential Medium (DMEM) (Sigma Aldrich, UK) 
10% (v/v) FCS (Sigma Aldrich, UK) 
2% (w/v) 200 mM L-Glutamine (Sigma Aldrich, UK) 
A549 
A549 (BVDV) 
A549 (PIV5-V) 
B95a 
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COS-7 
LtK- 
NT2/D1 
PANC-1 
Roswell Park Memorial Institute (RPMI 1640) (Sigma Aldrich, UK) 
10% (v/v) FCS (Sigma Aldrich, UK) 
2% (w/v) 200 mM L-Glutamine (Sigma Aldrich, UK) 
L929 
NCI-H292 
 
MEM (Sigma Aldrich, UK) 
14% (v/v) Lamb Serum (Sigma Aldrich, UK) 
2% (w/v) 200 mM L-Glutamine (Sigma Aldrich, UK) 
Mpf 
 
 
Ham’s F12 (Sigma Aldrich, UK) 
5% (v/v) Horse Serum (Life Technologies™ UK) 
2.5% (v/v) FCS (Sigma Aldrich, UK) 
2% (w/v) 200 mM L-Glutamine (Sigma Aldrich, UK) 
TM3 
 
 
 
DMEM (Sigma Aldrich, UK) 
20% (v/v) FCS (Sigma Aldrich, UK) 
2% (w/v) 200 mM  L-Glutamine (Sigma Aldrich, UK) 
1% (w/v) 10,000 units/mL Penicillin-Streptomycin (Sigma Aldrich, UK) 
1% (w/v) 250 mM Amphotericin B (Sigma Aldrich, UK) 
All primary cells 
0.5 mg/mL Gentamicin (Life Technologies™ UK)  
BioWhittaker® UltraCULTURE™ (Lonza, USA) 
2%(w/v) 200 mM L-Glutamine (Sigma Aldrich, UK) 
RK-13 
MucilAir™ Culture Medium  
(Epithelix Sarl, Switzerland) 
MucilAir™ HAE cells 
  
51 
 
Minimal Essential Medium (MEM, Sigma Aldrich UK) containing 4% (v/v) foetal calf serum (FCS, 
Sigma Aldrich UK), 2% (w/v) 200 mM L-Glutamine (Sigma Aldrich, UK), 1% (w/v) 10,000 units/mL 
Penicillin-Streptomycin (Sigma Aldrich, UK) and 1% (w/v) 250 mM Amphotericin B (Sigma Aldrich, 
UK) was used as a negative control for uninfected cells and for preparing virus dilutions, and is 
designated as “infection medium” throughout the text.  
2.1.3 Viruses 
The viruses used are detailed in Table 5. 
Table 5 – Viruses   
Virus Additional Information Source/Reference 
AFZ315 Clinical saliva sample collected from mumps 
patient 2 days after onset of symptoms, 
University of Hertfordshire 2002 
NIBSC 
GFP-expressing mumps 
(GFP-MuV) 
Recombinant JL-5 mumps virus  with 
enhanced GFP gene inserted at position 146 
prior to start of N gene 
Dr Ken Lemon, Queens 
University, Belfast 
HPA 1.1/P1V Clinical mumps isolate from nose/throat 
swab, 2009, passaged once on Vero cells 
Dr Kevin Brown, CFI 
Colindale, HPA 
Influenza PR8 High growth laboratory strain of Influenza A 
virus 
NIBSC 
Mu90 Clinical mumps isolate from passaged 4 
times on Vero cells, original isolate known as 
LO-1 from North London clinic 1988 
NIBSC (Afzal et al., 1997) 
RIT 4385 Live attenuated mumps virus component of 
Priorix® MMR vaccine, GSK, UK 
NIBSC (Tillieux et al., 2009) 
 
2.1.4 Standard and Real-Time PCR Primers and Probes 
Primers and probes used for both standard and reverse transcriptase and real-time PCR are detailed 
in Table 6 and Table 7, respectively. All of the listed oligonucleotides were designed using online 
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programme Primer3 Input v0.4.0 (http://frodo.wi.mit.edu/primer3/) and were obtained from Life 
Technologies™ or Eurofins MWG Operon.  
Table 6 – Standard PCR Primers  
Primer name Sequence (5’ to 3’) Gene GenBank Accession 
number used for primer 
design/Reference 
HN1Fw aaaaagcaagccagaacaaa   
HN2Rv caattcccctcaagaccaga   
HN3Fw tcttgttcagaccgcatcag   
HN4Rv tgtggtaggaggcaaaca MuV HN – LO-1 X98874 
RIT_HN117Fw ttccggccactaagaaaatg   
RIT_HN1069Rv tattccactccccactcctg   
RIT_HN947Fw agcccacctacccagaaact   
RIT_HN1925Rv aatgagacacgcccgtaaag MuV HN – RIT 4385 FJ211585 
F4Fw tgatcattaatcatgaaggctttt   
F946Rv ccaagatcctgtctggcaat   
F771Fw cggtctaatggagggtcaga   
F1627Rv acctgatgagatcatcgacac MuV F – Genotype C AY669145 
RIT_F7Fw gaccggtggtaattcgattg   
RIT_F847Rv cctccattagaccggcact   
RIT_F804Fw tgcagtggttcaagcaacat   
RIT_F1751Rv aaattgcaggacgaatcacc MuV F – RIT 4385 FJ211585 
N2Fw ggacattttgacactacctgga   
N894Rv gtgaatgcagccaatgacag   
N775Fw ctatgcaatggtgggtgaca   
N1707Rv gcaattgagggtggtttgat MuV N – Genotype C AY669145 
RIT_N1Fw ccaaggggagaatgaatatgg   
RIT_N914Rv tgtcacccaccattgcatag   
RIT_N798Fw tatgcaatggtgggtgacat   
RIT_N1776Rv acttgcaactgtgcgttttg MuV N – RIT 4385 FJ211585 
JLSH1Fw agtagtgtcgatgatctcat   
JLSH2Rv gctcaagccttgatcattga   
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JLSH3Fw gtcgatgatctcattaggtac   
JLSH4Rv agctcacctaaagtgacaat MuV SH – RIT 4385 FJ211585 
GAPDHFw aacatcatccctgcttccactggt  (Svitek & von Messling, 
2007) GAPDHRv tgttgaagtcgcaggagacaacct Ferret – GAPDH 
IL-2Fw tgctgctggacttacagttgctct  (Svitek & von Messling, 
2007) IL-2Rv caattctgtggccttcttgggcat Ferret – IL-2 
IL-6Fw caaatgtgaagacagcaaggaggca  (Svitek & von Messling, 
2007) IL-6Rv tctgaaactcctgaagaccggtagtg Ferret IL-6 
IL-10Fw tccttgctggaggactttaagggt  (Svitek & von Messling, 
2007) IL-10Rv tccaccgccttgctcttattctca Ferret IL-10 
 
Table 7 – Real-Time PCR Primers  
Primer/Probe 
name 
Sequence 
(5’ – 3’) 
Gene Accession number 
used for primer 
design/Reference 
JLSHF atccaacctcccttatacctaac  
 
MuV - SH 
 
JLSHR gatcaaaaccccagcgagagaag  
JLSHP (Probe) FAM – tattaactataagacggcggtgcgat – BHQ1 FJ211585 
AFZ315SHF gccattacctacaagactgc  
 
MuV - SH 
 
AFZ315SHR ctggggttctgtgttgtatt  
AFZ315P (Probe) FAM – gctgcatttgaatgatgccg – BHQ1 AB618040 
GAPDH535F atcactgccacccagaagac  
 
Ferret - GAPDH 
 
(Svitek & von 
Messling, 2007) 
GAPDH680R gtgagcttcccattcagctc 
GAPDHP (Probe) JOE – ccactggtgcagccaaggctgtag – BHQ1 
 
2.1.5 Molecular Biology Reagents, Chemicals and Buffers 
Reagents (including assay kits) were obtained from QIAGEN® UK, Bioline UK, Roche UK, Sigma 
Aldrich UK, Life Technologies™ UK or Calbiochem® UK and used as detailed in the text. 
Chemicals and reagents prepared in-house are detailed in Table 8.  
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Table 8 – In-House Chemicals and Reagents  
Chemical/Reagent Recipe 
5% CMC For 50 mL: 
2.5 g (5% w/v)carboxymethylcellulose  
(Fisher Scientific, UK) 
50 mL PBS A (1x) 
FACS Buffer 2.5 g (0.5% w/v) Probumin™ BSA (Millipore, USA) 
0.1 g MgCl2 6H2O (Merck, UK) 
0.1 g MnCl2 4H2O (Merck, UK) 
0.1 g CaCl2 2H2O (Merck, UK) 
Adjust to final volume of 500 mL with distilled H2O 
FACS Fix 150 mL PBS A (1x) 
325 mL distilled H2O 
25 mL 40% Paraformaldehyde  
(Sigma Aldrich, UK)  
Methanol/Acetone (50:50) For 500 mL: 
250 mL Methanol (AnalR, UK) 
250 mL Acetone (AnalR, UK) 
Methyl violet For 1 L: 
200 mL IMS (Tennant, UK) 
5.0 g (0.5% w/v) Methyl violet (Merck, UK) 
800 mL distilled H2O 
4% Paraformaldehyde For 500 mL: 
50 mL 40% Paraformaldehyde  
(Sigma Aldrich, UK) 
450 mL PBS A (1x) 
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PBS A (1x) 1.0 g NaCl (Fisher Scientific, UK) 
0.25 g KCl (Merck, UK) 
1.44 g Na2HPO4 anhydrous (Merck, UK) 
0.25 g KH2PO4 (Merck, UK) 
Adjust to final volume of 1 L with distilled H2O 
pH 7.5 (adjusted with NaOH or HCl)  
PBS Flow 500 mL Sodium azide cell wash  
(Becton Dickinson, UK) 
25 mL FCS (Sigma Aldrich, UK) 
PBS 6-Salt 80 g NaCl (Fisher Scientific, UK) 
2.0 g KCl (Merck, UK) 
1.3 g CaCl2 2H2O (Merck, UK) 
1.0 g MgCl2 6H2O (Merck, UK) 
29 g Na2HPO 12H2O (Fisher, UK) 
2.0 g KH2PO4 (Merck, UK) 
Adjust to final volume of 10 L with distilled H2O 
TBE (1x) For 1 L: 
100 mL 10 x TBE 
900 mL distilled H2O 
TBE (10x) 109.03 g Tris Base (Fisher Scientific, UK) 
55.65 g Boric Acid (Sigma Aldrich, UK) 
9.31 g EDTA (Merck, UK) 
Adjust to final volume of 1 L with distilled H2O 
pH 7.5 (adjusted with NaOH or HCl) 
TBS  60.6 g Tris HCl (Merck, UK) 
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13.9 g Tris Base (Merck, UK) 
87.66 g NaCl (Fisher Scientific, UK) 
Adjust to final volume of 10 L with distilled H2O 
pH 7.6 (adjusted with NaOH or HCl) 
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2.2 Cell Culture 
2.2.1 Routine Cell Culture 
Continuous cell lines listed in Table 3 were examined microscopically on a regular basis and were 
sub-cultured every 3 to 4 days dependent upon rate of cell growth, appearance and cell 
requirements for experiments. They were routinely grown in T75 flasks (Scientific Lab Supplies, UK) 
containing 20 mL of the relevant culture medium (Table 4).  
For routine sub-culture of cells, spent medium was decanted from flasks and the cell layer washed 
twice with phosphate buffered saline (PBS A). Cells were then washed gently with 5 mL 0.25% 
Trypsin/EDTA solution (Sigma Aldrich, UK), the trypsin was decanted and flasks were incubated at 
37°C, 5% CO2 until the cells detached from the flask surface. An appropriate volume of medium for 
the chosen sub-culture ratio was added to each flask, cells were re-suspended and then transferred 
into new T75 flask(s) containing 20 mL of fresh medium.  
All cell culture procedures were carried out in a class II microbiological safety cabinet using standard 
aseptic techniques.   
2.2.2 Routine Maintenance of MucilAir™ HAE Cells 
MucilAir™ are human airway epithelial (HAE) cells that have been reconstituted on a porous 
Transwell membrane and cultured at the air-liquid interface allowing the cells to become fully 
differentiated. They are polarised and form tight junctions (Huang et al., 2011).   
Every 2 to 3 days, the Transwell support containing the cells was transferred using sterile forceps, to 
a well of a fresh 24-well plate containing 0.7 mL MucilAir™ culture medium pre-warmed to 37°C. As 
these cells naturally produce mucus, once the Transwell was transferred into fresh medium, the 
mucus was washed from the cell surface by the gentle addition and removal of 100 µL sterile PBS A 
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pre-warmed to 37°C. This wash step was carried out 10 times. The cells were routinely incubated at 
37°C, 5% CO2.  
2.2.3 Preparation of Primary Cells 
Primary cells were prepared from Cynomolgus Macaque kidney and testis tissues as follows. 
Tissue explants were placed in a 100 mL sterile container with 20 mL PBS A and then transferred to a 
petri dish containing 10 mL PBS A. Sterile scissors and forceps were used to dissect the tissues into 
fragments of approximately 1-2 mm in diameter which were then transferred to a 50 mL centrifuge 
tube containing 15 mL PBS A. The tissue pieces were washed 3 times by removing and replacing the 
PBS A and after the third wash, the PBS A was removed and replaced with 15 mL of 0.25% 
Trypsin/EDTA solution (Sigma Aldrich, UK) and incubated overnight at 4°C. After this incubation 
period, the tubes were incubated at 37°C for 30 min and the contents pipetted vigorously to obtain 
small cell clumps, before adding 15 mL primary cell culture medium (Table 4) to stop further trypsin 
action. The cell suspensions were centrifuged at 470 g for 5 min at room temperature, and the 
resulting supernatant was decanted leaving the cell pellet. The pellet was re-suspended in 50 mL of 
medium and a cell count was performed using a haemocytometer and the trypan blue dye-exclusion 
method (Strober, 2001), with a 1 in 10 dilution of cells in trypan blue (Sigma Aldrich, UK). Cells were 
distributed evenly between T75 flasks at a density of ca 1x105 cells per flask and incubated at 37°C, 
5% CO2.  
 
2.3 Routine In Vitro Virology 
2.3.1 Virus Infection of Cells in 96-well Plates 
Cells were seeded into 96-well plates (Scientific Lab Supplies, UK) at a density of ca 1x105 cells per 
well in a 100 µL volume of infection medium and incubated overnight at 35°C, 5% CO2. Cells were 
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examined microscopically prior to inoculation for appropriate appearance and confluency (70-90%). 
Virus stocks were thawed on ice and diluted in infection medium to result in an approximate MOI of 
0.001 pfu (plaque forming units) per cell in a final volume of 100 µL. Spent medium was aspirated 
from the wells and replaced with the diluted virus inoculum, then incubated at 35°C, 5% CO2 for ca 
90 min. Following the incubation period, inocula were aspirated from the cells and replaced with 100 
µL of infection medium per well prior to re-incubating at the previously described conditions.  
2.3.2 Virus Infection of Cells and Preparation of Progeny Virus 
Cells were seeded into 24 well plates or T25 flask(s) (both Scientific Lab Supplies, UK) at a density of 
ca 1x105 cells in a volume of 1 mL infection medium per well for plates or 5 mL per flask, and 
incubated overnight at 35°C, 5% CO2. Cells were examined microscopically prior to inoculation for 
appropriate appearance and confluency. Viruses were thawed on ice and diluted in infection 
medium to result in an approximate MOI of 0.003 pfu/cell. In the case of neat clinical isolates, 50 µL 
of sample was added to infection medium for inoculation. Spent media was aspirated from the cells 
and replaced with either 2 mL of diluted virus per T25 flask or 200 µL per well of each plate, and 
then incubated at 35°C, 5% CO2 for ca 90 min. Following the incubation period, inocula were 
removed from the cells and replaced with 5 mL of infection medium per flask or 1 mL per well for 24 
well plates. Cells were re-incubated at the previously described conditions.  
Cells were examined microscopically on a daily basis for signs of cytopathic effect (CPE) and frozen at 
-80°C either when ca 80% CPE was evident or on day 7 post infection.  
Frozen flasks or plates of cells were thawed at room temperature and the cell lysates centrifuged at 
470 g for 5 min at room temperature. The resulting supernatants containing virus were aliquoted, 
stored at -80°C and designated as progeny virus. All progeny viruses were titrated via plaque assay 
on Vero cells as detailed in section 2.3.5.  
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2.3.3 Passaging of Viruses through Cell Lines 
Mumps viruses were passaged 5 times through various cell lines. For P1 to P5, T25 flasks of each cell 
line were seeded, infected and aliquots of progeny virus prepared from cell lysates as described in 
section 2.3.2. Dilutions (1 in 50) of each progeny were prepared in infection medium prior to each 
passage.  
2.3.4 Infection of MucilAir™ HAE Cells 
Each Transwell membrane was transferred to fresh culture medium and surface mucus was washed 
from the cells as described in section 2.2.2. Viruses were thawed on ice and diluted in infection 
medium to result in an approximate MOI of 0.001 pfu/cell in a final volume of 200 µL. In the case of 
neat clinical isolates, 50 µL of sample was added to 150 µL of infection medium. The virus inoculum 
was added to the apical surface of the cells and incubated at 37°C, 5% CO2 for ca 90 min.  
Following the incubation period, the virus inoculum was removed from the apical cell surface by 
pipetting and the cells were re-incubated at the conditions previously described.  
Apical and basal samples were harvested at 6, 12 and then every 24 hours for 7 days post infection. 
Cells were also examined microscopically for evidence of CPE at these time points.  
To harvest viruses released from the apical cell surface, 300 µL of MEM pre-warmed to ca 37°C was 
added to the surface and incubated at 37°C for ca 30 min. Following the incubation period, the MEM 
was removed by pipetting and 4% (v/v) FCS, 2% (w/v) 200 mM L-Glutamine, 1% (w/v) 10,000 
units/mL Penicillin-Streptomycin and 1% (w/v) 250 mM Amphotericin B were added to the sample 
before storing at -80°C. 
To harvest viruses released from the basal cell compartments, each Transwell support was first 
transferred to a fresh 24-well plate containing culture medium as described in section 2.2.2. The 
spent cell culture medium was harvested and 4% (v/v) FCS, 2% (w/v) 200 mM L-glutamine, 1% (w/v) 
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10,000 units/mL Penicillin-Streptomycin and 1% (w/v) 250 mM Amphotericin B were added to the 
sample before storing at -80°C.  
To prepare MucilAir™ cells for histological cross sectioning, each membrane was washed 3 times in 
PBS A and then immersed in 4% paraformaldehyde (Table 8) for 1 hour at room temperature. After 
the incubation period cell membranes were washed 3 times with PBS A and then stored in universal 
containers with 10 mL PBS A at 4°C. The fixed cells were sent to Propath UK Limited for preparation 
of histological slides. 
2.3.5 Titration of Viruses 
Viruses were titrated by plaque assay on Vero cells. Briefly, confluent T75 flasks of Vero cells were 
trypsinised into 50 mL infection medium and cells (1 mL per well) were added to 24-well plates. 
Serial 10-fold dilutions (1 in 10 to 1 in 100,000) of virus were prepared in infection medium, and 50 
µL of each dilution was added to 3 wells of a 24-well plate. A negative control consisting of infection 
medium only was included. Cells were incubated for ca 3 hours at 35°C, 5% CO2 to allow the cells to 
settle in the wells.  
After the incubation period, inocula were aspirated from all wells and replaced with 5% CMC overlay 
medium (Table 8) consisting of MEM, 5% (v/v) CMC, 4% (v/v) FCS, 2% (w/v) 200 mM L-Glutamine, 1% 
(w/v) 10,000 units/mL Penicillin-Streptomycin, and 1% (w/v) 250 mM Amphotericin B. Cells were re-
incubated at the same conditions as before. The cells were stained with methyl violet (Table 8) at 7 
days post infection and the virus titres calculated from the plaque counts obtained, taking into 
account the volume of the inoculum and dilution factor.   
2.3.6 Plaque Reduction Neutralisation (PRN) Assays 
Serum samples were thawed on ice and heat-inactivated by incubating in a water bath at 56°C for 30 
min to inactivate the complement pathway.   
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96-well plates were labelled and 150 µL of infection media was added to all wells. 150 µl of serum 
sample was added to the first well of the relevant sample row to create an initial 1 in 2 dilution, and 
using a multi-channel pipette, 150 µL of this dilution was added to the next well and mixed. This was 
repeated from left to right into a further 4 wells to create a range of doubling dilutions from 1 in 2 to 
1 in 64. 150 µL of the serum/media mix was discarded from the last wells. 6 wells were included for 
a virus control each containing 150 µL infection media plus 150µL of an appropriate dilution of 
control mumps virus prepared in infection media. The control mumps virus was referred to 
throughout as the challenge virus, and 150 µL of this was then added to all remaining wells on the 
plate. 96-well plates containing the samples were then incubated at 4°C for ca 90 min. 
Before the end of the incubation period, T75 flasks of confluent Vero cells were trypsinized into 50 
mL of infection medium and cell suspensions were pooled.  
After the incubation period, 50 µL of from each well of the 96-well plate containing sera/virus was 
added to 3 wells of a 24 well plate. 
1.0 mL of the Vero cell suspension was then added to each well, and the 24-well plates were 
incubated at 35°C, 5% CO2 for ca 3 hours to allow cells to settle in the wells. 
After this incubation period, inocula was aspirated from all wells and replaced with 1 mL per well of 
5% CMC overlay media as described in section 2.3.5. Cells were incubated at the previously 
described conditions for 10 days, and on day 10 post infection, cells were stained with methyl violet. 
Plaques were counted and the counts obtained entered into a standardised NIBSC PRN Excel 
spreadsheet configured with the equations required for analysis. 50% neutralising end-point titres 
(ND50) were calculated as the serum dilution capable of reducing the mean number of plaques by 
50% or greater as compared to the mean number of plaques in virus control wells using the 
Spearman-Karber formula (Finney, 1971).  
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2.4 Routine Molecular Virology 
2.4.1 RNA Extraction 
RNA was extracted from samples using the Trizol® LS Reagent (Life Technologies™ UK) method 
according to the manufacturer’s instructions.  
RNA was isolated using the recommended 3 volumes of Trizol® LS to 1 volume of sample.  
Briefly, samples were thawed on ice and once fully thawed, Trizol® LS was added. Samples were 
vortexed to mix and 2 µL of glycogen (Life Technologies™ UK) was added to increase the yield of the 
RNA pellet. An appropriate volume of chloroform (Sigma Aldrich, UK) was added to each sample to 
allow phase-separation and incubated at room temperature for 5 min. Samples were then 
centrifuged at 18000 g for 10 min at 4°C, and the resulting top aqueous layer containing RNA was 
transferred to a clean nuclease free tube. An appropriate volume of isopropanol (Sigma Aldrich, UK) 
was added to each sample to precipitate the RNA, and incubated at -20°C for ca 1 hour to precipitate 
the RNA.                                                                                                                                                                                             
After this incubation period, samples were centrifuged at 18000 g for 10 min at 4°C, and the 
resulting supernatant was carefully removed by pipetting, leaving the RNA pellet. 500 µL of ice-cold 
70% ethanol was added to each pellet and then centrifuged at 18000 g for 10 min at 4°C as a wash 
step. After this final centrifugation step, the resulting supernatant was removed carefully by 
pipetting and the RNA pellets were allowed to air-dry in a class II microbiological safety cabinet for 5 
to 10 min. RNA pellets were re-suspended in 15-30µL diethyl pyrocarbonate (DEPC)-treated H2O 
(Sigma Aldrich, UK) and stored at -20°C.  
2.4.2 Reverse-Transcriptase (RT) PCR 
RT-PCR was performed on RNA samples using either the QIAGEN® One-Step RT-PCR kit and protocol 
or Bioline MyTaq™ One-Step RT-PCR kit and protocol, both according to the manufacturer’s 
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instructions. All primers were used at a working concentration of 10 µM and the sequences are 
detailed in Table 6, section 2.1.4.  
For each sample to be amplified using the QIAGEN® kit, 2 µL of template RNA was added to 10 µL 5x 
buffer, 2 µL dNTP, 1.5 µL of each forward and reverse primer, 2 µL RT enzyme and 31 µL DEPC H2O in 
a reaction tube. The RT-PCR cycle programme used was: 1) 50°C for 30 min, 2) 95°C for 15 min, 3) 
94°C for 1 min followed by 50°C for 30 seconds and 72°C for 1 min. Step 3 was repeated 35 times 
followed by a final extension cycle of 72°C for 10 min and then held at 4°C.  
For each sample to be amplified using the Bioline kit, 2 µL of template RNA was added to 25 µL 2x 
MyTaq™ one-step mix, 1.5 µL of each forward and reverse primer, 1 µL RiboSafe RNase inhibitor, 0.5 
µL RT enzyme and 18.5 µL DEPC H2O in a reaction tube. The RT-PCR cycle programme used was:  1) 
48°C for 20 min, 2) 95°C for 1 min, 3) 95°C for 15 seconds followed by 50°C for 15 seconds and 72°C 
for 30 seconds. Step 3 was repeated 35 times followed by a final extension cycle of 72°C for 10 min 
and then held at 4°C.  
All RT-PCR reactions were carried out using an Eppendorff Mastercycler® gradient machine.  
RT-PCR products were analysed on a 1 x Tris-borate-EDTA (TBE) 1% agarose (Sigma Aldrich, UK) gel 
stained with ethidium bromide (10 mg/mL, Promega, USA), and electrophoresed for ca 30 min at 
110 V. 5 µL of Bioline Hyper Ladder II or V was included as a marker. Gels were viewed using an 
Auto-Chemi® UV Transilluminator (UVP Bio-Imaging Systems). RT-PCR products were stored at -20°C.  
2.4.3 Standard PCR 
Standard PCR was performed on RT-PCR products (nested PCR) using the QIAGEN® HotStartTaq™ 
Master Mix kit and protocol according to the manufacturer’s instructions. All primers were used at a 
working concentration of 10 µM and the sequences are detailed in Table 6, section 2.1.4.  
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For each sample to be amplified, 2 µL of template DNA was added to 25 µL HotStartTaq™ Master 
Mix, 1 µL of each forward and reverse primer and 18 µL DEPC H2O in a reaction tube. The PCR cycle 
programme used was: 1) 95°C for 15 min, 2) 94°C for 30 seconds followed by 50°C for 30 seconds 
and 72°C for 1 min. Step 2 was repeated 35 times followed by a final extension cycle of 72°C for 10 
min and then held at 4°C.  
All PCR reactions were carried out using an Eppendorff Mastercycler® gradient machine.  
PCR products were gel electrophoresed as described in section 2.4.2 and were stored at -20°C.  
2.4.4 PCR Product Purification 
RT and standard PCR products were gel purified using either the QIAGEN® QIAquick® Gel Extraction 
kit and protocol for microcentrifuge or the Bioline ISOLATE PCR and Gel kit, both according to the 
manufacturer’s instructions.  
 For the QIAquick® Gel Extraction Kit, centrifugation conditions throughout was 18000 g for 1 min at 
room temperature:  
DNA band(s) were excised from the gel using a sterile scalpel and weighed in a nuclease free tube. 3 
volumes of Buffer QG were added per 1 volume of gel and incubated in a water bath at 50°C for ca 
10 min, with brief vortexing every 2 to 3 min to dissolve the gel. 1 volume of isopropanol was added 
per 1 volume of gel and mixed via brief vortexing, and each sample was applied to a QIAquick® 
column placed in a collection tube and then centrifuged. The expelled liquid was discarded and 500 
µL Buffer QG was added to the column which was then centrifuged. 750 µL of Buffer PE was applied 
to the column and centrifuged as a wash step. The flow-through liquid was discarded and the spin 
columns centrifuged for a final 1 min at 18000 g at room temperature. Each column was placed into 
a clean, nuclease free 1.5 mL microcentrifuge tube and 30 µL Buffer EB was applied to the column(s) 
which were left to stand for 1 min before centrifuging.  The eluted purified PCR products were 
stored at -20°C.  
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When using the Bioline ISOLATE PCR and Gel kit, centrifugation conditions throughout were 10000 g 
for 1 min at room temperature apart from where stated otherwise: 
DNA band(s) were excised from the gel using a sterile scalpel and place in a nuclease free tube. 650 
µL Gel Solubilizer was added and samples were incubated in a water bath at 50°C for ca 10 min or 
until the gel was fully dissolved. 50 µL Binding Optimizer was added and vortexed briefly to mix, and 
then 750 µL of sample was applied to a spin column placed in a collection tube and centrifuged. The 
expelled liquid was discarded and any remaining sample was loaded onto the column and 
centrifuged. 750 µL Wash Buffer A was applied to the spin column and centrifuged, and this wash 
step was repeated, with any expelled liquid being discarded between each step. Spin column(s) were 
centrifuged for 2 min to ensure removal of Wash Buffer and then placed in a clean nuclease free 
tube. 30 µL Elution Buffer was applied to the Spin Column membrane and incubated at room 
temperature for ca 1 min before centrifugation at 6000 g for 1 min at room temperature. The eluted 
purified PCR products were stored at -20°C.  
2.4.5 Sequencing Reactions 
Purified PCR products were sent to Eurofins MWG Operon to be sequenced using the Value Read 
Tube Service. 15 µL of each product plus 2.25 µL of either forward or reverse primer (Table 6, section 
2.1.4) at a concentration of 100 µM was provided to Eurofins for sequencing. The reactions were 
performed using chain termination Sanger sequencing technology and date was analysed using 
Lasergene8.0-SeqMan software (DNASTAR) and aligned using ClustalW software (EMBL-EBI).  
2.4.6 Preparation of Standard Curves for Real-Time Quantitative RT-PCR 
Standard curves were prepared for use in real-time RT-PCR as positive controls and in order to 
obtain an approximate limit of detection for each assay.  
10 fold serial dilutions of each virus were prepared in MEM to provide a dilution range from neat 
virus to 10-7. In order to calculate the number of pfu in each dilution, virus titres were pre-
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determined via plaque assay on Vero cells (described in section 2.3.5). RNA was extracted from the 
viral dilutions as previously described in section 2.4.1 and standard curve samples were stored at -
20°C.  
2.4.7 Real-Time Quantitative RT-PCR 
Real-time RT-PCR was performed on RNA samples using the QIAGEN® QuantiTect™ Probe RT-PCR kit 
and protocol according to the manufacturer’s instructions.  All primers and probes were used at a 
working concentration of 10 µM and the sequences are detailed in Table 7, section 2.1.4.  
For each sample to be amplified, 3 µL of RNA was added to 12.5 µL 2x Master Mix, 1 µL of each 
forward and reverse primer, 0.5 µL probe, 0.25 µL RT enzyme and 6.75 µL DEPC H2O in a well of a 
reaction plate (MicroAmp® Fast Optical 96-well reaction plate, Applied Biosystems® by Life 
Technologies™, UK). The RT-PCR cycle programme used was: 1) 50°C for 30 min, 2) 95°C for 15 min 
and 3) 94°C for 15 seconds followed by 52°C for 1 min. Step 3 was repeated 40 times.  
All real-time RT-PCR reactions were carried out using an ABI 7900HT Fast Real-Time PCR machine 
and SDS V2.4 software (Applied Biosystems® by Life Technologies™, UK).  
2.4.8 SYBR® Green Real-Time RT-PCR 
SYBR® Green real-time RT-PCR was performed on RNA samples using the QIAGEN® QuantiTect 
SYBR® Green RT-PCR kit and protocol according to the manufacturer’s instructions. All primers and 
were used at a working concentration of 10 µM and the sequences are detailed in Table 7, section 
2.1.4.  
For each sample to be amplified, 1 µL of RNA was added to 12.5 µL 2x SYBR® Green Master Mix, 0.5 
µL of each forward and reverse primer, 0.25 µL RT enzyme and 10.25 µL DEPC H2O in a well of a 
reaction plate (MicroAmp® Fast Optical 96-well reaction plate, Applied Biosystems® by Life 
Technologies™, UK). The PCR programme used was: 1) 50°C for 30 min, 2) 95°C for 15 min and 3) 
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94°C for 15 seconds followed by 52°C for 30 seconds and 72°C for 30 seconds. Step 3 was repeated 
40 times.  
All SYBR® Green RT-PCR reactions were carried out using an ABI 7900HT Fast Real-Time PCR machine 
and SDS V2.4 software (Applied Biosystems® by Life Technologies™, UK).  
 
2.5 Immunohistochemistry 
2.5.1 Optimisation of Antibody Dilutions 
Primary and secondary antibodies were titrated to determine optimal working dilutions and 
diluents.  
Rabbit polyclonal MuV anti-F antibody (kindly provided by Steven Rubin, FDA) and anti-β-tubulin 
mouse monoclonal antibody (Sigma Aldrich, UK) were diluted in PBS A containing 1% (w/v) Bovine 
Serum Albumin (BSA) and 1% (v/v) Tween-20 (both Sigma Aldrich, UK) or PBS A containing 5% (w/v) 
non-fat dried milk powder and 1% (v/v) Tween-20. Both antibodies were diluted to a range from 1 in 
100 to 1 in 10,000. MuV anti-F antibody was titrated on LLC-MK2 cells (Rhesus Monkey Kidney) in 8-
well chamber slides (Fisher Scientific, UK) infected with mumps virus Mu90 fixed at 72 hours post 
infection as described in section 2.3.4. The mouse monoclonal anti-β-tubulin antibody was titrated 
on MCF-7 cells (human breast adenocarcinoma) in 8-well chamber slides fixed 24 hours after seeding 
as described in section 2.3.4. Secondary antibodies Goat Anti-Rabbit IgG conjugated to fluorescein 
isothiocyanate (FITC) and Goat Anti-Mouse TEXAS RED® conjugate (both Calbiochem®, UK) were 
diluted in either 1% (w/v) BSA/PBS A or 5% (w/v) non-fat dried milk/PBS A over a range of 1 in 50 to 
1 in 400.  
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All slides were mounted with glass cover slips using VECTASHIELD mounting medium (Vector 
Laboratories, UK) and images acquired using an Olympus IX71 fluorescence microscope and Leica 
camera FC345FX.  
2.5.2 Staining of MucilAir™ Histological Sections 
Histological sections of infected MucilAir™ HAE cells (see section 2.3.4) were received from Propath 
UK Limited on glass slides and de-paraffinized in xylene and ethanol and then rinsed in running tap 
water.  
Slides were blocked in 1% (w/v) BSA/PBS A for ca 1 hour at room temperature. The section slides 
were then washed once with PBS A and co-stained with rabbit polyclonal MuV anti-F antibody and 
anti-β-tubulin IV mouse monoclonal antibody diluted appropriately in 1% (w/v) BSA/1% (w/v) 
Tween-20/PBS A, and incubated overnight at 4°C.  
After the incubation period, slides were washed 3 times with ice-cold PBS A and primary antibodies 
were detected using FITC-Goat Anti-Rabbit IgG and Goat Anti-Mouse TEXAS RED® diluted 
appropriately in 1% (w/v) BSA/PBS A and incubated for ca 1 hour at room temperature in the dark. 
The sections were washed 3 times with ice cold PBS A before mounting with glass cover slips using 
VECTASHIELD mounting medium.  Photomicrographs were obtained using a LSM 5 Pascal Axioplan 2 
imaging confocal microscope and LSM Image Browser software (Zeiss).   
 
2.6 Sialic Acid Investigations 
2.6.1 Sialic Acid Quantification Bioassay 
The concentration of sialic acid in a defined quantity of cells was measured using the EnzyChrom™ 
Sialic Acid Assay Kit (BioAssay Systems, USA) according to the manufacturer’s instructions. 
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Briefly, one confluent T75 flask of each cell line to be analysed was trypsinized into 30 mL PBS A and 
centrifuged at 470 g for 5 min at room temperature to remove debris and pellet the cells. Cells were 
counted as described in section 2.2.3 and re-suspended at a concentration of 2x105 cells in a final 
volume of 20 µL PBS A.  
20 µL cells in PBS A were mixed with 80 µL Hydrolysis Reagent in a 1.5 mL screw cap tube and 
incubated in a waterbath at 80°C for 1 hour to release sialic acid bound to cell membranes. The 
sample was then cooled to room temperature and centrifuged at 21000 g for 1 min at room 
temperature. 20 µL Neutralisation Reagent was added to stop the hydrolysis reaction, mixed by 
vortexing and then centrifuged at 21000 g for 30 seconds at room temperature.  
For the colorimetric procedure, samples and reagents were equilibrated to room temperature and a 
1 mM sialic acid Standard Premix was prepared by mixing 50 µL of the 10 mM Standard with 450 µL 
H2O. This was then diluted as set out in Table 9.  
Table 9 – Standard Preparation for Sialic Acid Bioassay 
Number Premix + H2O Total Volume (µL) Sialic Acid (mM) 
1 100µL + 0µL 100 1.0 
2 60µL + 40µL 100 0.6 
3 30µL + 70µL 100 0.3 
4 0µL + 100µL 100 0 
 
10 µL of standards and 10µL of samples were transferred to separate wells of a clear, flat-bottomed 
96 well plate (Scientific Lab Supplies, UK) in triplicate. For each reaction well, 93 µl Assay Buffer, 1 µL 
Dye Reagent and 1 µL Enzyme was mixed in a 1.5 mL screw cap tube, and 90 µL of this working 
reagent was then transferred to each reaction well and mixed gently by pipetting contents up and 
down several times. The reaction plate was incubated at room temperature for ca 1 hour and then 
optical density (OD) at 570 nm was measured using a FLUOstar OPTIMA plate reader (BMG LABTECH, 
71 
 
USA). Replicate OD readings were analysed by linear regression of the assay standard using 
GraphPad PRISM® 5.0 software.   
2.6.2 Fluorescence Activated Cell Sorting (FACS) Analysis 
Relative quantities of α2,3 and α2,6 sialic acid linkages expressed on cell surfaces was determined 
using the Digoxigenin (DIG) Glycan Differentiation Kit (Roche, UK) with some modifications from the 
manufacturer’s protocol.  
Briefly, one confluent T75 flask of each cell line to be analysed was trypsinized into 10 mL infection 
medium and centrifuged at 470 g for 5 min at room temperature to remove debris. The cell pellet 
was re-suspended in 20 mL PBS A and counted as described in section 2.2.3. Cells were added to 9 
replicate wells of a clear, flat-bottomed 96 well plate at a concentration of 2x105 cells per well in 200 
µL FACS buffer (Table 8). Plates were centrifuged at 470 g for 5 min at room temperature to wash 
cells. The resulting supernatant was removed by over-turning the plates onto absorbent paper and 
the cells re-suspended by tapping the plate gently to prepare them for lectin incubation.  
DIG-labelled lectins Sambucus nigra agglutinin (SNA) and Maackia amurensis agglutinin (MAA) were 
diluted appropriately in FACS buffer to give working concentrations of 1 µg/mL. 10 µL of SNA, MAA 
or FACS buffer was added to 3 of the 9 replicate wells of cells and incubated at room temperature 
for 30 min with gentle shaking. After the incubation period cells were washed 3 times in PBS A. 10 µL 
of FITC conjugated anti-DIG antibody (5 µg/mL) (Roche, UK) was added to all wells and incubated at 
room temperature for 30 min with gentle shaking. Cells were then washed twice in PBS Flow (Table 
8) and after the final wash each well of cells was re-suspended in 200 µL FACS Fix buffer (Table 8). 
Samples were analysed by FACS using a BD FACSCanto™ II machine (Becton Dickinson, UK).  
2.6.3 Sialic Acid Blocking 
Cells were treated with lectin from MAA (Sigma Aldrich, UK) prior to infection to block α2,3 sialic 
acid linkages.  
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Briefly, cells were seeded into 24 well plates as described in section 2.3.2. Plated cells were washed 
once with PBS A and an appropriate volume of 1 mg/mL MAA lectin diluted in PBS A was added to 
each well. Control cells were treated with PBS A only. Cells were incubated at 35°C, 5% CO2 for 1 
hour before aspirating the lectin solution or control, then were washed once with PBS A and infected 
as described in section 2.3.2 with Mu90. Media from cells infected with Mu90 were harvested every 
24 hours for 5 days and progeny virus titrated via plaque assay as described in section 2.3.5.  
This experiment was also performed as described using lectin from SNA (Sigma Aldrich, UK) to block 
α2,6 sialic acid linkages, and with a simultaneous treatment of both MAA and SNA lectins to block 
both α2,3 and 6 linkages.  
 
2.7 Human Cytokine ELISA 
Levels of cytokines secreted into the basal medium of MucilAir™ cells infected with clinical mumps 
virus AFZ315 were measured using the Multi-Analyte ELISArray™ kit for human inflammatory 
cytokines (SABiosciences™, a QIAGEN® company) according to the manufacturer’s instructions. 
Briefly, basal samples taken at 6, 12, 24 hours and days 4, 7 and 10 post infection were centrifuged 
at 1000 g for 10 minutes and stored on ice. All reagents and buffers were prepared as per 
manufacturer’s protocol and equilibrated to room temperature. 50 µL of assay buffer plus 50 µL of 
samples, dilution buffer (negative control) or antigen standard cocktail (positive controls) were 
added to the relevant wells of the ELISA plate and incubated at room temperature for 2 hours. After 
the incubation period, contents of all wells were decanted and each well was washed 3 times with 
350 µL of wash buffer before the addition of 100µl per well of detection antibodies. ELISA plate was 
incubated for 1 hour at room temperature and then washed 3 times as previously described. 100 µL 
of Avidin-horse radish peroxidise (HRP) was added to each well and incubated in the dark at room 
temperature for 30 minutes before washing each well 4 times as previously described. 100 µL of 
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development solution was added to each well, ELISA plate incubated for 15 minutes at room 
temperature in the dark and the reaction then stopped by the addition of 100 µL per well of 
stopping solution.  
The absorbance was read at 450 nm using a Multiskan Ascent plate reader and software (Thermo 
Scientific, UK).  
 
2.8 In Vivo Virology 
2.8.1 Animals 
Male ferrets aged between 6 – 12 months were used in the three in vivo studies in this PhD project. 
All animal procedures were performed by fully trained and licensed NIBSC Biological Services 
Division (BSD) staff.  
For the initial study designated A, one group of three ferrets was inoculated intranasally with ca 
7x103 pfu in 400 µL (200 µL per nostril) of neat mumps clinical sample AFZ315.  A second group of 
three ferrets was inoculated intranasally with ca 2x104 pfu in 400 µL (200 µL per nostril) of the RIT 
4385 mumps vaccine strain diluted in MEM. 
Study A ran for 28 days with pre-bleed samples collected 7 days prior to inoculation, and blood 
samples were taken on 7, 14, 21 and 28 days post infection. Nasal washes, urine and faeces samples 
were collected on days 1, 4, 7, 14, 21 and 28. On day 28, all ferrets were terminated and tissues 
were collected (Table 10).   
For the study designated B, one group of three ferrets was inoculated intranasally with ca 2x104 pfu 
in 400 µL (200 µL per nostril) of heat-inactivated RIT 4385 diluted in MEM. The virus was heat-
inactivated prior to inoculation by incubating in a water bath at 60°C for 30 min.   
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Study B ran for 28 days with pre-bleed samples collected 9 days prior to inoculation, and blood 
samples were taken on 7, 14, 21 and 28 days post infection. On day 28, all ferrets were terminated.  
For the study designated C, one group of eight ferrets was inoculated intranasally with ca 7x103 pfu 
in 400 µL (200 µL per nostril) of neat AFZ315.  
Study C ran for 14 days with pre-bleed samples collected 9 days prior to inoculation. Oral swabs 
were taken from all animals still on study every 24 hours for 14 days. On 1, 4, 7 and 14 days post 
infection, two ferrets were terminated and tissues (Table 10) and terminal bleeds collected.  
The final in vivo investigation was designated as study D, and included four ferrets inoculated 
intranasally with ca 1x105 pfu in 400 µL (200 µL per nostril) of AFZ315 virus harvested at day 10 post 
infection from MucilAir™ HAE cells. 
Study D ran for 7 days. On days 4 and 7 post infection, two ferrets were terminated and tissues 
collected (Table 10).  
2.8.2 Blood Sample Processing 
Blood samples were collected in either serum-gel clotting activator tubes (Sarstedt, UK) or Becton 
Dickinson EDTA Vacutainers® (Fisher Scientific, UK).  
Samples collected in serum-gel clotting activator tubes were allowed to clot at room temperature 
for 20 to 30 min. The tubes were centrifuged at 15000 g for 5 min at 4°C to separate the serum and 
red blood cells. Serum was carefully removed by pipetting from the top layer of the separation gel 
and split into 2 aliquots before being stored at -80°C.  
Blood samples collected in Vacutainers® were used for peripheral blood mononuclear cell (PBMC) 
isolation. 4 mL ferret blood was added to 4 mL PBS A pre-warmed to 37°C and mixed by gentle 
inversion. The blood/PBS A mixture was deposited gently onto 4.5 mL Ficoll-Paque™ PLUS (GE 
Healthcare Life Sciences, UK) and centrifuged at 1400 rpm for 40 min at room temperature. PBMC’s 
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were removed from the resulting gradient by pipetting and washed 3 times in PBS A pre-warmed to 
37°C before storing at -80°C.  
2.8.3 Nasal Wash Processing 
Nasal washes were collected using L-15 (Liebovitz) medium (Sigma Aldrich, UK) supplemented with 
2% (w/v) BSA, 2% (w/v) 200 mM L-Glutamine, 2% (w/v) 10,000 units/mL Penicillin-Streptomycin and 
2% (w/v) 250 mM Amphotericin B. Samples were received on ice and split into 2 aliquots of ca 600 
µL and stored at -80°C. 
2.8.4 Urine Sample Processing 
Urine samples were provided as compressed paper animal bedding soaked with urine in a 50 mL 
centrifuge tube on ice. 5 mL of infection medium supplemented with 50 mg/mL (v/v) Gentamicin 
(Life technologies™ UK) was added to each tube, and the soaked bedding/media were then 
transferred into a 50 mL syringe (VWR International, UK). All liquid from the bedding and syringe was 
then expelled back into the same collection tube. A further 4% (v/v) FCS was added to each sample 
before storing at -80°C.  
2.8.5 Faeces Sample Processing 
Faeces samples were received in 50 mL centrifuge tubes on ice. 10 mL of infection media 
supplemented with 50 mg/mL (v/v) Gentamicin was added to each tube and vortexed vigorously for 
1 to 3 min until a homogenate was achieved. Each tube was then made up to a final volume of 50 mL 
with the same media and mixed well by shaking and inverting the tube several times. Faeces 
homogenates were stored at -80°C.  
2.8.6 Oral Swab Processing 
Oral swabs were taken using Sterilin pink-cap swabs containing virus transport medium sponges 
(Fisher Scientific, UK) and received on ice. Each swab was pressed and rubbed against the sponge for 
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ca 30 seconds. The sponge was removed from the tube using sterile forceps and transferred into a 
15 mL centrifuge tube containing infection media supplemented with 50 mg/mL (v/v) Gentamicin. 
Samples were stored at -80°C.  
2.8.7 Tissue Homogenate Preparation 
Tissues removed from the ferrets for homogenate preparation are listed in Table 10. Tissues were 
received in sterile containers on ice and each was weighed and 20% homogenates prepared in 
infection media. To prepare the 20% homogenates, each tissue was cut into small, even fragments 
using sterile scalpels and forceps, and placed into Precellys 24® homogenisation tubes (Peqlab, UK) 
containing an appropriate volume of media. Homogenisation was carried out using a Precellys 24® 
cell lysis and tissue homogeniser (Bertin Technologies, France). For adrenal glands, parotid glands, 
lymph nodes, turbinates, salivary glands and tonsils, a programme of 1 x 3000 g for 20 s was used, 
and for all other tissues a programme of 1 x 4000 g for 20 s was used.  
The resulting homogenates were then transferred, and pooled where necessary, into sterile 
containers, and an appropriate volume of infection media was added to make the final 20% 
homogenate. All samples were stored at -80°C.  
 
Table 10 – Ferret Tissues Analysed  
In vivo study A - Tissues In vivo studies C and D - Tissues 
Adrenal gland Brain 
Brain Kidney 
Colon Lung 
Heart Lymph node** 
Kidney Pancreas 
Liver Parotid gland 
Lung Spleen 
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Lymph node Testes 
Pancreas Tonsil 
Parotid gland  
Salivary gland*  
Small intestine  
Spleen  
Testes  
Tongue  
Tonsil  
Turbinates  
*BSD staff unable to locate and remove salivary glands from 2 out of 3 ferrets infected with AFZ315 
**BSD staff unable to locate and remove lymph nodes from 2 out of 8 ferrets from study C 
 
2.8.8 Preparation of Tissue Homogenates Spiked with Mumps Virus 
20% homogenates of spleen, brain and kidney tissues taken from a ferret terminated on day 1 post 
infection during study C were spiked with a known titre of clinical mumps virus AFZ315. 10 fold serial 
dilutions of virus were prepared in each homogenate to provide a dilution range from 10-1 to 10-8 
and RNA was extracted from each sample as described in section 2.4.1.  
Spiked tissue homogenate dilutions were used as standard curve for real-time RT-PCR in order to 
confirm the ability of MuV to be extracted from ferret tissues and to obtain a limit of detection for 
quantitative real-time PCR assays.  
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CHAPTER 3 – IN VITRO RESULTS 
Mumps virus is capable of growth in continuous cell lines, and serial passage in cell culture is the 
basis of attenuation for all live mumps vaccines. African Green Monkey kidney (Vero) cells are 
currently the “gold-standard” for MuV isolation and propagation, and it is likely that their deficiency 
in interferon production (Desmyter et al., 1968) is the reason that they are so permissive for MuV. 
Although Vero cells are commonly used, it has been suggested that they may be selective, 
insensitive and unsuitable for the production of virus isolates to be used in research (Afzal et al., 
2005). A previous study also demonstrated that Vero cells produce virus populations that are 
different from the original parent virus (Yates, 1995). This has not been investigated further to any 
great extent, and one of the aims of this project was to determine how serial passage of MuVs in 
Vero cells affects the viral genome and plaque phenotype.  
Concurrently, a cell line investigation was performed using representative wild-type and vaccine 
MuVs and a GFP-expressing MuV in order to identify any cell types which may offer an alternative to 
Vero’s. As mumps is a solely human disease, it may be more stable in a human line so as well as 
various continuous human cell lines, ex-vivo human airway epithelial (HAE) cells were investigated as 
a model for MuV infection. HAE cells have already been well-documented for their use in 
experimental infections of other negative-sense ssRNA viruses, and have the potential to be useful 
for investigative MuV research.  
It is currently unknown what factors or properties of a cell line make it suitable for efficient MuV 
growth and replication. Virus infection of a cell is a complex, multi-factorial process of which the 
initial step is binding of the virus to the host cell receptor. Sialic acid is known to be the receptor for 
MuV (Markwell, 1991) and exists as various analogues including α2,3 and α2,6 linked, and another 
aim of this project was to investigate whether or not the quantity or linkage type of expressed sialic 
acid on a cell’s surface is a determinant of ability to successfully propagate MuV.  
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3.1 Initial Cell Line Screen 
3.1.1 Cell Line Screen using a MuV Expressing Green Fluorescent Protein (GFP) 
GFP-MuV was used to screen a panel of cell lines in order to determine which could effectively 
support MuV infection and protein expression. Fluorescence intensity (FI), which is indicative of both 
viral protein expression and cellular infection, was measured every 24 hours for 10 days. FI levels 
were reported as FI Units and an arbitrary value of 8,000 FI Units was designated as the value for 
separating high and low levels of GFP expression. Infections were performed in triplicate and values 
recorded were background-corrected. Data is presented as high and low GFP-expressing cell lines, 
with the low group being further divided into human and non-human cell lines to aid visualisation of 
the data, and is shown in Figure 3.   
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a) High GFP-expressing cell lines (>8000 FI units) 
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b) Low GFP-expressing cell lines (human, <8000 FI units) 
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c) Low-GFP expressing cell lines (all other cells, non-human, <8000 FI) 
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Figure 3 – GFP expression levels of various cell lines infected with GFP-MuV over 10 days. Cells 
were infected with GFP-expressing MuV at an MOI of 0.01 pfu per cell in triplicate in 96-well plates. 
Fluorescence was measured every 24 hours for 10 days using the well-scan grid mode of the BMG 
FLUOStar OPTIMA plate reader. GFP expression (FI units) is separated into high (a), low – human (b) 
and low – all other cells (c) based on an arbitrary “high” value of 8000 FI units. Values displayed 
represent the mean and standard deviation of triplicate readings and are background-corrected. 
Data in blue is from cell lines of human origin, grey data from non-human primate cell lines, murine 
cell lines are shown in green and all “other” cells are shown in red.  
 
The highest recorded value was 55376 FI units on day 10 post infection of LLC-MK2 cells. The peak FI 
for the “gold standard” Vero cells was 33979 on day 5 post infection, and after this time point the 
recorded FI values reached a plateau. Several cell lines other than those shown in Figure were also 
infected with GFP-MuV however these exhibited no detectable GFP expression throughout the time 
course. Cells showing no GFP expression were MRC-5, IMR-90, 293T, RK-13, 2° Ferret Lung, Mpf, 
TM3, DBS FrhL2, BHK-21, MDCK, CHO-K1 and SH-SY5Y.  
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3.1.2 Cell Line Screen using Representative Wild-Type and Vaccine MuV’s 
The same panel of cell lines screened with GFP-MuV were infected with Mu90 (wild-type) and RIT 
4385 (vaccine) mumps viruses at an equal MOI of 0.001 pfu per cell. This was carried out in order to 
determine which cells were capable of supporting MuV growth and producing high yields of 
infectious progeny virus. At 7 days post infection, virus was harvested from cells and titrated by 
plaque assay on Vero cells in triplicate. Mock-infected controls were all valid. Mu90 and RIT 4385 
passage 1 progeny virus titres are shown in Figure 4.  
 
a) Mu90 progeny virus titres 
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b) RIT 4385 progeny virus titres 
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Figure 4 – MuV titres after 1 passage on various cells lines infected with either Mu90 (a) or RIT 
4385 (b). Cells were infected at an MOI of 0.001 pfu per cell in triplicate and virus harvested on day 7 
post infection by freeze-thawing cells and lysate clarification. P1 titres were obtained by plaque 
assay on Vero cells and values displayed represent the mean and standard deviation of triplicate 
infections. The bisecting dotted line represents the inoculum titres.  
 
The four cell lines producing the highest titres of Mu90 virus are HGT-1 (6.23 log10 pfu/mL), Vero 
(5.83 log10 pfu/mL), COS-7 (5.75 log10 pfu/mL) and CaCO2 (5.47 log10 pfu/mL). However, this is not 
entirely mirrored by the four cell lines producing the highest RIT 4385 virus titres, which are COS-7 
(5.86 log10 pfu/mL), CaCO2 (5.84 log10 pfu/mL), Vero (5.32 log10 pfu/mL) and MA-104 (4.31 log10 
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pfu/mL). Cell lines demonstrate a reduced ability to produce infectious RIT 4385 viruses when 
compared with Mu90, with the exceptions of Vero, COS-7, CaCO2, and MA-104 which all produce 
approximately the same titre for both. CEF cells produce higher titres of progeny RIT 4385 virus (6.20 
log10 pfu/mL) when compared with Mu90 progeny (4.04 log10 pfu/mL), however this was to be 
expected as CEF’s are the cells used to propagate RIT 4385 by the vaccine manufacturer (Tillieux et 
al., 2009). Although only slight, LtK- cells also demonstrate an increase in titre from Mu90 progeny 
(1.56 log10 pfu/mL) to RIT 4385 progeny (2.14 log10 pfu/mL). MRC-5, 293T, 2° Ferret lung, CHO-K1, 
DBS FrhL2 and Mpf cells did not produce any infectious Mu90 or RIT 4385 progeny virus. 
No obvious correlation between levels of GFP expression and ability to produce high yields of 
infectious progeny was observed from the data. Several high GFP-expressing cell lines produced 
relatively low titres of progeny MuV (L20B, L929, LtK- and Detroit 562), and several cell lines 
expressing lower levels of GFP produced relatively high titres of progeny MuV (HGT-1, MA-104, A549 
(BVDV) and A549 (PIV5-V)). 
The dotted lines bisecting graphs (a) and (b) in Figure 4 represent the titre of the inoculated virus 
and all cell lines producing progeny Mu90 or RIT 4385 above this threshold (3.3 log10 pfu/mL) were 
subject to further investigation. Table 11 provides a summary of these successful cells and their 
origin. Although primary CEF and Cynomolgus Macaque kidney cells produced high titres of progeny 
Mu90 virus and RIT 4385 in the case of CEFs, these cells were not studied further due to lack of 
availability.  
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Table 11 – Cell Lines Selected from Initial Screen for Further Investigation 
Cell Line Origin 
Human Non-Human Primate Murine Other 
Mu90 RIT 4385 Mu90 RIT 4385 Mu90 RIT 4385 Mu90 RIT 4385 
A549 
(BVDV) 
A549 
(PIV5-V) 
B95a COS-7   BHK-21 MDCK 
A549 
(PIV5-V) 
CaCO2 BSC-1 MA-104   JH4 Clone 
1 
 
CaCO2  COS-7 Vero   MDCK  
Hep2C  LLC-MK2      
HGT-1  MA-104      
MCF-7  Vero      
PANC-1        
RD        
 
The majority of the cells studied further were of human origin, followed by non-human primate and 
then a mixed group designated as “other” including Syrian hamster (BHK-21) guinea pig (JH4 Clone 
1) and canine (MDCK) cells. No murine cell lines were used in further investigations.  
 
3.2 Mumps Virus Serial Passage through Various Cell Lines 
Passage 1 (P1) viruses obtained from designated “successful” cell lines (section 3.2.2, Table 11) were 
passaged through the same cells a further four times, resulting in a total of five passages. Each 
passage was performed independently and in triplicate, resulting in three separate virus samples per 
passage, per cell line. Progeny viruses from P2, P3, P4 and P5 were titrated via plaque assay on Vero 
cells in triplicate and plaque morphologies at each stage examined to determine any phenotypic 
changes. Plaque assays were performed directly on each cell line using the parent Mu90 virus in 
order to determine whether or not they were able to support MuV plaque formation.  
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RNA was isolated from cell supernatants containing virus, and nucleoprotein (N), fusion (F), 
haemagglutinin-neuraminidase (HN) and small hydrophobic (SH) genes from parent Mu90 and RIT 
4385 viruses, and P5 viruses were analysed by RT-PCR, sequenced and the alignments compared in 
order to assess the genetic stability provided by each of the investigated cell lines. The specific 
primers used for each MuV gene are detailed in section 2.1.4, Table 6.  
In all cases, mock-infected and negative controls were valid.  
The following sections (3.2.1 to 3.2.17) provide a summary of the results obtained for all cell lines 
investigated.  
3.2.1 Vero 
P1 to P5 titres of Mu90 and RIT 4385 progeny viruses from Vero (African Green Monkey kidney) cells 
are shown in Figure 5. 
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Figure 5 –Titres of Mu90 and RIT 4385 progeny viruses over 5 serial passages in Vero cells. Cells 
were infected with a 1 in 50 dilution of the previous passage sample (E.g. P2 used to infect P3) 
prepared in infection medium and virus harvested on day 7 post infection by freeze-thawing cells 
and lysate clarification. Progeny virus titres were obtained by plaque assay on Vero cells and values 
displayed represent the mean and standard deviation of triplicate, independent infections. 
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Mu90 progeny virus titres from Vero cells are highest at P2 (7.3 log10 pfu/mL) before a decrease at 
P3 (5.4 log10 pfu/mL) followed by a steady increase to 6.9 log10 pfu/mL at level P5. The highest titre 
of RIT 4385 progeny virus occurs at P2 (6.2 log10 pfu/mL) and the lowest at P4 (2.0 log10 pfu/mL).  
Figure 6 demonstrates the plaque morphologies from P1 to P5 of Mu90 and RIT 4385 progeny 
viruses. 
 
a) Mu90 plaque morphologies  
 
b) RIT 4385 plaque morphologies 
 
Figure 6 – Plaque morphologies of Mu90 (a) and RIT 4385 (b) progeny viruses over 5 serial 
passages in Vero cells. Dilutions of viruses photographed for each example of morphology at each 
passage are noted below each image.   
 
Mu90 P1 plaques appear to contain a mixture of medium sized and smaller morphologies which is 
maintained throughout five serial passages. RIT 4385 P1 plaques appear larger and more 
homogeneous, however smaller plaques begin to appear in P3 and more are present by P5.  
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Results from the genetic stability studies in which N, F, HN and SH genes of parent and P5 viruses 
were sequenced and aligned are summarised in Table 12 as amino acid changes. Full nucleotide and 
amino acid alignments are detailed in appendices 1-8.  
 
Table 12 – Amino acid substitutions in P5 progeny Mu90 and RIT 4385 virus proteins from Vero 
cells  
Protein Mu90 RIT 4385 
Nucleoprotein (N) R194I N/A 
 Q199H 
 G544A  
 D545T  
 W546G  
Fusion (F) M140I I244T 
 E153K 
R381Q 
Haemagglutinin-neuraminidase (HN) T24A F15S 
 V575F V43A 
  D151E 
  F157L 
Small hydrophobic (SH) F48L N/A 
 H50R 
N/A – not applicable, no substitutions  
The number of mutations present indicates that the attenuated vaccine virus RIT 4385 is more 
genetically stable than the wild-type Mu90 virus in Vero cells.  
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3.2.2 A549 (BVDV) 
P1 to P5 titres of Mu90 progeny viruses from A549 (BVDV) (human lung carcinoma expressing the 
NPro protein of BVDV) cells are shown in Figure 7. These cells did not produce high enough titres of 
RIT 4385 progeny virus (> 3.3 log10 pfu/mL) at passage 1 to be investigated further with this MuV.  
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Figure 7 – Titres of Mu90 progeny viruses over 5 serial passages in A549 (BVDV) cells. Infection and 
titration details as per Figure 5.  
 
Mu90 virus titres increase slightly from P1 (4.48 log10 pfu/mL) to P3 (5.4 log10 pfu/mL) and then 
reach their highest titres at P5 (6.5 log10 pfu/mL).  
Figure 8 demonstrates the plaque morphologies from P1 to P5 of Mu90 progeny viruses from A549 
(BVDV) cells. 
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Figure 8 – Plaque morphologies of Mu90 progeny viruses over 5 serial passages in A549 (BVDV) 
cells. As per Figure 6.  
 
Mu90 P1 plaques appear as a homogeneous population of round, medium-sized plaques. Smaller 
plaques appear at P2 and are seen throughout until P5.  
Results from the genetic stability studies in which N, F, HN and SH genes of parent and P5 viruses 
were sequenced and aligned are summarised in Table 13 as amino acid changes. Full nucleotide and 
amino acid alignments are detailed in appendices 1-4.  
 
Table 13 – Amino acid substitutions in P5 progeny Mu90 virus proteins from A549 (BVDV) cells  
Protein Mu90 
Nucleoprotein (N) E235K 
 R241Q 
 G264R 
 Q508K 
 D509X 
Fusion (F) I28M 
Haemagglutinin-neuraminidase (HN) T24A 
 H94Y 
 L576S 
 T577N 
 R578Q 
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 L579I 
 T580D 
 I581Y 
 T582H 
 -583L (extra amino acid) 
Small hydrophobic (SH) F48L 
 H50R 
 
Amino acid substitutions were present in all four proteins investigated in these experiments. The HN 
protein contained ten substitutions, making the protein one amino acid (position 583, leucine) 
longer than that of the parent MuV. The F protein from the P5 progeny MuV was found to be 18 
amino acids shorter than that of the parental virus.  
3.2.3 A549 (PIV5-V) 
P1 to P5 titres of Mu90 and RIT 4385 progeny viruses from A549 (PIV5-V) (human lung carcinoma 
expressing V protein of PIV-5) cells are shown in Figure 9. 
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Figure 9 – Titres of Mu90 and RIT 4385 progeny viruses over 5 serial passages in A549 (PIV5-V) 
cells. Infection and titration details as per Figure 5. 
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Mu90 progeny virus titres increase from P1 (5.0 log10 pfu/mL) to P5 (7.5 log10 pfu/mL) with another 
peak at P2 (7.3 log10 pfu/mL). Titres of RIT 4385 progeny viruses increase from P1 (3.7 log10 pfu/mL) 
to P4 (7.3 log10 pfu/mL) and then decrease slightly at P5 (6.9 log10 pfu/mL).  
Figure 10 demonstrates the plaque morphologies from P1 to P5 of Mu90 and RIT 4385 progeny 
viruses. 
 
a) Mu90 plaque morphologies 
 
b) RIT 4385 plaque morphologies 
 
Figure 10 – Plaque morphologies of Mu90 (a) and RIT 4385 (b) progeny viruses over 5 serial 
passages in A549 (PIV5-V) cells. As per Figure 6.  
 
Mu90 P1 plaques appear to contain a mixture of medium sized and smaller morphologies. The 
smaller plaques begin to decrease in number from P2 and are no longer evident by P5. RIT 4385 P1 
plaques appear larger and more homogeneous, and this is maintained through the serial passages.  
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Results from the genetic stability studies in which N, F, HN and SH genes of parent and P5 viruses 
were sequenced and aligned are summarised in Table 14 as amino acid changes. Full nucleotide and 
amino acid alignments are detailed in appendices 1-8.  
 
Table 14 – Amino acid substitutions in P5 progeny Mu90 and RIT 4385 virus proteins from A549 
(PIV5-V) cells  
Protein Mu90 RIT 4385 
Nucleoprotein (N) N/A I433T 
  F451L 
  V455A 
  L457S 
  V460A 
  F468P 
Fusion (F) I536S -539Q 
Haemagglutinin-neuraminidase (HN) T24A S509N 
 H94Y V575C 
 L576S L576A 
 T577N A577S 
 R578Q R578Q 
 L579I L579I 
 T580D T580D 
 I581Y I581H 
 T582H T582H 
 -583L (extra amino acid) -583L (extra amino acid) 
Small hydrophobic (SH) F48L N/A 
 H50R  
N/A – not applicable, no substitutions  
More mutations were present in the N protein of the P5 RIT 4385 progeny virus when compared to 
Mu90. The F protein of RIT 4385 P5 has an extra amino acid (position 539, glutamine) compared with 
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the parent and both Mu90 and RIT 4385 have nine amino acid substitutions in the HN protein. Some 
of these are present in both progeny virus HN proteins (R578Q, L579I, T580D and T582H) and both 
are also one amino acid (position 583, leucine) longer than their respective parental viruses.  
3.2.4 CaCO2 
P1 to P5 titres of Mu90 and RIT 4385 progeny viruses from CaCO2 (human colorectal 
adenocarcinoma) cells are shown in Figure 11. 
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Figure 11 – Titres of Mu90 and RIT 4385 progeny viruses over 5 serial passages in CaCO2 cells. 
Infection and titration details as per Figure 5.  
 
Mu90 and RIT 4385 P1 to P5 progeny viruses from CaCO2 follow the same trend. The virus titres 
peak at P2 and then decrease from P3 to P5, with P5 titres being lower than P1. Mu90 titres range 
from a minimum of 5.3 log10 pfu/mL (P5) to 7.9 log10 pfu/mL (P2), and RIT 4385 titres from 4.3 log10 
pfu/mL (P4) to a maximum of 8.0 log10 pfu/mL (P2).  
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Figure 12 demonstrates the plaque morphologies from P1 to P5 of Mu90 and RIT 4385 progeny 
viruses. 
 
a) Mu90 plaque morphologies 
 
b) RIT 4385 plaque morphologies 
 
Figure 12 – Plaque morphologies of Mu90 (a) and RIT 4385 (b) progeny viruses over 5 serial 
passages in CaCO2 cells. As per Figure 6. 
 
Mu90 P1 plaques appear to contain a mixture of medium sized and smaller morphologies, with the 
smaller plaques becoming the more dominant size by P5. RIT 4385 P1 plaques appear medium-sized 
with less smaller plaques however as for Mu90, the small plaque morphology is more dominant by 
P5.  
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Results from the genetic stability studies in which N, F, HN and SH genes of parent and P5 viruses 
were sequenced and aligned are summarised in Table 15 as amino acid changes. Full nucleotide and 
amino acid alignments are detailed in appendices 1-8.  
 
Table 15 – Amino acid substitutions in P5 progeny Mu90 and RIT 4385 virus proteins from CaCO2 
cells  
Protein Mu90 RIT 4385 
Nucleoprotein (N) N/A F451L 
Fusion (F) R537T I244T 
Haemagglutinin-neuraminidase (HN) T24A N/A 
 H94Y  
 L576S  
 T577N  
 R578Q  
 L579I  
 T580D  
 I581Y  
 T582H  
 -583L (extra amino acid)  
Small hydrophobic (SH) Q45H N/A 
 F48L  
 H50R  
N/A – not applicable, no substitutions 
The RIT 4385 virus was relatively genetically stable when passaged through CaCO2 cells, compared 
to Mu90, with only one amino acid substitution in the N (F451L) and F (I244L) proteins. There were 
no substitutions in the HN or SH proteins. There were several substitutions in the HN protein of the 
P5 Mu90 virus, which resulted in it being one amino acid (position 583, leucine) longer than that of 
the parent.  
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3.2.5 Hep 2C 
P1 to P5 titres of Mu90 progeny viruses from Hep 2C (human cervical carcinoma) cells are shown in 
Figure 13. These cells did not produce high enough titres of RIT 4385 progeny virus (> 3.3 log10 
pfu/mL) at passage 1 to be investigated further with this MuV.  
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Figure 13 – Titres of Mu90 progeny viruses over 5 serial passages in Hep 2C cells. Infection and 
titration details as per Figure 5. 
 
Mu90 progeny virus titres from Hep 2C cells increase steadily from P1 (3.7 log10 pfu/mL) to P5 (6.2 
log10 pfu/mL).  
Figure 14 demonstrates the plaque morphologies from P1 to P5 of Mu90 progeny viruses. 
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Figure 14 – Plaque morphologies of Mu90 progeny viruses over 5 serial passages in Hep 2C cells. As 
per Figure 6.  
Mu90 P1 plaques appear to be of a small, homogeneous population with larger morphologies 
present from P2 to P5.   
Results from the genetic stability studies in which N, F, HN and SH genes of parent and P5 viruses 
were sequenced and aligned are summarised in Table 16 as amino acid changes. Full nucleotide and 
amino acid alignments are detailed in appendices 1-4.  
 
Table 16 – Amino acid substitutions in P5 progeny Mu90 virus proteins from Hep 2C cells  
Protein Mu90 
Nucleoprotein (N) N/A 
Fusion (F) N/A 
Haemagglutinin-neuraminidase (HN) T24A 
 H94Y 
 L576S 
 T577N 
 R578Q 
 L579I 
 T580D 
 I581Y 
 T582H 
 -583L (extra amino acid) 
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Small hydrophobic (SH) F48L 
 H50R 
  N/A – not applicable, no substitutions 
There were no amino acid substitutions observed in N or F proteins from Mu90 P5 progeny virus 
from Hep 2C cells, however there were a total of nine in the HN protein, resulting in it being one 
amino acid (position 583, leucine) longer than that of the parent virus.  
3.2.6 MCF-7 
P1 to P5 titres of Mu90 progeny viruses from MCF-7 (human breast carcinoma) cells are shown in 
Figure 15. These cells did not produce high enough titres of RIT 4385 progeny virus (> 3.3 log10 
pfu/mL) at P1 to be investigated further with this MuV. 
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Figure 15 – Titres of Mu90 progeny viruses over 5 serial passages in MCF-7 cells. Infection and 
titration details as per Figure 5.  
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Mu90 progeny virus titre production from MCF-7 cells maintains a steady rate over P1 to P5, with 
only little variation. For example, the lowest titre was 3.4 log10 pfu/mL (P4) and the highest 3.9 log10 
pfu/mL (P5).  
Figure 16 demonstrates the plaque morphologies from P1 to P5 of Mu90 progeny viruses. 
 
 
Figure 16 – Plaque morphologies of Mu90 progeny viruses over 5 serial passages in MCF-7 cells. As 
per Figure 6. 
 
Mu90 P1 plaques appear to contain a mixture of medium sized and smaller morphologies, with the 
smaller plaques becoming the more dominant size by P5.  
Results from the genetic stability studies in which N, F, HN and SH genes of parent and P5 viruses 
were sequenced and aligned are summarised in Table 17 as amino acid changes. Full nucleotide and 
amino acid alignments are detailed in appendices 1-4.  
Table 17 – Amino acid substitutions in P5 progeny Mu90 virus proteins from MCF-7 cells  
Protein Mu90 
Nucleoprotein (N) G264R 
Fusion (F) A3D 
 F4I 
 I221M 
Haemagglutinin-neuraminidase (HN) T24A 
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 H94Y 
 V575F 
Small hydrophobic (SH) F48L 
 H50R 
 
Amino acid substitutions were present in all four proteins investigated in these experiments.  
3.2.7 PANC-1 
P1 to P5 titres of Mu90 progeny viruses from PANC-1 (human pancreatic carcinoma) cells are shown 
in Figure 17. These cells did not produce high enough titres of RIT 4385 progeny virus (> 3.3 log10 
pfu/mL) at P1 to be investigated further with this MuV.  
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Figure 17 – Titres of Mu90 progeny viruses over 5 serial passages in PANC-1 cells. Infection and 
titration details as per Figure 5. 
 
Mu90 progeny virus was only detected by plaque assay at passage levels 1 and 3, with the virus 
titres being 3.8 log10 pfu/mL and 0.5 log10 pfu/mL respectively.   
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Figure 18 demonstrates the plaque morphologies of P1 and P3 Mu90 progeny viruses. 
 
 
Figure 18 – Plaque morphologies of Mu90 progeny viruses from P1 and P3 in PANC-1 cells. As per 
Figure 6  
 
Mu90 P1 plaques appear to contain a mixture of medium sized and smaller morphologies, with only 
small plaques present at P3.  
Due to the fact that there was only infectious progeny virus production at passages 1 and 3, no P5 
genetic stability studies were carried out using PANC-1 cells.  
3.2.8 HGT-1 
P1 to P5 titres of Mu90 progeny viruses from HGT-1 (human stomach carcinoma) cells are shown in 
Figure 19. These cells did not produce high enough titres of RIT 4385 progeny virus (> 3.3 log10 
pfu/mL) at P1 to be investigated further with this MuV. 
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Figure 19 – Titres of Mu90 progeny viruses over 5 serial passages in HGT-1 cells. Infection and 
titration details as per Figure 5. 
 
HGT-1 was the only cell line to produce higher titres of P1 progeny virus than the “gold standard” 
Vero cells. (6.0 log10 pfu/mL and 5.8 log10 pfu/mL respectively). HGT-1 Mu90 titres decrease at P3 
(5.0 log10 pfu/mL) and then increase steadily to peak at P5 (6.6 log10 pfu/mL).   
Figure 20 demonstrates the plaque morphologies from P1 to P5 of Mu90 progeny viruses. 
 
 
Figure 20 – Plaque morphologies of Mu90 progeny viruses over 5 serial passages in HGT-1 cells. As 
per Figure 6. 
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Mu90 P1 plaques appear to contain a mixture of medium sized and smaller morphologies, with the 
smaller plaques becoming the more dominant size by P5.  
Results from the genetic stability studies in which N, F, HN and SH genes of parent and P5 viruses 
were sequenced and aligned are summarised in Table 18 as amino acid changes. Full nucleotide and 
amino acid alignments are detailed in appendices 1-4.  
 
Table 18 – Amino acid substitutions in P5 progeny Mu90 virus proteins from HGT-1 cells  
Protein Mu90 
Nucleoprotein (N) N/A 
Fusion (F) R537T 
 Y538H 
Haemagglutinin-neuraminidase (HN) T24A 
Small hydrophobic (SH) F48L 
 H50R 
  N/A – not applicable, no substitutions 
No amino acid substitutions were observed in the N protein, and overall, a total of five substitutions 
were observed in the four proteins investigated. This low number indicates that the Mu90 MuV is 
relatively genetically stable under serial passage in HGT-1 cells.  
3.2.9 RD 
P1 to P5 titres of Mu90 progeny viruses from RD (human muscle rhabdomyosarcoma) cells are 
shown in Figure 21. These cells did not produce high enough titres of RIT 4385 progeny virus (> 3.3 
log10 pfu/mL) at P1 to be investigated further with this MuV. 
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Figure 21 – Titres of Mu90 progeny viruses over 5 serial passages in RD cells. Infection and titration 
details as per Figure 5. 
 
Mu90 progeny viruses from RD cells maintained steady titres throughout the serial passages, with 
the lowest recorded as 4.1 log10 pfu/mL (P2) and the highest 5.2 log10 pfu/mL (P4).  
Figure 22 demonstrates the plaque morphologies from P1 to P5 of Mu90 progeny viruses. 
 
 
Figure 22 – Plaque morphologies of Mu90 progeny viruses over 5 serial passages in RD cells. As per 
Figure 6. 
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Mu90 P1 plaques appear to contain a mixture of medium sized and smaller morphologies, with the 
smaller plaques becoming the more dominant size by P5.  
Results from the genetic stability studies in which N, F, HN and SH genes of parent and P5 viruses 
were sequenced and aligned are summarised in Table 19 as amino acid changes. Full nucleotide and 
amino acid alignments are detailed in appendices 1-4.  
 
Table 19 – Amino acid substitutions in P5 progeny Mu90 virus proteins from RD cells  
Protein Mu90 
Nucleoprotein (N) N/A 
Fusion (F) I221M 
 R537T 
Haemagglutinin-neuraminidase (HN) T24A 
 H94Y 
 N142K 
 L576S 
 T577N 
 R578Q 
 L579I 
 T580D 
 I581Y 
 T582H 
 -583L (extra amino acid) 
Small hydrophobic (SH) F48L 
 H50R 
 
Amino acid substitutions were present three out of four proteins investigated in these experiments 
with none present in the nucleoprotein. There are a total of eleven amino acid substitutions in the 
P5 Mu90 HN protein, making it one amino acid (position 583, leucine) longer than the parent.  
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3.2.10 BSC-1 
P1 to P5 titres of Mu90 progeny viruses from BSC-1 (African Green Monkey kidney) cells are shown 
in Figure 23. These cells did not produce high enough titres of RIT 4385 progeny virus (> 3.3 log10 
pfu/mL) at P1 to be investigated further with this MuV. 
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Figure 23 – Titres of Mu90 progeny viruses over 5 serial passages in BSC-1 cells. Infection and 
titration details as per Figure 5. 
 
Mu90 progeny viruses from BSC-1 cells maintained steady titres throughout the serial passages, with 
the lowest recorded as 4.2 log10 pfu/mL (P1) and the highest 5.1 log10 pfu/mL (P3).  
Figure 24 demonstrates the plaque morphologies from P1 to P5 of Mu90 progeny viruses. 
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Figure 24 – Plaque morphologies of Mu90 progeny viruses over 5 serial passages in BSC-1 cells. As 
per Figure 6. 
 
Mu90 P1 plaques appear to contain a mixture of medium sized and smaller morphologies, which is 
maintained throughout the five serial passages.  
Results from the genetic stability studies in which N, F, HN and SH genes of parent and P5 viruses 
were sequenced and aligned are summarised in Table 20 as amino acid changes. Full nucleotide and 
amino acid alignments are detailed in appendices 1-4.  
 
Table 20 – Amino acid substitutions in P5 progeny Mu90 virus proteins from BSC-1 cells  
Protein Mu90 
Nucleoprotein (N) E235K 
 G264S 
Fusion (F) I536H 
 R537Q 
 Y538V 
 -539L (extra amino acid) 
Haemagglutinin-neuraminidase (HN) T24A 
 N142K 
 L576S 
 T577N 
 R578Q 
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 L579I 
 T580D 
 I581Y 
 T582H 
 -583L (extra amino acid) 
Small hydrophobic (SH) F48L 
 H50R 
 
Amino acid substitutions were present in all four proteins investigated in these experiments. F and 
HN proteins of the P5 progeny virus were one amino acid (position 539, leucine and position 583, 
leucine, respectively) longer when compared with the parent virus.  
3.2.11 COS-7 
P1 to P5 titres of Mu90 and RIT 4385 progeny viruses from COS-7 (African Green Monkey kidney, SV-
40 transformed) cells are shown in Figure 25. 
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Figure 25 – Titres of Mu90 and RIT 4385 progeny viruses over 5 serial passages in COS-7 cells. 
Infection and titration details as per Figure 5.  
110 
 
Mu90 and RIT 4385 P1 to P5 progeny viruses from COS-7 cells follow the same trend. The virus titres 
peak at P2 and then decrease at P3, before increasing again at P5, with P5 titres being lower than P1. 
Mu90 titres range from a minimum of 4.8 log10 pfu/mL (P3) to a maximum of 7.1 log10 pfu/mL (P2), 
and RIT 4385 titres from 2.7 log10 pfu/mL (P4) to 6.4 log10 pfu/mL (P2).  
Figure 26 demonstrates the plaque morphologies from P1 to P5 of Mu90 and RIT 4385 progeny 
viruses. 
 
a) Mu90 plaque morphologies 
 
b) RIT 4385 plaque morphologies 
 
Figure 26 – Plaque morphologies of Mu90 (a) and RIT 4385 (b) progeny viruses over 5 serial 
passages in COS-7 cells. As per Figure 6.  
 
Mu90 P1 plaques appear to contain a mixture of medium sized and smaller morphologies, with the 
smaller plaques becoming the more dominant size by P5. RIT 4385 P1 plaques are medium-sized 
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with fewer small plaques evident however as for Mu90, the small plaque morphology is more 
dominant by P5.  
Results from the genetic stability studies in which N, F, HN and SH genes of parent and P5 viruses 
were sequenced and aligned are summarised in Table 21 as amino acid changes. Full nucleotide and 
amino acid alignments are detailed in appendices 1-8.  
 
Table 21 – Amino acid substitutions in P5 progeny Mu90 and RIT 4385 virus proteins from COS-7 
cells  
Protein Mu90 RIT 4385 
Nucleoprotein (N) N/A S264L 
  G265R 
  R513Q 
  E516K 
Fusion (F) Q268L I244T 
-539R (extra amino acid) 
Haemagglutinin-neuraminidase (HN) T24A N/A 
 H94Y  
 L576S  
 T577N  
 R578Q  
 L579I  
 T580D  
 I581Y  
 T582H  
 -583L (extra amino acid)  
Small hydrophobic (SH) K35N N/A 
 A42S  
 F48L  
 H50R  
N/A – not applicable, no substitutions 
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Although the F protein of P5 RIT 4385 progeny MuV is one amino acid (position 539, arginine) longer 
than the parent and there are four amino acid substitutions in the N protein, RIT 4385 appears to be 
more genetically stable during serial passage in COS-7 cells compare to Mu90. There are a total of 
nine amino acid substitutions in the P5 Mu90 HN protein, making it one amino acid (position 583, 
leucine) longer than the parent.  
3.2.12 LLC-MK2 
P1 to P5 titres of Mu90 progeny viruses from LLC-MK2 (Rhesus Monkey kidney) cells are shown in 
Figure 27. These cells did not produce high enough titres of RIT 4385 progeny virus (> 3.3 log10 
pfu/mL) at P1 to be investigated further with this MuV. 
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Figure 27 – Titres of Mu90 progeny viruses over 5 serial passages in LLC-MK2 cells. Infection and 
titration details as per Figure 5. 
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Titres of Mu90 progeny MuV from LLC-MK2 cells do not increase or decrease at a steady rate over 5 
serial passages. The lowest titres were recorded at P5 (3.4 log10 pfu/mL) and the highest at P3 (6.3 
log10 pfu/mL).  
Figure 28 demonstrates the plaque morphologies from P1 to P5 of Mu90 progeny viruses. 
 
 
Figure 28 – Plaque morphologies of Mu90 progeny viruses over 5 serial passages in LLC-MK2 cells. 
As per Figure 6.  
 
Mu90 P1 plaques appear to contain a mixture of medium sized and smaller morphologies, which is 
maintained throughout serial passage to P5.  
Results from the genetic stability studies in which N, F, HN and SH genes of parent and P5 viruses 
were sequenced and aligned are summarised in Table 22 as amino acid changes. Full nucleotide and 
amino acid alignments are detailed in appendices 1-4.  
 
Table 22 – Amino acid substitutions in P5 progeny Mu90 virus proteins from LLC-MK2 cells  
Protein Mu90 
Nucleoprotein (N) N/A 
Fusion (F) A3D 
 F4I 
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Haemagglutinin-neuraminidase (HN) T24A 
 L576S 
 T577N 
 R578Q 
 L579I 
 T580D 
 I581Y 
 T582H 
 -583L (extra amino acid) 
Small hydrophobic (SH) F48L 
 H50R 
 
Amino acid substitutions were present in three out of four proteins investigated in these 
experiments with none present in the N protein. The HN protein of the P5 progeny virus was one 
amino acid (position 583, leucine) longer when compared with the parent virus.  
3.2.13 MA-104 
P1 to P5 titres of Mu90 and RIT 4385 progeny viruses from MA-104 (foetal Rhesus Monkey kidney) 
cells are shown in Figure 29. 
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Figure 29 – Titres of Mu90 and RIT 4385 progeny viruses over 5 serial passages in MA-104 cells. 
Infection and titration details as per Figure 5. 
 
Mu90 progeny viruses from MA-104 cells increase in titre steadily from P1 (5.0 log10 pfu/mL) to P5 
(6.2 log10 pfu/mL) with a slight decrease from P3 to P4 (6.0 log10 pfu/mL and 5.9 log10 pfu/mL 
respectively). RIT 4385 progeny virus titres maintain a steady rate with a slight peak at P2 (5.0 log10 
pfu/mL) and a minimum titre of 4.5 log10 pfu/mL at P1.  
Figure 30 demonstrates the plaque morphologies from P1 to P5 of Mu90 and RIT 4385 progeny 
viruses. 
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a) Mu90 plaque morphologies  
 
b) RIT 4385 plaque morphologies 
 
Figure 30 – Plaque morphologies of Mu90 (a) and RIT 4385 (b) progeny viruses over 5 serial 
passages in MA-104 cells. As per Figure 6.  
 
Mu90 P1 plaques appear to contain a mixture of medium sized and smaller morphologies, with the 
smaller plaques becoming the more dominant size by P5. RIT 4385 P1 plaques are medium-sized 
with fewer small plaques evident however as for Mu90, the small plaque morphology is more 
dominant by P5.  
Results from the genetic stability studies in which N, F, HN and SH genes of parent and P5 viruses 
were sequenced and aligned are summarised in Table 23 as amino acid changes. Full nucleotide and 
amino acid alignments are detailed in appendices 1-8.  
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Table 23 – Amino acid substitutions in P5 progeny Mu90 and RIT 4385 virus proteins from MA-104 
cells  
Protein Mu90 RIT 4385 
Nucleoprotein (N) N/A N/A 
Fusion (F) R381Q I244T 
 C505L R537S 
 C506L Y538R 
 W507L  
 A508G  
 Y509L  
 I510V  
 A511C  
 T512N  
Haemagglutinin-neuraminidase (HN) T24A Y152C 
 L576S S553G 
 T577N I566M 
 R578Q  
 L579I  
 T580D  
 I581Y  
 T582H  
 -583L (extra amino acid)  
Small hydrophobic (SH) F48L N/A 
 H50R  
N/A – not applicable, no substitutions 
Although there are three amino acid substitutions in both the F and HN proteins of the P5 progeny 
virus from MA-104 cells, RIT 4385 appears to be more genetically stable during serial passage 
compared to Mu90. There are a total of nine amino acid substitutions in the P5 Mu90 HN protein, 
making it one amino acid (position 583, leucine) longer than the parent. There are also nine 
substitutions in the F protein and it is 26 amino acids shorter than the parent virus protein. There are 
no alterations in the N protein.  
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3.2.14 B95a 
P1 to P5 titres of Mu90 progeny viruses from B95a (Marmoset lymphoblast) cells are shown in Figure 
31. These cells did not produce high enough titres of RIT 4385 progeny virus (> 3.3 log10 pfu/mL) at 
P1 to be investigated further with this MuV. 
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Figure 31 – Titres of Mu90 progeny viruses over 5 serial passages in B95a cells. Infection and 
titration details as per Figure 5. 
 
Mu90 progeny viruses from B95a cells increase steadily in titre from P1 (4.7 log10 pfu/mL) to P5 (7.7 
log10 pfu/mL).  
Figure 32 demonstrates the plaque morphologies from P1 to P5 of Mu90 progeny viruses. 
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Figure 32 – Plaque morphologies of Mu90 progeny viruses over 5 serial passages in B95a cells. As 
per Figure 6.  
 
Mu90 P1 plaques appear to contain a mixture of medium sized and smaller morphologies, with the 
smaller plaques becoming the more dominant size from P2 to P5.  
Results from the genetic stability studies in which N, F, HN and SH genes of parent and P5 viruses 
were sequenced and aligned are summarised in Table 24 as amino acid changes. Full nucleotide and 
amino acid alignments are detailed in appendices 1-4.  
 
Table 24 – Amino acid substitutions in P5 progeny Mu90 virus proteins from B95a cells  
Protein Mu90 
Nucleoprotein (N) F481L 
Fusion (F) A3D 
 F4I 
 T7N 
 A12V 
 I18K 
 F420L 
Haemagglutinin-neuraminidase (HN) T24A 
 L576S 
 T577N 
 R578Q 
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 L579I 
 T580D 
 I581Y 
 T582H 
 -583L (extra amino acid) 
Small hydrophobic (SH) F48L 
 H50R 
 
There are a total of nine amino acid substitutions in the P5 Mu90 HN protein, making it one amino 
acid (position 583, leucine) longer than the parent. The N, F and SH proteins all contain a single 
phenylalanine (F) to leucine (L) substitution.  
3.2.15 BHK-21 
P1 to P5 titres of Mu90 progeny viruses from BHK-21 (Syrian Hamster kidney) cells are shown in 
Figure33. These cells did not produce high enough titres of RIT 4385 progeny virus (> 3.3 log10 
pfu/mL) at P1 to be investigated further with this MuV. 
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Figure 33 – Titres of Mu90 progeny viruses over 5 serial passages in BHK-21 cells. Infection and 
titration details as per Figure 5. 
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Titres of Mu90 progeny virus from BHK-21 cells are at a maximum at P1 (3.6 log10 pfu/mL) before 
decreasing at P2 (2.9 log10 pfu/mL) and then increasing to titres of 3.4 log10 pfu/mL and 3.3 log10 
pfu/mL at P4 and P5 respectively.  
Figure 34 demonstrates the plaque morphologies from P1 to P5 of Mu90 progeny viruses. 
 
 
Figure 34 – Plaque morphologies of Mu90 progeny viruses over 5 serial passages in BHK-21 cells. 
As per Figure 6.  
 
Mu90 P1 plaques appear to contain a mixture of medium sized and smaller morphologies, which is 
maintained through to P5. 
Results from the genetic stability studies in which N, F, HN and SH genes of parent and P5 viruses 
were sequenced and aligned are summarised in Table 25 as amino acid changes. Full nucleotide and 
amino acid alignments are detailed in appendices 1-4.  
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Table 25 – Amino acid substitutions in P5 progeny Mu90 virus proteins from BHK-21 cells 
Protein Mu90 
Nucleoprotein (N) G264R 
Fusion (F) N/A 
Haemagglutinin-neuraminidase (HN) T24A 
 H94Y 
 L576S 
 T577N 
 R578Q 
 L579I 
 T580D 
 I581Y 
 T582H 
 -583L (extra amino acid) 
Small hydrophobic (SH) F48L 
 H50R 
  N/A – not applicable, no substitutions 
There are a total of nine amino acid substitutions in the P5 Mu90 HN protein, making it one amino 
acid (position 583, leucine) longer than the parent. There are no substitutions in the F protein. 
3.2.16 JH4 Clone 1 
P1 to P5 titres of Mu90 progeny viruses from JH4 Clone 1 (Guinea Pig lung) cells are shown in Figure 
35. These cells did not produce high enough titres of RIT 4385 progeny virus (> 3.3 log10 pfu/mL) at 
P1 to be investigated further with this MuV. 
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Figure 35 – Titres of Mu90 progeny viruses over 5 serial passages in JH4 Clone 1 cells. Infection and 
titration details as per Figure 5. 
 
Titres of Mu90 progeny virus from JH4 Clone 1 cells increase from P1 to P2 (4.5 log10 pfu/mL) before 
decreasing at P3 (3.6 log10 pfu/mL) and then increasing to titres of 4.1 log10 pfu/mL and 4.4 log10 
pfu/mL at P4 and P5 respectively.  
Figure 36 demonstrates the plaque morphologies from P1 to P5 of Mu90 progeny viruses. 
 
 
Figure 36 – Plaque morphologies of Mu90 progeny viruses over 5 serial passages in JH4 Clone 1 
cells. As per Figure 6.  
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Mu90 P1 plaques appear to contain a mixture of medium sized and smaller morphologies, which is 
maintained through to P5. 
Results from the genetic stability studies in which N, F, HN and SH genes of parent and P5 viruses 
were sequenced and aligned are summarised in Table 26 as amino acid changes. Full nucleotide and 
amino acid alignments are detailed in appendices 1-4.  
 
Table 26 – Amino acid substitutions in P5 progeny Mu90 virus proteins from JH4 Clone 1 cells 
Protein Mu90 
Nucleoprotein (N) N/A 
Fusion (F) L535F 
Haemagglutinin-neuraminidase (HN) T24A 
 L576S 
 T577N 
 R578Q 
 L579I 
 T580D 
 I581Y 
 T582H 
 -583L (extra amino acid) 
Small hydrophobic (SH) F48L 
 H50R 
  N/A – not applicable, no substitutions   
There are a total of nine amino acid substitutions in the P5 Mu90 HN protein, making it one amino 
acid (position 583, leucine) longer than the parent.  
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3.2.17 MDCK 
P1 to P5 titres of Mu90 and RIT 4385 progeny viruses from MDCK (canine kidney) cells are shown in 
Figure 37. 
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Figure 37 – Titres of Mu90 and RIT 4385 progeny viruses over 5 serial passages in MDCK cells. 
Infection and titration details as per Figure 5. 
 
Mu90 progeny viruses from MDCK cells increase in titre steadily from P1 (3.7 log10 pfu/mL) to P5 (6.9 
log10 pfu/mL) with a slight decrease from P3 to P4 (5.3 log10 pfu/mL and 5.1 log10 pfu/mL 
respectively). RIT 4385 progeny virus titres increase a steady rate from P1 4.2 log10 pfu/mL) to P4 (7.2 
log10 pfu/mL) and then decrease to 5.1 log10 pfu/mL at P5.  
Figure 38 demonstrates the plaque morphologies from P1 to P5 of Mu90 and RIT 4385 progeny 
viruses. 
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a) Mu90 plaque morphologies 
 
b) RIT 4385 plaque morphologies 
 
Figure 38 – Plaque morphologies of Mu90 (a) and RIT 4385 (b) progeny viruses over 5 serial 
passages in MDCK cells. As per Figure 6.   
 
Mu90 P1 plaques appear to contain a mixture of medium sized and smaller morphologies, with the 
smaller plaques becoming the more dominant size by P5. RIT 4385 P1 plaques are heterogeneous 
and contain large, medium and small morphologies, however as for Mu90, the small plaque 
morphology is more dominant by P5.  
Results from the genetic stability studies in which N, F, HN and SH genes of parent and P5 viruses 
were sequenced and aligned are summarised in Table 27 as amino acid changes. Full nucleotide and 
amino acid alignments are detailed in appendices 1-8.  
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Table 27 – Amino acid substitutions in P5 progeny Mu90 and RIT 4385 virus proteins from MDCK 
cells 
Protein Mu90 RIT 4385 
Nucleoprotein (N) N/A N/A 
Fusion (F) I536L I244T 
Haemagglutinin-neuraminidase (HN) T24A N/A 
 L576S  
 T577N  
 R578Q  
 L579I  
 T580D  
 I581Y  
 T582H  
 -583L (extra amino acid)  
Small hydrophobic (SH) F48L N/A 
 H50R  
N/A – not applicable, no substitutions 
There are a total of nine amino acid substitutions in the MDCK P5 Mu90 HN protein, making it one 
amino acid (position 583, leucine) longer than the parent. No amino acid substitutions were evident 
in the N, HN and SH RIT 4385 MDCK P5 progeny virus proteins, and there was only one (I244T) in the 
F protein indicating that the virus is highly genetically stable when undergoing serial passage in 
MDCK cells.   
 
3.3 Assessment of Plaque Formation on Various Cell Lines 
 Plaque assays were performed directly on each of the “successful” cell lines (section 3.2.2, Table 11) 
using the parent Mu90 virus (MOI 0.001) in order to determine whether or not they were able to 
support MuV plaque formation. These assays were performed in triplicate in order to obtain a mean 
plaque count to determine how sensitive each cell line was. All mock-infected controls were valid.  
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From the 17 cell lines investigated, 6 were capable of supporting plaque formation. These cells were 
Vero, A549 (BVDV), A549 (PIV5-V), LtK-, L20B and LLC-MK2, and are shown in Figure 39. 
 
 
Figure 39 – Plaques formed by Mu90 on Vero, LtK-, L20B, LLC-MK2, A549 (BVDV) and A549 (PIV5-V) 
cells. Cells were infected with MuV Mu90 at an MOI of 0.001 pfu per cell in triplicate and incubated 
for 10 days before staining with methyl violet. Images are of a 1 in 100 virus dilution at day 10 post 
infection.  
  
With regards to the other cell lines included in these experiments, some did not form confluent 
monolayers (CaCO2, B95a, HGT-1, PANC-1, MCF-7, RD, and Hep 2C) and those that did form 
confluent monolayers showed no evident plaques (COS-7, MA-104, JH4 Clone 1, BHK-21, BSC-1 and 
MDCK). LtK and L20B cells demonstrated similar plaque morphology and “faded” stain appearance, 
both with smaller and more circular plaques than the Vero control, and both types of A549 cells also 
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had similar plaque morphologies to one another. The plaques exhibited by these cells are alike in 
shape to the Vero control, however smaller in size.  
 
Table 28 – Mean plaque counts from cell lines (Figure 39) 
Cell Line Mean Number of Plaques  
Vero  63 
A549 (BVDV) 40 
A549 (PIV5-V) 61 
L20B 42 
LtK- 30 
LLC-MK2 1.7 
 
From Table 28, A549 (PIV5-V) cells are the only ones to be as sensitive for plaque formation as the 
Vero control. Although still able to form plaques, A549 (BVDV), L20B and LtK- cells appear to be less 
sensitive and LLC-MK2 cells formed only 1 to 2 plaques in each of the triplicate wells. 
 
3.4 Sialic Acid Investigations  
3.4.1 Sialic Acid Bioassay  
A colorimetric bioassay technique was employed in order to quantify the relative amount of total 
sialic expressed on the cell surface of a panel of cell lines. Cells were chosen to include 
representatives from high, low and no GFP expressers, high and low titres and no infectious progeny 
virus, and human, non-human primate and other origins.  
Experiments were performed in triplicate, optical density (OD) measured at 570 nm and values 
blank-corrected. OD is directly proportional to quantity of total sialic acid in the sample (2x105 cells), 
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and the concentration in mM was calculated by linear regression analysis of the assay standard in 
GraphPad Prism® 5.0 software. Data is shown in Figure 40.  
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Figure 40 – Concentration of total sialic acid (mM) expressed on the surface of various cell lines. 
Total cell surface sialic acid was quantified using the EnzyChrom™ Sialic Acid Bioassay kit according 
to manufacturer’s instructions. The concentrations of the unknown cell lines were calculated using a 
sialic acid standard and linear regression analysis of the absorbance at 450 nm of these standards. 
Values displayed represent the mean of triplicate measurements.  
 
Vero cells contained the highest concentration of total sialic acid (1.245 mM) and MCF-7 the lowest 
(0.073 mM). There appeared to be no correlation between quantities of sialic acid and how efficient 
a cell line is at propagating MuV. For example, RK-13 cells expressed the highest amount of sialic 
acid after Vero cells (0.903 mM) however they demonstrated no GFP expression and did not 
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propagate MuV efficiently. MRC-5 cells did not produce any infectious progeny virus or express GFP 
yet they contain a similar quantity of total sialic acid (0.526 mM) to HGT-1 cells (0.458 mM), which 
generated the highest titres of infectious Mu90 virus at P1.  
3.4.2 FACS Analysis 
DIG glycan differentiation FACS analysis was performed on a panel of cell lines in order to determine 
the relative quantity of α2,3 and α2,6-linked sialic acid expressed on cell surfaces (2x105 cells per 
sample). Cells were chosen to include representatives from high, low and no GFP expressers, high 
and low titres and no infectious progeny virus, and human, non-human primate and other origins. 
DIG-labelled lectins and DIG-FITC antibodies were used for detection of α2,3 and α2,6 and 
experiments were performed in triplicate with values blank-corrected. Vero and MDCK-SIAT1 cells 
were included as experimental controls, as they have been reported to express slightly more α2,3 
sialic acid (Govorkova et al., 1996) or more α2,6 sialic acid (Matrosovich et al., 2003) respectively. 
The control data is shown in Figure 41, and Figure 42 summarises the data for the remaining cell 
lines.  
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Figure 41 – DIG-FITC expression levels for experimental control cells Vero and MDCK-SIAT1. Data 
was obtained by FACS analysis and the values displayed represent the mean and standard variation 
of triplicate measurements for each lectin.  
 
Controls were deemed to be valid as the Vero cells expressed slightly higher levels of α2,3 linked 
sialic acid (111 – α2,3 and 97 – α2,6), and MDCK-SIAT1 cells expressed higher levels of α2,6 linked 
sialic acid (α2,6 – 385 and α2,3 – 156) as expected.  
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Figure 42 – DIG-FITC expression levels demonstrating relative quantities of α2,3 and α2,6 linked 
sialic acid expressed on surface of various cell lines. Data was obtained by FACS analysis and the 
values displayed represent the mean and standard variation of triplicate measurements for each 
lectin.  
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There appeared to be no correlation between type of sialic acid expressed and how efficient a cell 
line is at propagating MuV. For example, CaCO2 and MA-104 cells both demonstrated high levels of 
GFP expression and generated high titres of progeny Mu90 and RIT 4385 viruses however, CaCO2 
express relatively more α2,3 (489) than α2,6 (47) linked sialic acid, and MA-104 express relatively 
more α2,6 (61) than α2,3 (20) linked sialic acid. No GFP expression or infectious progeny MuV was 
detected in MRC-5 and CHO-K1 cells. MRC-5 were shown to express relatively more α2,6 (55) than 
α2,3 (20) linked sialic acid, whereas CHO-K1 expressed relatively more α2,3 (3692 than α2,6 (199) 
linked sialic acid.  
3.4.3 Infection of MDCK-SIAT1 cells with MuV 
MDCK-SIAT1 cells have been reported to express increased quantities of α2,6 sialic acid with 
reduced levels of α2,3 sialic acid (Matrosovich et al., 2003) and demonstrate improved influenza 
isolation when compared with parental MDCK cells (Oh et al., 2008). MDCK-SIAT1 cells were infected 
with Mu90 or RIT 4385 viruses at an MOI of 0.001.This experiment was performed to investigate 
where or not an increased amount of α2,6 linkages has any effect on virus infection or production of 
progeny virus. MDCK and Vero cells were infected in the same way to act as controls. Virus was 
harvested from cell supernatants at 7 days post infection and titrated by plaque assay on Vero cells 
in triplicate. Mock-infected controls were valid. These data are shown in Figure 43. 
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Figure 43 – Mu90 and RIT 4385 progeny virus titres after 1 passage on Vero, MDCK and MDCK-SIAT 
cells. Cells were infected at an MOI of 0.001 pfu per cell and viruses were harvested on day 7 post 
infection by freeze-thaw of cells and lysate clarification. Titres were obtained by plaque assay on 
Vero cells in triplicate and the values displayed represent the mean and standard deviation. 
 
Infectious progeny virus was produced from MDCK-SIAT1 cells however Mu90 (0.59 log10pfu/mL) 
and RIT 4385 (2.8 log10pfu/mL) titres were significantly lower than those from parental MDCK cells 
(3.66 log10pfu/mL and 4.2 log10pfu/mL respectively). This may indicate that the increase in α2,6 and 
resultant decrease in α2,3 sialic acid linkages has a negative effect on MuV cellular infection and 
perhaps more α2,3 is required for efficient infection. 
3.4.4 Sialic Acid Blocking  
A panel of cell lines were treated with lectin from Maackia amurensis (MAA) to block α2,3 sialic acid 
residues and infected with Mu90 at an MOI of 0.001. This experiment was carried out in order to 
determine if blocking these sialic acid molecules would inhibit MuV infection. Cells were chosen that 
produced high titres of infectious progeny virus so that any differences could be easily identified. 
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Virus was harvested from cell supernatants every 24 hours post infection for 5 days and titrated by 
plaque assay on Vero cells in triplicate. Mock-infected and PBS controls were valid. These data are 
shown in Figure 44.  
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Figure 44 – Mu90 progeny virus titres from various cell lines treated with either PBS (blue) or 
lectin from MAA (red) prior to infection. Cells were incubated with either PBS or MAA lectin and 
then infected with MuV Mu90 at an MOI of 0.001 pfu per cell. Cell supernatant was harvested every 
24 hours for 5 days post infection and titrated on Vero cells in triplicate. Data displayed represent 
the mean and standard deviation.  
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Treatment of cells with lectin from MAA prior to infection does not appear to have a significant 
effect on production of infectious progeny virus when compared with the PBS treatment control. 
However, progeny virus was detected in supernatant from PBS-treated B95a cells 24 hours earlier 
than MAA-treated B95a cells. In order to confirm if this treatment of cells was an efficient blocking 
mechanism, Vero cells were treated with lectin from Sambucus nigra agglutinin (SNA) to block α2,6 
residues, and from MAA and SNA simultaneously. Data from this experiment is shown in Figure 45.  
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Figure 45 – Mu90 progeny virus titres from Vero cells treated with PBS, SNA or SNA and MAA prior 
to infection. Cells were incubated with either PBS, SNA lectin or a mixture of SNA and MAA lectins, 
and then infected with MuV Mu90 at an MOI of 0.001 pfu per cell. Cell supernatant was harvested 
every 24 hours for 5 days post infection and titrated on Vero cells in triplicate. Data displayed 
represent the mean and standard deviation.  
 
Treatment of Vero cells with only SNA or SNA plus MAA prior to infection appears to have no effect 
on production of progeny virus when compared with the PBS treatment control.  
The data from these sialic acid blocking experiments indicates that either this type of lectin blocking 
treatment does not form a tight enough block, or that MuV is capable of entry into the cell by 
another means.  
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3.5 Experimental Infection of MucilAir™ HAE with MuV 
3.5.1 Infection of HAE with Representative Wild-Type and Vaccine MuV’s 
HAE cells were infected via the apical membrane with Mu90 (wild-type) or RIT 4385 (vaccine) viruses 
at an MOI of 0.0001 pfu per cell in order to determine if these cells were capable of being infected 
with MuV and supporting MuV replication. Viruses released from apical and basal membranes were 
harvested at 6, 12, and then every 24 hours post infection for 10 days and titrated by plaque assay 
on Vero cells in triplicate. Mock-infected controls were valid. These data are demonstrated in Figure 
46. 
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a) Apically harvested viruses 
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b) Basally harvested viruses 
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Figure 46 – Titres of viruses harvested from apical (a) and basal (b) membranes of HAE cells 
infected with Mu90 or RIT 4385 over a 10 day time course. After washing mucus from cell surfaces, 
cells were infected via the apical membrane at an MOI of 0.0001 pfu per cell and samples were 
harvested from both apical and basal compartments at 6, 12 and then every 24 hours for 10 days 
post infection. Virus titres were obtained by plaque assay on Vero cells in triplicate and the data 
displayed represents the mean and standard deviation.  
142 
 
Mu90 and RIT 4385 progeny virus was detected in apical samples by plaque assay at every measured 
time point from 6 hours to 10 days post infection. Mu90 titres ranged from 3.3 log10 pfu/mL (6 
hours) to 5.2 log10 pfu/mL (24 hours). RIT 4385 titres ranged from 3.3 log10 pfu/mL (6 hours) to 5.8 
log10 pfu/mL (day 6). For both viruses, the 6 hour time point titre was equal to that of the input virus 
suggesting recovery of the inoculum and not replicating virus. Mu90 and RIT 4385 progeny virus was 
also detected in basal samples by plaque assay at every measured time point. Mu90 titres ranged 
from a minimum of 3.8 log10pfu/mL (6 hours) to 6.2 log10pfu/mL (day 8). RIT 4385 titres ranged from 
4.0 log10 pfu/mL (6 hours) to 6.24 log10 pfu/mL (day 7).  
To confirm that the plaques formed on Vero cells were caused by infectious MuV, RNA was isolated 
from Mu90 and RIT 4385 apical and basal samples from days 1 and 5 post infection and analysed by 
RT-PCR and gel electrophoresis for presence of MuV SH gene mRNA using JLSH1Fw and JLSH2Rv 
primers. Bands of expected size were generated for all apical samples examined. No RT-PCR 
products were obtained for any of the basal samples. This may indicate that what was observed on 
Vero cells from basal samples when compared to the apical viruses (Figure 47) were not viral 
plaques caused by MuV infection. Negative and positive controls included in RT-PCR were valid.  
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a)                                b)  
   
Figure 47 – Morphologies of plaques from progeny virus harvested from apical and basal surfaces 
of HAE cells infected with Mu90 (a) and RIT 4385 (b) at 7 days post infection. Dilutions of viruses 
photographed for each example of morphology of apical and basal samples are noted below each 
image.   
 
These findings indicate that HAE cells are susceptible to MuV infection and are capable of supporting 
replication and release of progeny virus via the apical membrane, but possibly not the basal cell 
membrane.    
3.5.2 Isolation of Clinical MuV Using HAE Cells 
HAE cells were infected via the apical membrane with neat clinical MuV AFZ315 in order to 
determine if these cells can be used for isolation of MuV from un-passaged clinical samples. Viruses 
were harvested from apical and basal surfaces at 6, 12 and then every 24 hours post infection for 10 
days and were titrated by plaque assay on Vero cells in triplicate. Mock infected controls were valid. 
These data are shown in Figure 48.  
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Figure 48 – Titres of clinical progeny virus AFZ315 harvested from apical or basal cell HAE 
membrane surfaces over a 10 day time course. After washing mucus from cell surfaces, cells were 
infected via the apical membrane with clinical sample AFZ315 and samples were harvested from 
both apical and basal compartments at 6, 12 and then every 24 hours for 10 days post infection. 
Virus titres were obtained by plaque assay on Vero cells in triplicate and the data displayed 
represents the mean and standard deviation.  
 
Infectious MuV from HAE cells inoculated with AFZ315 was detected in apical samples from day 5 to 
day 10 post infection with titres increasing from 3.1 log10 pfu/mL (day 5) to 5.2 log10 pfu/mL (day 10).  
Plaques were also evident on assays inoculated with basal samples from every measured time point, 
from 6 hours to 10 days post infection. Titres ranged from a minimum of 4.0 log10 pfu/mL (6 hours) 
to a maximum of 6.24 log10 pfu/mL (day 7). However, these were very small in size when compared 
to those from apical samples (Figure 49) and it was not possible to generate RT-PCR products from 
RNA isolated from any basal samples. RNA was isolated from apical samples and selected genes 
sequenced, the results of which are summarised in section 3.4.5.  
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Figure 49 – Morphologies of plaques from progeny virus harvested from apical and basal surfaces 
of HAE cells infected with AFZ315 at 7 days post infection. Dilutions of viruses photographed for 
each example of morphology of apical and basal samples are noted below each image.   
 
These results indicate that HAE cells can be used for isolation of clinical MuV directly from a patient 
sample via the apical membrane however MuV may not be released from basal cell membranes.  
3.5.3 Immunohistochemistry of HAE Cell Sections Infected with MuV 
3.5.3.1 Optimisation of Antibody Dilutions 
Prior to staining HAE cells, primary antibodies MuV anti-F protein, mouse anti-β-tubulin and their 
respective secondary antibodies Goat Anti-Rabbit IgG-FITC and Goat Anti-Mouse TEXAS RED® were 
titrated to achieve the optimal dilutions. All were diluted in either 1% (w/v) BSA/PBS A or 5% (w/v) 
non-fat dried milk/PBS A. MuV antibodies were titrated on infected LLC-MK2 cells and mouse 
antibodies on uninfected MCF-7 cells.  
After titration, MuV primary anti-F antibody was decided to be diluted 1 in 10,000 in 5% (w/v) non-
fat dried milk/PBS A and secondary antibody 1 in 200 in 1% (w/v) BSA/PBS A. Mouse anti-β-tubulin 
antibody was decided to be diluted 1 in 200 and secondary antibody 1 in 50, both in 1% (w/v) 
BSA/PBS A. These are shown in Figure 50.  
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a) MuV anti-F antibody (1°) and Goat Anti-Rabbit IgG-FITC (2°) 
 
 
b) Mouse anti-β-tubulin antibody (1°) and Goat Anti-Mouse TEXAS RED® (2°)  
 
 
 
Figure 50 – Optimal dilutions for immunofluorescence antibodies. Antibody dilutions 
selected for immunofluorescence staining of MuV F protein (a) and ciliated cell types 
(tubulin) (b). Figure (a) shows 1° and 2° antibodies diluted 1 in 10,000 and 1 in 200 
respectively on MuV infected and mock-infected LLC-MK2 cells. Figure (b) demonstrates 1° 
and 2° antibodies diluted 1 in 200 and 1 in 50 respectively. Cells stained with 2° antibody 
only is also shown here. 
2° Antibody only 
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3.5.3.2 Immunofluorescence Staining of HAE Cell Sections  
HAE cells infected with clinical MuV AFZ315 were fixed, sectioned and stained at day 7 post infection 
in order to visualise MuV protein location in infected cells. Antibodies and dilutions used were as 
described in section 3.4.3.1 and confocal images of infected and mock-infected cells are shown in 
Figure 51.  
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a) HAE cells infected with clinical MuV  b) HAE cells infected with clinical MuV 
 
 
 
c) Mock-infected HAE cells 
 
 
Figure 51 – HAE sections from day 7 post infection either infected with clinical MuV AFZ315 (a, b) 
or mock-infected (c).  Cells were fixed at day 7 post-infection after infection with neat 
clinical sample AFZ315 or MEM (mock), and histological cross-sections were prepared by 
Propath UK before staining in-house. Confocal images show MuV F protein staining is green 
and indicated by arrows, and tubulin (ciliated cells) red and is highlighted by stars.   
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The photomicrographs show the localisation of the F protein in the microvilli of apical, ciliated cells 
(Figure 51 a) and basal cells (Figure 51 b). The MuV F protein is excluded from cell nuclei and has a 
primarily cytoplasmic location. Mock-infected cells show tubulin staining of ciliated cells only (Figure 
51 c). 
3.5.4 Comparison of HAE and Vero Cells for Isolation of Clinical MuV 
HAE and Vero cells were inoculated with clinical MuV AFZ315 in triplicate under the same 
experimental conditions, and virus harvested from apical cell membranes or cell supernatant 
respectively at 6, 12 and then 24 hours for 10 days post infection. Released viruses were titrated by 
plaque assay on Vero cells and mock-infected controls were valid. This experiment was carried out 
as a direct comparison of the “gold-standard” Vero cells and the HAE model to see which, if either, 
was more efficient at isolating clinical MuV. The data are presented in Figure 52. 
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Figure 52 – Titres of clinical progeny virus AFZ315 harvested from the apical surface of HAE cells (a) 
or cell supernatant from Vero cells (b) over 10 days. Confluent monolayers of Vero cells or the 
apical surface of HAE cells were infected with clinical MuV AFZ315 in triplicate. Apical HAE samples 
and Vero cell supernatant were harvested at 6, 12 and then every 24 hours for 10 days post infection 
and virus titres were obtained by plaque assay on Vero cells. Data displayed represents the mean 
and standard deviation.  
 
Progeny MuV from HAE cells was detected in apical samples from day 5 to day 10 post infection with 
titres increasing from 3.1 log10 pfu/mL (day 5) to 5.2 log10 pfu/mL (day 10). MuV was detected in 
Vero supernatant from day 4 to day 10 post infection with infectious virus titres from 1.9 log10 
pfu/mL (day 4) to 7.0 log10 pfu/mL (day 8). These results indicate that Vero cells are capable of 
propagating and efficiently releasing clinical MuV 24 hours earlier than HAE cells and that the 
infectious titres are higher in Vero cells.  
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RNA was extracted from HAE apical and Vero supernatant virus samples harvested at 5, 6 and 7 days 
post infection and analysed by RT-PCR. Nucleoprotein, fusion, haemagglutinin-neuraminidase and 
small hydrophobic genes were sequenced and aligned with the parent virus sequences. Negative and 
positive controls included in RT-PCR were valid. This was carried out in order to assess and compare 
the genetic stability of a clinical MuV when propagated in either HAE or Vero cells.  
In viruses from HAE cells, nucleotide, and therefore amino acid sequences of N and SH genes were 
identical in all cases. Nucleotide change thymine (t) to cytosine (c) at position 1548 of the HN gene of 
days 5, 6 and 7 viruses resulted in an amino acid change from tyrosine to cysteine at position 539 
(Y539C). Nucleotide change adenine (a) to guanine (g) at position 1613 of the F gene of these viruses 
caused an amino acid change from Y to C at position 538 (Y538C). In viruses from Vero cells there 
were nucleotide, and amino acid alterations in all four genes and proteins analysed, and all of these 
mutations were identical in days 5, 6 and 7 viruses. Table 29 summarises the amino acid changes 
observed in the Vero and HAE progeny virus proteins and the full nucleotide and amino acid 
sequences are detailed in Appendices 9-16.  
Table 29 – Amino acid substitutions in N, F, HN and SH proteins of HAE and Vero AFZ315 progeny 
viruses 
Protein HAE Vero 
Nucleoprotein (N) N/A I121V 
Q450H 
M500I 
P502H 
Fusion (F) Y538C S4P 
T21I 
E61D 
S95P 
S181N 
Q329H 
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R464K 
A475S 
A489T 
I492V 
I498M 
D534V 
Haemagglutinin-neuraminidase (HN) Y539C A13T 
F69S 
T71I 
R76K 
H94Y 
S121N 
V125A 
A126S 
T130I 
S131N 
N203K 
N266D 
V287I 
I402T 
T473I 
A511T 
L538P 
S540P 
N542H 
Small hydrophobic (SH) N/A V16I 
I28V 
I29V 
L30S 
A31T 
Q39R 
G46R 
F57L 
N/A – not applicable, no substitutions 
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These results suggest that propagation of clinical MuV in Vero cells induces many mutations in the 
genome and that HAE cells produce more genetically stable progeny virus with very similar or 
identical genotypic properties to those of the parent virus.  
 
3.6 Results Summary 
A panel of human, non-human primate, murine and other cell lines were screened using a GFP-
expressing MuV and then infected with representative wild-type (Mu90) and attenuated vaccine (RIT 
4385) MuVs. Data that included levels of GFP expression and progeny virus titres after one passage 
allowed for the selection of a group of 17 (Table 11) out of a total of 41 cell lines which were 
deemed as being capable of efficiently supporting MuV growth and replication, however, GFP 
expression and virus titres from the various cell lines did not correlate (i.e. high levels of GFP 
expression did not necessarily mean high progeny virus titres in the same cell line). More cell lines 
were capable of successfully generating Mu90 progeny virus (17 cell lines) compared with RIT 4385 
(6 cell lines), and only Vero, COS-7, MA-104, CaCO2, A549 (BVDV) and MDCK cells efficiently 
propagated both wild-type and attenuated vaccine viruses.  
The highest levels of GFP expression were recorded for LLC-MK2 cells, followed by COS-7 and then 
the “gold-standard” Vero cells. HGT-1 cells produced the highest titre of wild-type MuV, with Vero 
cells producing the second highest. CEFs produced the highest titre of vaccine MuV followed by COS-
7. Parental A549 cells were not capable of propagating Mu90 or RIT 4385 MuVs, however A549 cells 
expressing the V protein of hPIV5 produced high titres of both progeny viruses and those expressing 
the NPro protein of BVDV generated high titres of Mu90.  
Analysis of P1 to P5 progeny virus titres of Mu90 and RIT 4385 MuVs showed varying trends in 
different cell lines. Some cells exhibited an increase in virus titres (A549 (BVDV), A549 (PIV5-V), Hep 
2C, MA-104, B95a and MDCK – Mu90 only) while others showed a slight decrease (Vero – RIT 4385 
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only, CaCO2, LLC-MK2, BHK-21 and MDCK – RIT 4385 only). The remaining cell lines maintained 
relatively stable MuV titres throughout P1 to P5.  
N, F, HN and SH genes of Mu90 and RIT 4385 parent MuVs and those passaged through cell lines five 
times were sequenced and compared. Nucleotide mutations resulting in amino acid changes were 
found in all four genes from P5 Mu90 viruses from all cell lines apart from A549 (PIV5-V) – N protein, 
CaCO2 - N protein, Hep 2C - N and F proteins, HGT-1 - N protein, RD – N protein, LLC-MK2 – N 
protein, MA-104 N protein, COS-7 - N protein, JH4 Clone 1 – N protein, MDCK – N protein and BHK-
21 – N and F proteins. RIT 4385 appeared to be more stable during serial passage as there were 
fewer protein amino acid substitutions. However there were still a number of nucleotide mutations 
resulting in amino acid substitutions in N, F and HN genes from the majority of P5 RIT 4385 viruses 
apart from Vero - N protein, CaCO2 - HN protein, COS-7 - HN protein, MA-104 - N protein and MDCK 
– N and HN proteins. The SH protein sequences from all P5 RIT 4385 viruses were identical to the 
parent sequence in all cell lines. In some cases, the amino acid substitutions were found to be the 
same throughout several cell lines, and these are summarised in Tables 30 and 31.  
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Table 30 – Summary of identical amino acid substitutions in P5 Mu90 MuVs from various cell lines 
 
  Cell Lines 
Protein Amino Acid 
Change 
Human Non-Human 
Primate 
Murine Other 
N R194I 
Q199H 
E235K 
R241Q 
G264R 
 
F481L 
Q508K 
D509X 
G544A 
D545T 
W546G 
 
 
A549 (BVDV) 
A549 (BVDV) 
A549 (BVDV) 
MCF-7 
 
A549 (BVDV) 
A549 (BVDV) 
Vero 
Vero 
BSC-1 
 
BSC-1 
 
B95a 
 
 
Vero 
Vero 
Vero 
N/A  
 
 
 
BHK-21 
F A3D 
 
F4I 
 
T7N 
A12V 
I18K 
I28M 
M140I 
E153K 
I221M 
 
Q268L 
R381Q 
 
F420L 
C505L 
C506L 
W507L 
A508G 
Y509L 
I510V 
A511C 
T512N 
L535F 
I536H 
I536L 
I536S 
R537Q 
R537T 
 
MCF-7 
 
MCF-7 
 
 
 
 
A549 (BVDV) 
 
 
MCF-7 
RD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HGT-1 
RD 
LLC-MK2 
B95a 
LLC-MK2 
B95a 
B95a 
B95a 
B95a 
 
Vero 
Vero 
 
 
COS-7 
Vero 
MA-104 
B95a 
MA-104 
MA-104 
MA-104 
MA-104 
MA-104 
MA-104 
MA-104 
MA-104 
 
BSC-1 
 
 
BSC-1 
 
 
N/A  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
JH4 Clone 1 
 
MDCK 
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Y538H 
 
Y538V 
-539L 
A549 (PIV5-V) 
HGT-1 
 
CaCO2 
 
 
BSC-1 
BSC-1 
HN T24A 
 
 
 
 
 
 
H94Y 
 
 
 
 
 
N142K 
V575F 
L576S 
 
 
 
 
T577N 
 
 
 
 
R578Q 
 
 
 
 
L579I 
 
 
 
 
T580D 
 
 
 
 
I581Y 
 
 
 
 
T582H 
 
A549 (BVDV) 
A549 (PIV5-V) 
CaCO2 
Hep 2C 
HGT-1 
MCF-7 
RD 
A549 (BVDV) 
A549 (PIV5-V) 
CaCO2 
Hep 2C 
MCF-7 
RD 
MCF-7 
 
A549 (BVDV) 
A549 (PIV5-V) 
CaCO2 
Hep 2C 
RD 
A549 (BVDV) 
A549 (PIV5-V) 
CaCO2 
Hep 2C 
RD 
A549 (BVDV) 
A549 (PIV5-V) 
CaCO2 
Hep 2C 
RD 
A549 (BVDV) 
A549 (PIV5-V) 
CaCO2 
Hep 2C 
RD 
A549 (BVDV) 
A549 (PIV5-V) 
CaCO2 
Hep 2C 
RD 
A549 (BVDV) 
A549 (PIV5-V) 
CaCO2 
Hep 2C 
RD 
A549 (BVDV) 
A549 (PIV5-V) 
Vero 
BSC-1 
COS-7 
LLC-MK2 
MA-104 
 
 
COS-7 
 
 
 
 
 
 
 
BSC-1 
COS-7 
LLC-MK2 
MA-1014 
 
BSC-1 
COS-7 
LLC-MK2 
MA-104 
 
BSC-1 
COS-7 
LLC-MK2 
MA-104 
 
BSC-1 
COS-7 
LLC-MK2 
MA-104 
 
BSC-1 
COS-7 
LLC-MK2 
MA-104 
 
BSC-1 
COS-7 
LLC-MK2 
MA-104 
 
BSC-1 
COS-7 
N/A BHK-21 
JH4 Clone 1 
MDCK 
 
 
 
 
BHK-21 
 
 
 
 
 
 
 
BHK-21 
JH4 Clone 1 
MDCK 
 
 
BHK-21 
JH4 Clone 1 
MDCK 
 
 
BHK-21 
JH4 Clone 1 
MDCK 
 
 
BHK-21 
JH4 Clone 1 
MDCK 
 
 
BHK-21 
JH4 Clone 1 
MDCK 
 
 
BHK-21 
JH4 Clone 1 
MDCK 
 
 
BHK-21 
JH4 Clone 1 
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-583L 
 
 
CaCO2 
Hep 2C 
RD 
A549 (BVDV) 
A549 (PIV5-V) 
CaCO2 
Hep 2C 
RD 
LLC-MK2 
MA-104 
 
BSC-1 
COS-7 
LLC-MK2 
MDCK 
 
 
BHK-21 
JH4 Clone 1 
MDCK 
SH K35N 
A42S 
Q45H 
F48L 
 
 
 
 
 
 
H50R 
 
 
CaCO2 
A549 (BVDV) 
A549 (PIV5-V) 
CaCO2 
Hep 2C 
HGT-1 
MCF-7 
RD 
A549 (BVDV) 
A549 (PIV5-V) 
CaCO2 
Hep 2C 
HGT-1 
MCF-7 
RD 
COS-7 
COS-7 
 
Vero 
BSC-1 
COS-7 
LLC-MK2 
MA-104 
 
 
Vero 
BSC-1 
COS-7 
LLC-MK2 
MA-104 
N/A  
 
 
BHK-21 
JH4 Clone 1 
MDCK 
 
 
 
 
BHK-21 
JH4 Clone 1 
MDCK 
 
N/A – not applicable 
Cell lines deficient in IFN production or insensitive to IFN highlighted in blue 
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Table 31 – Summary of identical amino acid substitutions in P5 RIT 4385 MuVs from various cell 
lines 
  Cell Lines 
Protein Amino Acid 
Change 
Human Non-Human 
Primate 
Murine Other 
N S246L 
G265R  
F451L 
 
I433T 
F451L 
V455A 
L457S 
V460A 
F468P 
R513Q 
E516K 
 
 
A549 (PIV5-V) 
CaCO2 
A549 (PIV5-V) 
A549 (PIV5-V) 
A549 (PIV5-V) 
A549 (PIV5-V) 
A549 (PIV5-V) 
A549 (PIV5-V) 
COS-7 
COS-7 
 
 
 
 
 
 
 
 
COS-7 
COS-7 
N/A N/A 
F I244T 
 
 
R537S 
Y538R 
-539Q 
-539R 
CaCO2 
 
 
 
 
A549 (PIV5-V) 
Vero 
COS-7 
MA-104 
MA-104 
MA-104 
 
COS-7 
N/A MDCK 
HN F15S 
V43A 
D151E 
Y152C 
F157L 
S509N 
S553G 
I566M 
V575C 
L576A 
A577S 
R578Q 
L579I 
T580D 
I581H 
T582H 
-583L 
 
 
 
 
 
A549 (PIV5-V) 
 
 
A549 (PIV5-V) 
A549 (PIV5-V) 
A549 (PIV5-V) 
A549 (PIV5-V) 
A549 (PIV5-V) 
A549 (PIV5-V) 
A549 (PIV5-V) 
A549 (PIV5-V) 
A549 (PIV5-V) 
Vero 
Vero 
Vero 
MA-104 
Vero 
 
MA-104 
MA-104 
N/A N/A 
SH N/A N/A N/A N/A N/A 
 
N/A – not applicable 
Cell lines deficient in IFN production or insensitive to IFN highlighted in blue 
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Only six out of the 17 cell lines subject to further investigation were capable of supporting MuV 
plaque formation. These were Vero, A549 (BVDV), A549 (PIV5-V), LLC-MK2, L20B and LtK-. A549 
(PIV5-V) cells appeared to be as sensitive for plaque formation as Vero cells.  
Sialic acid receptor studies of various cell lines using bioassay, FACS and SA-blocking lectin assay 
methodologies indicated that the concentration of total SA or relative quantities of α2,3 and α2,6 SA 
linkage expressed on the surface of a cell does not affect the ability of a cell line to support efficient 
MuV growth. The data also suggested that MuV may not exhibit a preference for type of SA when 
binding to the host cell receptor.  
Infection of HAE cultures with clinical (AFZ315), laboratory wild-type (Mu90) and attenuated vaccine 
viruses (RIT 4385) demonstrated that these types of primary cells are susceptible to MuV infection 
and that the viruses bud successfully from the apical cell surface. Smaller plaques were formed on 
Vero cells from basal HAE samples which initially suggested that the virus might also bud 
basolaterally, however no MuV RT-PCR products could be generated to confirm that the tiny plaques 
were as a result of MuV infection of the Vero cells. Direct inoculation of HAE cells with saliva taken 
from a mumps patient (AFZ315) established that these cells could also be used for isolation of MuV 
from a clinical sample. Vero and HAE cells were compared by inoculation with the same saliva 
sample and progeny viruses analysed which showed that both are capable of producing reasonably 
high progeny virus titres, with those from Vero cells being slightly higher. However, sequencing of N, 
F, HN and SH genes from parent and progeny viruses revealed that MuV from HAE is highly 
genetically similar to the parent virus, with no amino acid substitutions in N or SH genes, and only 
one substitution in the F and HN genes (Y538C and Y539C respectively), whereas Vero cell progeny 
MuV exhibited many amino acid substitutions in all four proteins examined.  
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3.7 Discussion 
3.7.1 Cell Line Screen 
One of the aims of this project was to investigate the effect of different cell substrates on MuV 
growth and replication, in order to identify cell lines which are permissive for MuV infection and can 
produce high titre progeny virus with similar genotypic and phenotypic properties to the parent virus 
in a clinical specimen. The data presented in this thesis show that propagation of MuV in Vero cells, 
which are most commonly used for growing MuV in laboratories worldwide, introduces a large 
number of mutations throughout the genome of the virus. Any other cell lines fitting the criteria 
above could therefore potentially be used as an alternative to Vero cells in diagnostic laboratories 
and would also be of use for propagating stock viruses in research laboratories.   
As GFP has been shown to be an early and sensitive indicator of cellular infection (Duprex et al., 
1999), cell lines were screened with a GFP-expressing MuV in order to identify those permissive for 
MuV infection. The results demonstrated no correlation between levels of GFP and ability to 
produce high titre progeny virus.  This could potentially be due to the rate at which new viruses are 
being assembled and released from the host cell. Expression of GFP is not only indicative of cellular 
infection but also viral protein expression, therefore it may be the case that cell lines exhibiting high 
GFP expression but low or no infectious progeny virus (e.g. L929 and L20B) express a large quantity 
of viral proteins but very few virus particles are fully assembled and released from the host cells. 
These types of abortive infection have already been described for MuV in cell lines of murine origin 
(Tsurudome et al., 1984; Yamada et al., 1984). The reverse may then be true of cell lines exhibiting 
low GFP expression but high titres of progeny virus (e.g. HGT-1 and A549 (PIV5-V)). New MuV 
particles could be fully assembled and released from host cells at a quicker rate, therefore it would 
be more difficult to visualise and measure an accumulation of viral proteins.  
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The data show a significant difference in the ability of cell lines to produce infectious progeny Mu90 
and RIT 4385 viruses, suggesting profound differences between the attenuated MuV vaccine and 
representative wild-type virus. All of the cell lines included in this study demonstrated a decreased 
ability to produce infectious progeny RIT 4385 virus compared to Mu90 and fewer numbers and 
types of cell lines were capable of supporting efficient RIT 4385 growth. This can be explained in part 
by the fact that RIT 4385 has been attenuated by serial passage in tissue culture which means that 
the virus will be less likely to exhibit cytopathic effects and may have restricted or selective cell line 
tropisms. An exception to this was observed in the CEF cells which produced a higher titre of 
progeny RIT 4385 virus than Mu90. This result was expected due to the Jeryl-Lynn mumps strain 
used in the GSK vaccine being developed by attenuation through passage in embryonated hen eggs 
(Buynak & Hilleman, 1966). If CEF cells had been more freely available during this project, it would 
have been of great interest to have serially passaged both Mu90 and RIT 4385 MuVs through these 
cells to examine progeny virus titres, plaque morphologies and genetic stability. The mechanisms of 
MuV attenuation to produce vaccine strains are currently unknown.  
Three general trends were observed with regards to the P1 to P5 progeny virus titres, which were 
increase, decrease or maintaining a relatively steady titre throughout. Viral fitness can be defined as 
the ability of a virus to reproduce itself, so to replicate and efficiently generate progeny viruses. MuV 
can be considered to show an increase in fitness in those cell lines that demonstrate an increase in 
MuV titre from P1 to P5, and this could be caused by the virus adapting to the cell substrate under 
the selective pressures that will be exerted by different host cells. A decrease in progeny virus titres 
from P1 to P5 may be due to the presence of DI particles. Although the initial MOI (0.003) for 
producing P1 Mu90 and RIT 4385 viruses was low, the MOIs for the passages that followed may have 
been too high, as a standard dilution of 1 in 50 was employed (section 2.3.3). This could have 
resulted in the formation of DI particles due to the Von Magnus phenomenon (Von Magnus, 1954), 
which in turn would have caused further induction of RIG-I leading to increased anti-viral IFN 
signalling and therefore reduced titres of infectious progeny virus. If a cell line is capable of 
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maintaining steady virus titres through to P5, MuV may not require adaptation and so genetic 
stability would be more likely to be maintained also.   
N, F, HN and SH genes from passage level five viruses from various cell lines were sequenced and 
compared to the parental MuV sequences in order to assess the genetic stability of the virus upon 
serial passage. It was hypothesised that as MuV is a solely human virus it may be more genetically 
stable in cell lines of human origin. It is true that the cell lines producing the lowest numbers of 
mutations in Mu90 progeny are human (HGT-1, MCF-7 and Hep 2C), however some human cell lines 
also generated progeny viruses with a large quantity of amino acid mutations (A549 (BVDV) and RD) 
and RIT 4385 progeny virus from A549 (PIV5-V) cells also had many alterations present. All of the 
non-human primate cell lines investigated produced P5 progeny Mu90 viruses with a relatively high 
number of amino acid alterations, and cells of hamster, guinea pig and canine origin were similar to 
Vero which may indicate that overall, human cell lines are better are retaining wild-type MuV 
genetic stability but there will be exceptions to this and it will vary between cell types. MuV may not 
have required as extensive adaptation in HGT-1, MCF-7 and Hep 2C host cell environments, 
therefore keeping any mutations to a minimum. With respect to the numbers of amino acid 
alterations, RIT 4385 appears to be more stable during serial passage which may be because the 
virus is attenuated having become adapted to tissue culture through extensive serial passage during 
vaccine strain development.  
The P5 progeny viruses from twelve out of seventeen cell lines showed an altered C-terminus amino 
acid sequence in the HN protein resulting in it being one residue longer than that of the parent virus. 
This group of cell lines were of human, non-human primate, guinea pig and canine origin so it 
appears these mutations are not specific to a certain host or cell type. The addition of an extra 
amino acid in all of these cell lines is likely to be due to the insertion of a nucleotide (thymine) at 
gene position 1725 (appendix III, page 300). Although this insertion is present in all seventeen cell 
lines, those not exhibiting the altered C-terminus amino acid sequence (MCF-7, HGT-1 and Vero) had 
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a nucleotide deletion at position 1716 (appendix III, page 300) which may have compensated for the 
thymine insertion. The additional residue was leucine (L), whereas the terminal HN parental virus 
protein is Threonine (T). With regards to the properties of these amino acids, L is hydrophobic and T 
has a hydrophilic-neutral charge, therefore the addition of an extra residue and the differences in 
biochemical properties may have an effect on the folding or conformation of the protein. Carboxyl 
methylation can occur on C-terminal L residues resulting in alterations to protein-protein 
interactions and/or protein function. T residues are also subject to post-translational modifications. 
If this happened it could cause problems for the virus binding to the host cell or for initiating fusion 
activity of the F protein which would affect the infection process. On the other hand the observed 
changes may be due to adaptation to the host cell and give the virus an advantage. The insertion of 
one nucleotide does suggest that the progeny P5 Mu90 MuV from these twelve cell lines no longer 
complies with the rule of six however this may have been compensated for in one of the other genes 
not sequenced in this project. It has not been possible to associate this HN protein alteration with 
viral fitness and/or plaque phenotype as no clear trend has emerged. These twelve cell lines are a 
group which demonstrate increase and decreases in progeny virus titre through P1 to P5, some show 
alterations in plaque morphology where others maintain the same plaque phenotype.  
A similar amino acid addition was observed in the F protein of P5 Mu90 progeny virus from BSC-1 
cells. One L residue was added on, making the terminal residue L instead of tyrosine (Y), which has 
similar properties to threonine. This extra amino acid was likely to be caused by the insertion of an 
extra nucleotide (cytosine) at position 1603 (appendix II, page 274). The addition of the L residue 
appears not to have had an effect on viral fitness (Figure 23) or plaque phenotype (Figure 24) 
therefore may have not had a detrimental effect on the virus. The insertion of one nucleotide does 
suggest that the Mu90 MuV from BSC-1 cells no longer complies with the rule of six however this 
may have been compensated for in one of the other genes not sequenced in this project.  
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The F proteins of Mu90 P5 progeny virus from A549 (BVDV) and MA-104 cells were shorter than the 
parental F protein by 18 and 26 amino acids respectively. This observed alteration in the A549 
(BVDV) viruses may be as a result of mutations at the nucleotide level, specifically, a thymine 
insertion at gene position 1561 (appendix II, page 273) and two deletions at positions 1574 and 1584 
(appendix II, page 274). The shortened F protein amino acid sequence in Mu90 MuV from MA-104 
cells is likely to be due to a nucleotide substitution at positions 1539 (appendix II, page 273) which 
results in a stop codon (TAA). Mutations such as these have the potential to affect protein folding, 
binding and protein-protein interactions and in the case of the F protein could affect virus-cell and 
cell-cell membrane fusion. Mu90 MuV in A549 (BVDV) cells demonstrates an increase in virus titre by 
P5 and there is no significant change in plaque phenotype, therefore this protein mutation may be 
providing the virus with a replicative or infective advantage. The Mu90 progeny virus from MA-104 
cells also increases in titre and therefore viral fitness, however a small plaque phenotype becomes 
more dominant by P5 which may be as a result of the shortened F protein amino acid sequence.  
Another interesting mutation observed in progeny Mu90 from the twelve cell lines exhibiting the 
altered C-terminal HN amino acid sequence was an L to serine (S) substitution at position 576. This 
could potentially be the introduction of a site for serine protease activity which causes protein 
cleavage. A T to asparagine (N) substitution at position 24 of the Mu90 P5 HN protein was present in 
progeny viruses from all cell lines indicating that this mutation may be specific to Mu90 virus during 
passage and not caused by a certain cell line or type.  
Phenylalanine (F) to L and isoleucine (I) to T substitutions were observed in the SH protein from 
Mu90 progeny viruses from all cell lines also. These amino acids have similar biochemical properties 
to one another and are likely to substitute for one another therefore it is possible the change had a 
minimal effect on structure and function of the proteins. The other amino acid substitutions that 
were present throughout the Mu90 and RIT 4385 progeny viruses appear to be unrelated and may 
be of a spurious relationship.  
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It has been reported many times that RNA viruses exist as quasispecies which have been defined as a 
population of the same viruses consisting of a so-called “master sequence” with a collection of 
mutant versions (Ruiz-Jarabo et al., 2000). These quasispecies are thought to be formed as a result 
of the high mutation rates of RNA viruses brought about by internal replication errors and their fast 
growth kinetics, which is reviewed in (Lauring & Andino, 2010). In theory if a virus population exists 
like this, then it would be possible for certain variants to be selected by the host cell environment 
over others, and this would result in this selected variant being the more predominant one through 
passage. It may be that this was not the case in the P5 viruses sequenced in the experiments in this 
project as analysis of the nucleotide sequences showed the traces were “clean” and did not consist 
of more than one peak. However, variant selection may have taken place before P5 and it would 
have been of interest to sequence the N, F, HN and SH genes at P2, P3 and P4.  
If time had permitted it would have been useful to have sequenced the remainder of the genome of 
the progeny Mu90 and RIT 4385 viruses to assess any nucleotide and amino acid mutations being 
introduced by serial passage through cell culture in the V/P/I, M and L proteins.  
Plaque assays were carried out on designated “successful” cell lines (Table 11), using Mu90 as the 
inocula. Interestingly, all of the cells capable of supporting MuV plaque formation apart from LLC-
MK2 are known to be deficient in an aspect of interferon production. Vero cells are well-known for 
this trait (Desmyter et al., 1968) (Emeny & Morgan, 1979). A549 (PIV5-V) cells constitutively express 
the V protein of hPIV5, and A549 (BVDV) cells constitutively express the NPro protein of BVDV. The 
hPIV5 V protein has been demonstrated to inhibit production of IL-6 (Lin et al., 2007),  and to inhibit 
interferon signalling by targeting STAT-1 for proteosome-mediated degradation (Didcock et al., 
1999), whilst the BVDV NPro protein inhibits DNA binding by IRF-3 and targets this factor for 
degradation (Hilton et al., 2006). LtK- cells have been reported not to induce an IFN response when 
treated with IFN-α (Mengheri et al., 1983) and IFN-β (Shan & Lewis, 1989) which suggests that these 
cells are deficient somehow in interferon production. L20B cells are derived  from LtK- (Mendelsohn 
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et al., 1989) so would be assumed to have this same characteristic. Although murine cells did 
support plaque formation, a smaller number of plaques were formed (42 and 30 respectively) 
compared to Vero cells (63), which could also indicate abortive infection. These data suggest that 
the ability of a cell line to support efficient MuV plaque formation is dependent upon whether or not 
the cells are able to produce IFN. This is in line with data observed for Foot-and-Mouth Disease virus 
plaque formation, which has also been reported to be dependent upon IFN suppression in cell 
cultures (Chinsangaram et al., 1999) as has vaccinia virus plaque formation (Gifford et al., 1963).  
Despite the high GFP expression levels and reasonably high titres of progeny virus production, LLC-
MK2 cells did not support plaque formation as efficiently as the other five cell lines and only 1 to 2 
plaques were evident in each of the triplicate wells. When observed microscopically using bright 
field, CPE can be seen in cultures of LLC-MK2 cells from 72 hours post infection as syncytia 
formation. However, over the seven days after the onset of CPE, no cell lysis is observed and the cell 
monolayer remains intact. This could potentially be due to the action of the SH protein which has 
recently been demonstrated to play a major role in preventing apoptosis of the host cells by 
targeting ataxin-1 ubiquitin-like interacting protein 4 (Woznik et al., 2010). It could also be as a result 
of the cells growing faster than the virus.  A549 (PIV5-V) were the only cells to be as sensitive for 
plaque formation as the Vero control, and both formed plaques of a similar morphology although 
those on A549 (PIV5-V) were smaller in size. A549 (BVDV) cells also produced plaques of a similar 
morphology to this although the cells appeared to be less sensitive. These cells also gave slightly 
different results with regards to GFP expression and progeny virus titres, with the PIV5-V cells 
expressing lower levels of GFP but producing slightly higher titres of progeny RIT 4385 and Mu90 
viruses when compared with the BVDV cells. The differences do not appear to be statistically 
significant, but they are noticeable from the data. 
Both of these cell lines have been genetically engineered to be insensitive to interferon (Young et al., 
2003) using A549 as the parent cell line. A549 cells were included in the experiments to act as a 
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control for the IFN-sensitive cells, and did not show any evidence of GFP expression or CPE and 
produced significantly lower titres of progeny virus than the genetically engineered cells. The 
differences in results may be due to the activities of the V and NPro proteins, for instance does one 
exert a stronger anti-viral effect than the other, or the levels of protein expression. This method of 
engineering cells has also been successfully carried out to allow increased viral replication in MRC-5 
and Hep2 cells (Young et al., 2003), and there is potential for these techniques to be used on other 
candidate cell lines, for example, engineering a cell line that produced no infectious MuV and 
demonstrated no GFP expression such as Mpf (ferret brain) to constitutively express an accessory 
protein known to interfere with the host cell IFN response. The data obtained from infection of the 
three A549 cell lines with GFP-MuV, Mu90 and RIT 4385 have demonstrated how important the anti-
viral response of a host cell is and that interfering with this response at a constant rate as in the 
genetically engineered cells, makes a cell line more permissive for MuV infection and replication.  
From the data obtained in these in vitro studies, A549 (PIV5-V) cells could be used as an alternative 
cell line to Vero’s for assessing plaque formation and morphology. It may be that there is not just 
one cell line suitable for all aspects of MuV propagation, but a few cell lines, which can be of value 
depending upon the purpose they are to be used for. For example, LLC-MK2 cells could be used for 
expressing large quantities of viral proteins, whereas HGT-1 cells could be used for producing high 
titres of wild-type or clinical progeny MuV. The data also suggests that cell lines of human origin 
maintain MuV genetic stability better than non-human primate cells, and that Hep 2C, HGT-1 and 
MCF-7 cells proved most successful in these experiments. One of these cell lines could be used as an 
alternative to Vero cells for propagating MuV stocks and if samples had been readily available, it 
would have been very interesting to find out how successful these cells are at isolating MuV from 
clinical patient samples.  
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3.7.2 Sialic Acid Studies 
The molecular reasons for a cell line being able to support successful MuV growth and replication 
are unclear. Virus infection of a host cell is a complex, multifactoral process and there are 
undoubtedly many elements involved. One aim of this project was to assess whether or not 
concentration of total sialic acid or type of linkage (α2,3 or α2,6) was one of these molecular 
determinants.  
The results from the sialic acid quantification bioassay suggested that concentration of total SA 
expressed (mM) does not correlate with how efficient a cell line is at propagating MuV, therefore it 
was hypothesised that the type of SA linkage present on a cells surface may be a factor involved in 
successful MuV infection and perhaps the virus demonstrates a preference for either α2,3 or α2, 6 
moieties. Receptor-binding SA preferences are well-characterised in human and avian influenza 
viruses. It has been shown that Adenovirus Type 37 binds preferentially to α2,3 SA (Arnberg et al., 
2000) and polyoma virus JC binds to both types of SA linkage (Dugan et al., 2008). In this thesis, DIG 
glycan differentiation FACS analysis was performed on a panel of 15 cell lines, including two controls 
(Vero and MDCK-SIAT1) and the results indicate that the type of SA linkage expressed on a cell 
surface does also not correlate with the success of a cell line at supporting MuV growth.  
Infection of MDCK-SIAT1 cells expressing increased α2,6 and reduced α2,3 moieties (Matrosovich et 
al., 2003) with Mu90 and RIT 4385 produced lower titres of progeny virus compared with parental 
MDCK cells expressing an approximately equal amount of both SA types (Matrosovich et al., 2003). 
This suggested that a lower amount of available α2,3 SA has a negative effect on the MuV host cell 
infection and/or replication process, which may indicate a preference for α2,3 SA despite the 
bioassay and FACS data. Treatment of various cell lines with lectin from MAA to block α2,3 residues 
did not significantly decrease progeny MuV titres or the time point at which MuV was released from 
the host cells when compared with PBS-treated cells, and the results were the same when cells were 
blocked with lectin from SNA to block α2,6 residues or with a mixture of both. There are several 
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potential explanations for the observed results from the blocking assays. The bonds formed between 
the lectins and SA molecules may not have been a tight enough “block” and the receptors may still 
have been exposed in some way for the MuVs to bind. If the lectin block had been effective, the 
virus possibly entered the cell by using another receptor molecule although this is unlikely due to the 
fact that treating cells with sialidase protects the cell from MuV infection (Markwell, 1991) and the 
HN glycoprotein possesses neuraminidase activity which specifically acts by cleaving sialic acid as 
part of the virus life cycle. SA also exists as an α2,8 analogue and if MuV binds non-preferentially to 
SA molecules then the virus may have entered the cell via α2,8 residues when α2,3 and α2,6 were 
blocked by the lectins. It would have been useful to treat several continuous cell lines and HAE 
cultures with a neuraminidase to confirm that the destruction of SA residues completely prevents 
MuV infection. If time had permitted, the Biacore (GE Healthcare) surface plasmon resonance (SPR) 
facility which is newly available at NIBSC could have been employed as a means of studying the 
molecular interaction between the different types of SA receptor residue and the HN glycoprotein. 
SPR operates on the basis of measuring changes in the refractive index of optical waves extremely 
close to a sensor surface, which is normally the protein or ligand of interest (E.g. MuV HN) 
immobilised on a chip.  The other molecule of interest (E.g. sialic acid-containing compounds) is 
passed over the chip in solution and the binding and release of the compounds changes the 
refractive index, therefore the kinetics of binding can be measure to a highly precise level (reviewed 
in (McDonnell, 2001)). SPR has previously been used successfully for identification of a panel of 
human glycoproteins using lectins (Safina et al., 2011) and the Biacore system has recently been 
applied to analysing the binding kinetics of RNA aptamers to the haemagglutinin protein of influenza 
virus (Misono & Kumar, 2005). This technique would provide new and interesting data on MuV 
receptor binding.  
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3.7.3 Investigation of HAE Cells  
HAE cells have been used to generate data on – ssRNA viruses however have not been previously 
used to investigate MuV infection. RIT4385, Mu90 and clinical AFZ315 MuVs were used to 
demonstrate that HAE cells are susceptible to MuV infection and are capable of effectively 
propagating clinical, laboratory wild-type strain, and attenuated vaccine MuVs, as well as being able 
to isolate the virus directly from a clinical sample. The delay in clinical virus replication and/or 
release when compared with Mu90 and RIT 4385 may be due to the fact that the latter two viruses 
have both become adapted to in vitro cell systems whereas the clinical isolate came from a patient 
and required a certain adaptation period to the cell culture environment. The titre of the virus in the 
saliva could also have been of an extremely low titre and therefore a much lower MOI. This is a 
common problem when attempting to isolate MuV in a diagnostic setting.  
In stained sections of infected HAE cells, the F protein was shown to be located in both apical and 
basal cells, but appears to be more prominent in the basal cell section. As the presence of a protein 
does not automatically infer viral replication, the clinical MuV may have a greater affinity for 
replication in basal cell types or it may be visualised in this area as a result of virus ‘leaking’ from 
apical cells caused by the breakdown of tight junctions. As a means of confirming if this was a factor 
in the accumulation of MuV in basal cells, the HAE sections could have been counter-stained with an 
antibody against the tight junction protein zonula occludens (ZO)-1 (Stevenson et al., 1986). If the 
virus was replicating efficiently in the basolateral cells, it would be expected that MuV would be 
released from these cells into the basal medium otherwise the progeny viruses may need to traverse 
back up to the apical cells to be released. When the basal medium was titrated on Vero cells, tiny 
plaques were observed from samples at every time point from 6 hours to 10 days post infection. 
MuV typically takes on average 48 to 72 hours to start showing signs of CPE in tissue culture 
therefore it was a surprise to find evidence of infectious progeny virus at such early time points. No 
MuV RNA was detected by RT-PCR in any of the basal samples therefore it is possible that the small 
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plaques observed were not caused by the virus. They may have been artefactual plaques caused by a 
molecule(s) that was being secreted by the HAE cells in response to infection. Another possibility is 
that there were inhibitory compounds present in the basal medium that exerted their effect during 
RNA isolation or RT-PCR, and the tiny plaques were indeed caused by MuV. The small plaque 
phenotype could be due to the effect of cytokines or IFNs being secreted by the cell which would be 
present in the sample upon inoculation onto Vero cells. Although these cells are known not to be 
capable of producing IFN (Emeny & Morgan, 1979), they can be treated with IFN. Vero cells treated 
with IFN have previously been demonstrated to have an inhibitory effect on Herpes Simplex Virus 
(HSV)-2 plaque formation (Petrera & Coto, 2006). To investigate this further, the HAE basal samples 
from various time points could have been inoculated onto Vero or other cell cultures and observed 
for formation of MuV CPE.  
Ciliated cells are known to express more α-2,3 than α-2,6-linked sialic acid, whereas non-ciliated 
cells express a higher quantity of α-2,6-linked sialic acid molecules (Thompson et al., 2006). The 
images do not conclusively indicate that MuV is capable of infecting both ciliated and non-ciliated 
cells, and further studies of this type at earlier time points with different MuVs would be useful to 
validate the sialic acid assay results obtained in this project which indicate that MuV does not exhibit 
a preference for one type over the other.  
It has recently been suggested that Vero cells may produce viruses with altered gene sequences that 
are unsuitable for research purposes (Afzal et al., 2005), however this had not yet been established. 
MuV titres from Vero cells were higher than those from HAE cells, but this was at a price. The data in 
these experiments has shown that propagating a clinical MuV in Vero cells results in mutations of 
varying severity in at least four (N, F, HN and SH) out of seven MuV genes, indicating that Vero cells 
should not be used for growth of clinical isolates that will be used for research.  In contrast, HAE cells 
produce more genetically stable progeny virus with very similar or identical genotypic properties to 
those of the parent virus, albeit with infectious progeny viruses detected 24 hours later and with 
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slightly lower infectious titres. Nucleotide substitutions at positions 1548 and 1613 of the progeny 
virus HN and F genes respectively both resulted in tyrosine to cysteine amino acid residue 
alterations. Both have polar, uncharged side chains and due to their similar biochemical properties, 
are likely to substitute for each other in a situation where mutations may arise.  
Due to the similarities between tyrosine and cysteine, the mutations seen in the day 5, 6 and 7 
progeny virus HN and F proteins may be ineffectual to protein function and structure. The MuV HN 
envelope glycoprotein is responsible for binding to the cellular sialic acid receptor and therefore 
plays a major role in infection. The N terminus contains a hydrophobic sequence of 19 amino acids 
responsible for the anchoring of the protein in the virus envelope (Waxham et al., 1988) and 
potential glycosylation sites of the HN protein have also been identified (Kovamees et al., 1989).  
Amino acid change S466D was shown to reduce receptor binding affinity and neuraminidase activity 
in a wild-type MuV (Malik et al., 2007) and amino acid change E335K in the HN protein has also been 
demonstrated to alter receptor binding specificity of the Urabe strain of MuV (Reyes-Leyva et al., 
2007). The Y539C substitution was not located in the vicinity of or upstream of any known significant 
sites. The F envelope glycoprotein of MuV drives virus to cell and cell to cell fusion, resulting in entry 
of viral genomic information into the host cell which are essential activities for virus spread. A 
protease-dependent cleavage site is known to be located between amino acids 102 and 103, with a 
membrane anchor region of 30 hydrophobic residues in the C terminus (Waxham et al., 1987). A 
leucine residue at position 383 of a wild-type MuV was shown to confer fusogenicity in B95a cells 
(Yoshida & Nakayama, 2010), and this amino acid is present in the parent and progeny clinical 
viruses from this study. The Y538 mutation identified in the F protein is not located in any of the 
known regions significant for function.   
In conclusion, the in vitro MucilAir™ HAE cell model is capable of efficient propagation of both wild-
type and vaccine mumps viruses. These cells can be used for direct MuV isolation from a clinical 
sample, producing high titre progeny virus with highly similar genotypic properties to that of the 
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parent titre when compared with “gold standard” Vero cells. If time had permitted, it would have 
been of value to have sequenced the entire genome of the parent AFZ315 and HAE progeny viruses 
in order to determine if there were any significant amino acid alterations in any of the other viral 
proteins not included in these experiments (V/P/I, M and L). It would have been of interest to infect 
these cells with a large panel of MuVs representing different genotypes, phenotypes and also to 
determine if HAE cells are capable of isolating clinical MuV from different types of patient samples 
(E.g. urine or nose/throat swabs) in order to further confirm and elaborate on the data obtained in 
this PhD project. The data demonstrate for the first time that growth of MuV in Vero cells results in 
mutations in genes important in virus transcription, entry and spread, and these mutations are 
introduced not only through serial passage but also during persistent replication in a single culture. 
HAE cells have a potential to be a very valuable tool for diagnostic and mumps research laboratories.  
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CHAPTER 4 – IN VIVO RESULTS 
There is currently no animal model for mumps virus, and one of the aims of this project was to 
assess ferrets as an in vivo model for experimental MuV infection. 
Ferrets have been used effectively as an animal model for many pathogenic organisms including 
strains of Campylobacter (Bell & Manning, 1990) and Helicobacter (Fox et al., 1990) bacteria, and the 
viruses SARS (Martina et al., 2003) and CDV as model for human Measles virus (Pillet et al., 2009). 
The ferret may be best known within the field of virology for its use as an experimental model for 
influenza infection, pathogenesis and transmission, which is reviewed in (Maher & DeStefano, 2004). 
Influenza and MuV are both negative-sense ssRNA viruses and share other biological properties such 
as the use of sialic acid-containing molecules as a cellular receptor, and both contain proteins with 
haemagglutinin and neuraminidase activities. The respiratory tract of the ferret is known to present  
cells with similar sialic acid patterns as that of the human respiratory tract (van Riel et al., 2007), and 
this has recently been extensively characterised using multiplex staining with various plant lectins 
and human adapted influenza haemagglutinins (Jayaraman et al., 2012). These data indicate that 
ferrets may be a suitable model for mumps virus.  
Four separate ferret studies were carried out in this project, using male animals in all experiments.  
The initial study designated A was performed with clinical and vaccine strains of MuV over 28 days to 
assess clinical signs of infection, virus shedding in nasal washes, urine and faeces, production of 
neutralising antibodies and ability to recover virus from tissues on day 28 post infection. The second 
study designated B was carried out in order to investigate whether or not the antibodies produced 
by ferrets in A were specific to MuV, by using a heat-inactivated vaccine virus. The purpose of the 
study designated C, was to investigate virus shedding in oral fluid, cytokine mRNA levels in PBMCs 
and ability to recover virus from tissues at days 1, 4, 7 and 14 post infection with the same clinical 
virus used in study A. The final in vivo study designated D, was carried out in order to assess whether 
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or not a higher titre of inoculum virus would increase the likelihood of virus recovery from tissues at 
days 4 and 7 post infection.  
 
4.1 Ferret Study A 
4.1.1 Clinical Signs of Infection 
Two groups of 3 male ferrets (designated 1, 2 and 3) were inoculated intranasally with either clinical 
mumps sample AFZ315 or RIT 4385 vaccine strain mumps virus (designated 4, 5 and 6). For 28 days 
post infection, body weight, temperature, testes width and depth, and parotid swelling around the 
head and from ear to ear were measured and values recorded. Figure 53 provides a summary of 
Study A.  
 
 
Figure 53 – Ferret study A summary. Clinical observations made and samples collected from ferrets 
inoculated with either clinical or attenuated vaccine MuV over a 28 day period. 
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 Clinical data are presented in Figure 54. No significant increases or decreases in body weight or 
temperature were recorded for any of the ferrets. The recorded increase in testes width and depth 
was due to the fact that the ferrets were at an age associated with reaching sexual maturity and the 
testes were growing in size, however, it was noted by NIBSC BSD staff that on day 4 post infection 
the testes of ferret 3 were noticeably redder. Testes width and depth could not be measured on 
ferrets 1 and 2 as no testes were visible on these 2 males. The recorded increases in parotid swelling 
of all ferrets at various time points throughout the study were also due to growth of the ferrets. No 
changes in behaviour were noticed in any of ferrets 1 to 6 and the animals appeared healthy, and 
with no loss of appetite for the entire 28 days of the study.  
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a) Ferrets 1-3, clinical mumps virus 
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b) Ferrets 4-6, vaccine mumps virus 
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Figure 54 – Ferret Study A Clinical Symptoms Observations. Body weight, temperature, size of 
testes and parotid swelling of animals inoculated with 7 x 103 pfu in saliva from a mumps patient (a) 
or with 2 x 104 pfu of the RIT 4385 mumps vaccine (b). 
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4.1.2 Isolation of Virus from Nasal Washes, Urine and Faeces 
Processed and clarified nasal washes, urine and faeces samples from ferrets 1-6 were inoculated 
onto Vero cells, incubated at 35°C, 5% CO2 for 10 days and examined daily for signs of CPE. The 
resulting cell lysates were blind-passaged once onto Vero cells and incubated and examined as 
before. None of the inoculated cell cultures demonstrated evidence of CPE.  
RNA was isolated from all cell lysates from nasal wash, urine and faces samples and analysed by 
standard RT-PCR and then nested PCR for presence of MuV SH gene mRNA. This was done using 
primers JLSH1Fw and JLSH2Rv, and JLSH3Fw and JLSH4Rv respectively. All RT and nested PCR 
products were found to be negative when electrophoresed on a 1% agarose gel.  
RNA was also extracted from neat nasal washes, urine and faeces samples, and analysed by real-
time RT-PCR for presence of MuV SH gene mRNA using either AFZ315SHF, AFZ315SHR and AFZ315P 
primers and probe for ferrets 1 to 3, or JLSHF, JLSHR and JLSHP primers and probe for ferrets 4 to 6. 
All of the test samples were found to be negative.  
Negative and positive controls included in these experiments were valid, and all were performed in 
triplicate. 
No clinical or vaccine mumps viruses were detected by cell culture or PCR methods in nasal washes, 
urine or faeces at 1, 4, 7, 14, 21 or 28 days post infection.  
4.1.3 PRN Assays 
PRN assays measure the serum dilution required to reduce plaque formation by the virus in cell 
cultures by 50%. These were carried out in order to determine whether or not the test ferrets 
elicited an antibody response to infection with MuV. The average plaque count obtained from the 
positive control (no sera, challenge vaccine virus only) was 50. Figure 55 shows the results obtained. 
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All animals produced anti-mumps antibodies by day 28 as demonstrated by increased ND50 values 
(Figure 55). The ND50 value of the human mumps serum 93/582 was lower than any of these values, 
which showed that the antibodies produced by the ferrets had a higher neutralising activity than the 
human serum. For example, the serum from ferret 1, day 28 post infection would require an 
approximate 1 in 42 dilution to reduce plaque formation by 50%, whereas 93/582 would require 
being more concentrated, with an approximate 1 in 11 dilution. 
Pre-bleed samples were taken from all ferrets 7 days prior to inoculation to act as a control, yet they 
also showed a reduction in plaque number, and had ND50 values similar to those obtained from day 7 
and day 14 sera samples. 
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a) Ferrets 1-3, clinical mumps virus and human reference serum 
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b) Ferrets 4-6, vaccine mumps virus and human reference serum 
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Figure 55 – Ferret study A Mean ND50 values of neutralising antibodies produced in response to 
infection with clinical AFZ315 (a) or attenuated RIT 4385 vaccine (b) mumps viruses. Sera obtained 
from ferrets inoculated with AFZ315 or RIT 4385 were challenged with MuVs LO-1 or RIT 4385 
respectively and the dilution required to reduce number of plaques by 50% (ND50 titre) was 
calculated. A human reference standard (93/582) used in MMR batch release assays at NIBSC was 
included as a reference control. All PRN assays were performed in triplicate and the data represents 
the mean and standard deviation. 
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4.1.4 Recovery of Virus from day 28 Ferret Tissues 
Ferrets infected with clinical or vaccine mumps viruses were terminated on day 28 post infection and 
tissues harvested (Table 10). The tissues were chosen based on those that have been implicated in 
mumps cases in humans, and several others that are often affected during viral infection in general.  
Whole tissues were used to prepare 20% homogenates and these were analysed for presence of 
cultivable MuV and viral RNA which would give an indication of the tropism of these viruses.  
Clarified homogenates were inoculated onto Vero cells, incubated at 35°C, 5% CO2 for 10 days and 
examined daily for signs of CPE. The resulting cell lysates were blind-passaged once onto Vero cells 
and incubated and examined as before. None of the inoculated cell cultures demonstrated evidence 
of CPE. RNA was isolated from all cell lysates from tissue homogenate samples and analysed by 
standard RT-PCR and nested PCR for presence of MuV SH gene mRNA using JLSH1Fw and JLSH2Rv, or 
JLSH3Fw and JLSH4Rv respectively. All RT-PCR products were found to be negative when 
electrophoresed on a 1% agarose gel. Negative (H2O) and positive (AFZ315 or RIT 4385 parent 
viruses) controls included in these experiments were valid.  
RNA was also extracted directly from the 20% tissue homogenates and analysed for the presence of 
MuV SH gene mRNA using either AFZ315SHF, AFZ315SHR and AFZ315P primers and probe for ferrets 
1 to 3, or JLSHF, JLSHR and JLSHP primers and probe for ferrets 4 to 6.  Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) gene mRNA was measured using GAPDH535Fw, GAPDH680Rv and GAPDH 
primers and probe. GAPDH is an enzyme involved in carbohydrate metabolism and due to its 
ubiquitous presence in eukaryotic organisms, is often referred to as a “housekeeping” gene. GAPDH 
was included in these experiments as a control to confirm that the total RNA extracted from each 
sample was present and amplifiable. Each RT-PCR reaction was performed in triplicate. 
GAPDH mRNA was detected in varying quantities in all of the tissue samples from ferrets 1-6, apart 
from ferrets 1, 2 and 3 colon, and ferrets 4, 5 and 6 small intestine homogenates. Salivary glands 
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from ferrets 2 and 3 were unable to be located and removed at the time of tissue harvest, so there is 
no data available for these. The data is shown in Figure 56. This demonstrates that the total RNA 
isolated was capable of being amplified by the real-time RT-PCR method used. 
RNA extractions and real-time PCR reactions were performed three times on the colon and small 
intestine samples and were unsuccessful on all occasions, which may have been due to the large 
amounts of faeces present in the tissues upon harvest.  
The MuV positive controls included were standard dilution curves of clinical AFZ315 and vaccine RIT 
4385 viruses. The dilutions ranged from neat virus to 10-7 and each contained a known quantity of 
virus measured in plaque-forming units (pfu). Both of these virus controls were valid and the values 
are shown in Figure 56. All negative non-template controls (NTC) were valid.  
All of the day 28 tissue homogenate samples from ferrets 1-6 were negative when analysed by real-
time RT-PCR.  
In summary, no cultivable clinical or vaccine mumps viruses or viral RNA were recovered from any of 
the ferret tissues by the methods employed here.  
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a) Ferrets 1-3, clinical mumps virus, GAPDH internal control mRNA levels 
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Figure 56 – Ferret study A, ferrets 1 to 3 inoculated with AFZ315 day 28 tissues real-time PCR data. 
GAPDH mRNA levels in 20% tissue homogenates from ferrets infected with MuV AFZ315 were 
measured by real-time PCR as an internal control. No MuV mRNA was detected in any of the ferret 
tissues, and the positive control included demonstrates that the lowest virus quantity which could 
be detected by this method is 38 pfu. Assays were performed in triplicate and the data displayed 
represents the mean and standard deviation. 
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b) Ferrets 4-6, vaccine mumps virus, GAPDH internal control mRNA levels 
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Figure 56 – Ferret study A, ferrets 4 to 6 inoculated with RIT 4385 day 28 tissues real-time PCR 
data. GAPDH mRNA levels in 20% tissue homogenates from ferrets infected with MuV RIT 4385 were 
measured by real-time PCR as an internal control. No MuV mRNA was detected in any of the ferret 
tissues, and the positive control included demonstrates that the lowest virus quantity which could 
be detected by this method is 38 pfu. Assays were performed in triplicate and the data displayed 
represents the mean and standard deviation.  
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4.2 Ferret Study B 
4.2.1 Heat-inactivation of MuV 
Mumps vaccine virus RIT 4385 was heat-inactivated by incubating at 56°C for 30 min. To confirm 
that this process had eliminated the infectivity of the virus a plaque assay on Vero cells was 
performed, including a live RIT 4385 as a positive control.  
No plaques or CPE were evident by day 10 post infection on the Vero cells inoculated with the heat-
inactivated virus, and the positive and negative controls were valid.  
RNA was extracted from 10-fold dilution series of live and heat-inactivated RIT 4385 containing 
known quantities of virus and analysed by real-time RT-PCR using JLSHF, JLSHR and JLSHP primers 
and probe to confirm that the heat-inactivated virus was still genetically stable and intact. Each 
reaction was performed in triplicate and all negative NTC controls were valid.  
The real-time PCR data from this experiment is shown in Figure 57. 
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Figure 57 – Live versus heat-inactivated MuV RIT 4385 real-time PCR data. Real-time RT-PCR was 
performed on 10-fold serial dilutions of live and heat-inactivated RIT 4385 MuV vaccine virus and 
levels of detectable MuV RIT 4385 SH gene mRNA were compared. Assays were performed in 
triplicate and data displayed represents the mean and standard deviation.  
 
4.2.2 PRN Assays 
Three male ferrets were inoculated intranasally with heat-inactivated RIT 4385 attenuated vaccine 
virus, and blood samples were collected every 7 days until day 28 post infection. Figure 58 provides 
a summary of Study B.  
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Figure 58 – Ferret study B summary. Samples collected from ferrets inoculated with heat-
inactivated attenuated vaccine MuV over a 28 day period. 
 
PRN assays were performed and ND50 values calculated as described in section 4.1.3, using serum 
samples from 3 male ferrets (designated A, B and C) inoculated with ca 2x104 pfu heat-inactivated 
RIT 4385. Live RIT 4385 mumps vaccine virus was used as the challenge virus. The average plaque 
count obtained from the positive control (no sera, challenge vaccine virus only) was 10. The data 
obtained were compared against those for the live RIT 4385 virus (section 4.1.3, Figure 55 b) and are 
shown in Figure 59.  
The ND50 titres calculated for ferrets A to C showed a slight increase at day 28 compared to the pre-
bleed samples. To establish if the ND50 values obtained for day 28 sera from ferrets A to C were 
significantly increased, unpaired two-tail T tests were performed using GraphPad Prism 5.0 to 
compare the day 28 and pre-bleed data from each animal. This statistical analysis was also 
performed on the data from ferrets 4 to 6 (study A).  
P values for ferrets A, B and C were 0.0640, 0.5126 and 0.2711 respectively, and the differences 
between pre-bleed and day 28 sera samples were not statistically significant. However, the P values 
for ferrets 4, 5 and 6 were 0.0007, 0.0004 and >0.0001 respectively, and the increase in ND50 values 
from pre-bleed to 28 days were statistically significant.  
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These results indicate that the neutralising antibody response exhibited by ferrets 1 to 6 in study A, 
was specific to mumps virus.  
To confirm this result further, PRN assays were performed on day 28 sera from ferrets 1 to 6 (study 
A) using a high growth influenza laboratory strain (PR8) or a clinical MuV isolate (HPA1.1/P1V) as 
challenge viruses. As mumps is thought to be serologically monotypic, the animal sera should 
neutralise HPA1.1/P1V but not PR8.  
The results in Figure 60 demonstrate that the day 28 sera from all 6 animals are not capable of 
effectively neutralising the influenza virus, however did show neutralising activity when challenged 
with clinical MuV HPA1.1/P1V.   
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Figure 59 – Ferret study B, plaque reduction neutralisation assay data. Sera obtained from ferrets 
inoculated with live (red) or heat-inactivated (blue) RIT 4385 were challenged with RIT 4385 and the 
dilution required to reduce number of plaques by 50% (ND50 titre) was calculated. All PRN assays 
were performed in triplicate and the data represents the mean and standard deviation. 
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Figure 60 – Ferret study B, Influenza PR8 and MuV HPA1.1/P1V challenge plaque reduction 
neutralisation assay data. Day 28 sera obtained from ferrets inoculated with AFZ315 (red) or RIT 
4385 (blue) in study A, were challenged with influenza PR8 or MuV HPA1.1/P1V and the dilution 
required to reduce number of plaques by 50% (ND50 titre) was calculated. All PRN assays were 
performed in triplicate and the data represents the mean and standard deviation. 
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4.3 Ferret Study C 
Eight male ferrets were inoculated intranasally with clinical MuV AFZ315. Oral swabs were collected 
daily and 2 animals sacrificed with tissues collected on days 1, 4, 7 and 14 post infection. Figure 61 
provides a summary of Study C.  
 
Figure 61 – Ferret study C summary. Clinical observations and samples collected from ferrets 
inoculated with clinical MuV over a 14 day period. 
 
4.3.1 Isolation of Virus from Oral Swabs 
Processed and clarified oral swab samples from ferrets 1.1 to 1.8 were inoculated onto Vero cells, 
incubated at 35°C, 5% CO2 for 10 days and examined daily for signs of CPE. The resulting cell lysates 
were blind-passaged once onto Vero cells and incubated and examined as before. None of the 
inoculated cell cultures demonstrated evidence of CPE.  
RNA was isolated from all cell lysates from oral swab samples and analysed by standard RT-PCR and 
then nested PCR for presence of MuV SH gene mRNA. This was done using primers JLSH1Fw and 
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JLSH2Rv, and JLSH3Fw and JLSH4Rv respectively. All RT and nested PCR products were found to be 
negative when electrophoresed on a 1% agarose gel.  
RNA was also extracted directly from oral swabs and analysed by real-time RT-PCR for presence of 
MuV SH gene mRNA using AFZ315SHF, AFZ315SHR and AFZ315P primers and probe. All of the test 
samples were found to be negative.  
Negative and positive controls included in these experiments were valid, and all were performed in 
triplicate. 
No mumps virus was detected by cell culture or PCR methods in oral swabs from days at 1 to 14 post 
infection.  
4.3.2 Recovery of Virus from Ferret Tissues 
Two ferrets infected with clinical mumps virus AFZ315 were terminated on days 1, 4, 7 and 14 post 
infection and tissues harvested (Table 10). The tissues were chosen based on those that have been 
implicated in mumps cases in humans. Whole tissues were used to prepare 20% homogenates and 
these were analysed for presence of cultivable MuV and viral RNA which would give an indication of 
the biological distribution of the virus at specific time points.  
Clarified homogenates were inoculated onto Vero cells, incubated at 35°C, 5% CO2 for 10 days and 
examined daily for signs of CPE. The resulting cell lysates were blind-passaged once onto Vero cells 
and incubated and examined as before. None of the inoculated cell cultures demonstrated evidence 
of CPE. RNA was isolated from all cell lysates from tissue homogenate samples and analysed by 
standard RT-PCR and nested PCR for presence of MuV SH gene mRNA using JLSH1Fw and JLSH2Rv, or 
JLSH3Fw and JLSH4Rv respectively. All RT-PCR products were found to be negative when 
electrophoresed on a 1% agarose gel. Negative and positive controls included in these experiments 
were valid.  
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RNA was also extracted directly from the 20% tissue homogenates and analysed for presence of 
MuV SH gene mRNA using AFZ315SHF, AFZ315SHR and AFZ315P primers and probe. GAPDH gene 
mRNA was measured using GAPDH535Fw, GAPDH680Rv and GAPDH primers and probe, and was 
included as an internal control to confirm that the total RNA extracted from each sample was 
present and amplifiable. Each RT-PCR reaction was performed in triplicate. 
GAPDH mRNA was detected in varying quantities in all of the tissue samples from ferrets 1.1 to 1.8 
and this data is shown in Figure 62. Lymph nodes were unable to be located and removed from 
ferrets 1.4 and 1.7 at the time of tissue harvest therefore there is no data available for these. This 
demonstrates that the total RNA isolated was capable of being amplified by the real-time RT-PCR 
method used. 
The MuV positive control included was a standard dilution curve of clinical AFZ315 MuV. The 
dilutions ranged from neat virus to 10-7 and contained a known quantity of virus measured in pfu. 
The virus control was valid and the values are shown in Figure 62. All negative NTC controls were 
valid.  
All of the tissue homogenate samples from ferrets 1.1 to 1.8 were negative when analysed by real-
time RT-PCR.  
No cultivable mumps virus or viral RNA was recovered from any of the ferret tissues by the methods 
used in these experiments.   
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Figure 62 – Ferret study C, Ferrets 1.1 to 1.8 tissues real-time PCR data.  GAPDH mRNA levels in day 
1, 4, 7 and 14 20% tissue homogenates from ferrets infected with MuV AFZ315 were measured by 
real-time PCR as an internal control. No MuV mRNA was detected in any of the ferret tissues, and 
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the positive control included demonstrates that the lowest virus quantity which could be detected 
by this method is 3.8 pfu. Assays were performed in triplicate and the data displayed represents the 
mean and standard deviation.  
 
4.3.3 Spiking of Uninfected Ferret Tissue Homogenates with MuV 
Clinical MuV AFZ315 virus was used to spike 20% brain, kidney and spleen homogenates from ferret 
1.1 and serial dilutions up to 10-7 were prepared in each homogenate. The same virus dilutions were 
prepared in MEM to act as a control. This was carried out to determine the ability of MuV to be 
extracted from ferret tissues and to obtain an approximate limit of detection for the real-time PCR 
assays performed throughout the in vivo studies.  
Brain, spleen and kidney were chosen due to the differences between each of the tissue types. For 
example the brain is a fatty tissue, the spleen contains a large quantity of blood and the kidney 
represents a tissue which proved reasonably difficult to homogenate.  
RNA was isolated from the spiked 20% tissue homogenate dilution series and the MEM/virus 
control, and analysed for presence of MuV SH gene mRNA using AFZ315SHF, AFZ315SHR and 
AFZ315P primers and probe. Each reaction was performed in triplicate and the real-time RT-PCR 
data is shown in Figure 63. All negative NTC controls were valid.  
The data indicates that by this method, the assay is capable of detecting 3.8 pfu of MuV per µL of 
template RNA when diluted in MEM only, and can detect 38 pfu of MuV per µL of template RNA 
isolated from the tissue homogenates. The limit of detection was shown to be the same for all 3 
tissues types. Based upon the weight of the animal and tissue and volume of media added to result 
in a 20% homogenate, the minimum amount of clinical mumps virus that can be detected by this 
method can be calculated to be approximately 6000 pfu per gram of ferret.  
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Figure 63 – Limit of detection of mumps virus AFZ315 in ferret tissues by real-time RT-PCR. MEM 
and uninfected ferret brain, spleen and kidney 20% homogenates were spiked with serial dilutions of 
a known quantity of MuV AFZ315 to compare MuV SH gene mRNA levels detectable by real-time RT-
PCR. Assays were performed in triplicate and the data displayed represents the mean and standard 
deviation.  
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4.3.4 Detection of MuV in Ferret PBMCs 
PBMCs were isolated from ferret terminal bleeds at 1, 4, 7 and 14 days post infection and were 
analysed for the presence of MuV mRNA. This was carried out to determine whether or not clinical 
MuV is lymphotropic in ferrets.  
RNA was extracted from PBMCs isolated from ferret terminal bleeds and analysed for presence of 
MuV SH gene mRNA using AFZ315SHF, AFZ315SHR and AFZ315P primers and probe. GAPDH gene 
mRNA was measured using GAPDH535Fw, GAPDH680Rv and GAPDH primers and probe, and was 
included as an internal control to confirm that the total RNA extracted from each sample was 
present and amplifiable. Each RT-PCR reaction was performed in triplicate. 
GAPDH mRNA was detected in varying quantities in all of the PBMC samples from ferrets 1.1 to 1.8 
and this data is shown in Figure 64. This demonstrates that the total RNA isolated was capable of 
being amplified by the real-time RT-PCR method used. 
The MuV positive control included was a standard dilution curve of clinical AFZ315 MuV. The 
dilutions ranged from neat virus to 10-7 and contained a known quantity of virus measured in pfu. 
The virus control was valid and the values are shown in Figure 64. All negative NTC controls were 
valid.  
All of the samples from ferrets 1.1 to 1.8 were negative for MuV when analysed by real-time RT-PCR.  
No viral RNA was recovered from any of the ferret PBMCs by the methods used in this experiment.   
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Figure 64 – Ferret study C, ferrets 1.1 to 1.8 PBMCs real-time PCR data.  GAPDH mRNA levels in 
PBMCs isolated from terminal bleeds of ferrets infected with MuV AFZ315 were measured by real-
time PCR as an internal control. No MuV mRNA was detected in any PBMCs, and the positive control 
included demonstrates that the lowest virus quantity which could be detected by this method is 3.8 
pfu. Assays were performed in triplicate and the data displayed represents the mean and standard 
deviation.  
 
4.3.5 Detection of Cytokines in Ferret PBMCs 
RNA isolated from ferret PBMCs was analysed by SYBR® Green real-time RT-PCR for the presence of 
IFN-γ, IL-2, IL-6 and IL-10 at various time points post infection with clinical MuV. These cytokines 
were chosen for this experiment as they have been previously shown to increase significantly in CSF 
of patients with mumps meningitis (Ichiyama et al., 2005), and due to the availability of ferret PCR 
primers at the time (Svitek & von Messling, 2007).  
Cytokine mRNA levels were detected using IFNGAMMAFw, IFNGAMMARv, IL2Fw, IL2Rv, IL6Fw, IL6Rv 
and IL10Fw and IL10Rv primer pairs. GAPDH gene mRNA was measured using GAPDHFw, GAPDHRv 
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primers, and was included as an internal control to confirm that the total RNA extracted from each 
sample was present and amplifiable. Each RT-PCR reaction was performed in duplicate. 
GAPDH mRNA was detected in varying quantities in all of the PBMC samples from ferrets 1.1 to 1.8. 
This demonstrates that the total RNA isolated was capable of being amplified by the SYBR® Green 
PCR method used. 
The fold change in mRNA levels between pre-bleed and test bleeds for each cytokine gene was 
calculated using the level of GAPDH for each sample as a control. To do this, the Ct value for GAPDH 
is first subtracted from the Ct value of the unknown gene (ΔCt) from the pre-bleed sample. The 
mRNA fold change is then calculated by subtracting the pre-bleed ΔCt value of the gene of interest 
from the ΔCt values of the gene at each time point (days 1, 4, 7 and 14). These values were then 
changed into absolute values by using the equation: fold mRNA change = 2-ΔΔCt (Svitek & von 
Messling, 2007)  
IFN-γ levels showed no change on days 1 (ferrets 1.1 and 1.2), 4 (ferrets 1.3 and 1.4) or 7 (ferrets 1.5 
and 1.6) post infection, however a mean fold increase of 2.0 on day 14 post infection (ferrets 1.7 and 
1.8) was observed. IL-2, IL-6 and IL-10 levels peaked on day 4 post infection as demonstrated by a 
mean increase in fold mRNA change of 20, 2x104 and 600, respectively. This data is shown in Figure 
65.  
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Figure 65 – Ferret study C, detection of cytokines in ferret PBMCs at various time points SYBR® 
Green real-time PCR data. Fold change of IFN-γ, IL-2, IL-6 and IL-10 mRNA levels in PBMCs isolated 
from ferret blood at days 1, 4, 7 and 14 post infection with clinical MuV AFZ315 was calculated using 
the differences in Ct values in the equation: fold mRNA change = 2-ΔΔCt  
 
4.3.6 Human Cytokine ELISA 
Basal samples from MucilAir™ HAE cells infected with clinical MuV AFZ315 were assayed using a 
Multi-Analyte ELISArray™ Kit for human inflammatory cytokines. Included in the panel of cytokines 
were IL-2, IL-6, IL-10 and IFN-γ and this assay was carried out in order to assess any correlation 
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between the cytokine levels observed in ferret PBMCs and those secreted from infected HAE cells at 
similar time points (days 1, 4, 7 and 10 post infection).  
The absorbance was measured at 450 nm and the data analysed using Ascent® software (Thermo 
Scientific, UK), where the value for optical density (OD450) is proportional to the quantity of cytokine 
present in the experimental sample.  
Quantities of IL-2 and IL-10 peak at day 7 post infection with a noticeable decrease by day 10 post 
infection. IL-6 levels appear to be highest at day 1 post infection and decrease steadily until 10 days 
post infection. Levels of IFN-γ  peak at day 1 post infection, followed by a sharp decrease at day 4 
and an increase by day 7, and this level is maintained at day 10 post infection. The data is shown in 
Figure 66.  
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Figure 66 – Measurement of cytokine levels in basal HAE cell samples at various time points, ELISA 
data.  IL-2, IL-6, IL-10 and IFN-γ levels in basal samples from MucilAir™ HAE cells at days 1, 4, 7 and 
10 post infection with clinical MuV AFZ315 were measured using a Multi-Analyte ELISArray™ Kit for 
human inflammatory cytokines and reading absorbance at 450nm.  
 
4.4 Ferret Study D 
4.4.1 Recovery of Virus from Ferret Tissues 
Two ferrets infected with clinical mumps virus AFZ315 harvested from the apical surface of 
MucilAir™ HAE at day 10, were terminated on days 4 and 7 post infection and tissues harvested 
(Table 10). Figure 67 provides a summary of Study D. The tissues were chosen based on those that 
have been implicated in mumps cases in humans. Whole tissues were used to prepare 20% 
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homogenates and these were analysed for presence of cultivable MuV and viral RNA which would 
give an indication of the biological distribution of the virus at specific time points.  
 
 
 
Figure 67 – Ferret study D summary. Clinical observations and samples collected from ferrets 
inoculated with clinical MuV isolated from HAE cells over a 4 day period. 
 
Clarified homogenates were inoculated onto Vero cells, incubated at 35°C, 5% CO2 for 10 days and 
examined daily for signs of CPE. The resulting cell lysates were blind-passaged once onto Vero cells 
and incubated and examined as before. None of the inoculated cell cultures demonstrated evidence 
of CPE. RNA was isolated from all cell lysates from tissue homogenate samples and analysed by 
standard RT-PCR and nested PCR for presence of MuV SH gene mRNA using JLSH1Fw and JLSH2Rv, or 
JLSH3Fw and JLSH4Rv respectively. All RT-PCR products were found to be negative when 
electrophoresed on a 1% agarose gel. Negative and positive controls included in these experiments 
were valid.  
RNA was also extracted directly from the 20% tissue homogenates and analysed for presence of 
MuV SH gene mRNA using AFZ315SHF, AFZ315SHR and AFZ315P primers and probe. GAPDH gene 
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mRNA was measured using GAPDH535Fw, GAPDH680Rv and GAPDH primers and probe, and was 
included as an internal control to confirm that the total RNA extracted from each sample was 
present and amplifiable. Each RT-PCR reaction was performed in triplicate. 
GAPDH mRNA was detected in varying quantities in all of the tissue samples from ferrets 1 to 4 and 
this data is shown in Figure 68. This demonstrates that the total RNA isolated was capable of being 
amplified by the real-time RT-PCR method used. 
The MuV positive control included was a standard dilution curve of clinical AFZ315 MuV. The 
dilutions ranged from neat virus to 10-7 and contained a known quantity of virus measured in pfu. 
The virus control was valid and the values are shown in Figure 68. All negative NTC controls were 
valid.  
All of the tissue homogenate samples from ferrets 1 to 4 were negative when analysed by real-time 
RT-PCR.  
In summary, no cultivable mumps virus or viral RNA was recovered from any of the ferret tissues by 
the methods used in these experiments.   
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Figure 68 – Ferret study D, ferrets 1 to 4 tissues real-time PCR data. GAPDH mRNA levels in day 4 
and 7 20% tissue homogenates from ferrets infected with MuV AFZ315 harvested from the apical 
surface of HAE cells at day 10 post infection were measured by real-time PCR as an internal control. 
No MuV mRNA was detected in any of the ferret tissues, and the positive control included 
demonstrates that the lowest virus quantity which could be detected by this method is 3.8 pfu. 
Assays were performed in triplicate and the data displayed represents the mean and standard 
deviation.  
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4.5 Summary of Results 
Clinical symptoms including temperature, body weight, appetite, alertness, physical appearance, and 
swelling of parotid gland areas and testes were recorded on a daily basis for all of the ferrets 
included in studies A to D. No signs were observed at any point during these studies that would 
indicate mumps-like disease or any other type of illness.  
PRN assays were performed using sera from ferrets inoculated with clinical MuV AFZ315 or 
attenuated vaccine virus RIT 4385 (study A) and these tests showed that the animals were all 
capable of producing antibodies that neutralised MuV by day 28 post infection. PRN assays were 
then carried out using sera from ferrets inoculated with heat-inactivated RIT 4385 (study B), which 
was not able to effectively neutralise MuV. Sera from animals on day 28 (study A) were also capable 
of neutralising another clinical MuV (HPA1.1/P1V) but not a laboratory strain of influenza.  
In studies A, C and D attempts were made to recover infectious virus or viral RNA from nasal washes, 
urine, faeces, oral swabs, PBMCs and 20% tissue homogenates by culture on Vero cells and real-time 
quantitative RT-PCR. However, no MuV RNA or live virus was detected by these methods. A spiking 
experiment as part of study C in which uninfected brain, kidney and spleen homogenates were 
“spiked” with known quantities of clinical MuV AFZ315 demonstrated that it is possible to detect this 
virus in ferret tissues if present at a minimum of 38 pfu per µL of RNA template.  
PBMCs from ferret terminal bleeds (study C) were used to determine levels of IFN-γ, IL-2, IL-6 and IL-
10 present over 14 days by SYBR® Green RT-PCR. The results were calculated to represent the fold 
change in mRNA and demonstrated no change in IFN-γ mRNA levels until a peak at day 14, whereas 
IL-2, IL-6 and IL-10 mRNA levels all peaked at day 4 post infection. In an attempt to correlate these 
results with a human infection, a human cytokine ELISA was performed using the basal media from 
HAE cells infected with the same clinical MuV over 10 days. Levels of IFN-γ, IL-2, IL-6 and IL-10 were 
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all found to change over the time course, however a different time course trend was observed than 
that seen in ferret PBMCs.  
 
4.6 Discussion 
As previously mentioned, no animals in any of the studies A to D exhibited any clinical symptoms of 
illness. However the fact that they elicited a serum antibody response after inoculation with a live 
clinical or vaccine MuV indicates that although the ferrets did not demonstrate physical signs of 
disease, suggests that they probably were infected. Guinea pigs have been shown to be an efficient 
model for studying influenza virus infection and transmission, yet they have been reported not to 
display clinical signs (Palese et al., 2006). The levels of IFN and cytokine production observed in the 
PBMCs also indicate a response to viral infection.  
Male ferrets were chosen for these studies to aid observation of external clinical symptoms by 
measurement of testicular swelling, as orchitis is common in mumps disease in male patients. The 
equivalent in female patients is oophoritis, however this occurs at a less frequent rate than orchitis 
and it would not have been feasible in this project to examine animals’ ovaries as a means of 
observing clinical symptoms. Female mice have been reported to have a more severe reaction to 
influenza A infection than males, with increased hypothermia, loss of body weight and mortality 
rates (Robinson et al., 2011). This was associated with sex-specific hormones and differences in viral 
infection outcome between males and females have also been reported for HIV and herpes viruses 
(Klein & Huber, 2010). Performing the studies described in this thesis using female ferrets may have 
been of interest and produced different results, however there has not been any evidence reported 
that mumps occurs with higher incidence in males or females, or that either of the sexes is more 
prone to mumps disease with complications (Hviid et al., 2008).  
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The neutralising antibodies (NAb’s)  produced by the ferrets in response to infection with clinical or 
attenuated vaccine MuVs (study A) can be said to be mumps-specific as sera from ferrets inoculated 
with the heat-inactivated vaccine virus RIT 4385 (study B) were not capable of significantly 
neutralising MuV. Also, the day 28 sera from study A effectively neutralised another clinical MuV as 
well as Mu90 and RIT 4385 challenge viruses, but had no neutralising effect when challenged with a 
laboratory strain of influenza. MuV is reported to be serologically monotypic (Rubin et al., 2006) 
which means that antibodies effective against one strain or genotype of the virus should be able to 
neutralise all other MuVs. This was shown to be the case with the ferret NAb’s as they successfully 
neutralised RIT 4385 (genotype A), Mu90 (genotype D) and clinical virus HPA1.1/P1V (genotype G). 
All of these data taken together indicate that the neutralising antibody response elicited by ferrets 
during these studies was mumps-specific. This data correlates with that produced from a previously 
documented study in which  antibodies that neutralised MuV were detected in the sera of ferrets 
after intranasal inoculation with the Enders strain of MuV (Gordon et al., 1956).  
Analysis of PBMCs from terminal bleeds of animals infected with clinical MuV AFZ315 demonstrated 
increases in the mRNA levels of IFN-γ (day 14), IL-2, IL-6 and IL-10 (all day 4) which correlates with 
previous studies in which the concentrations of these immune molecules were found to be elevated 
in patients CSF in cases of mumps meningitis (Ichiyama et al., 2005).  In a similar experiment, mRNA 
levels of IFN-γ, IL-2, IL-6 and IL-10 in PBMCs from ferrets infected with non-lethal CDV have also 
been demonstrated to increase at days 3 or 7 post-infection (Svitek & von Messling, 2007). The 
authors suggested that elevations in mRNA levels of these genes in the CDV study indicated  that 
innate (IL-6), T helper cell 1 (Th1) (IFN-γ and IL-2) and T helper cell 2 (Th-2) (IL-10) types of immune 
responses were all stimulated,  which suggests that this may also be the case in ferrets after 
infection with clinical MuV. It would have been useful to have carried out the same PBMC analysis 
from the ferrets inoculated with heat-inactivated MuV as a comparison, and also to have further 
confirmed the lack of serum antibody response observed in study B from animals infected with heat-
inactivated RIT 4385.  
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The functions of IL-2, IL-6, IL-10 and IFN-γ are extensive and varied and are reviewed in (Meager & 
Wadhu, 2007) and (Schroder et al., 2004). IL-6 is involved in the acute phase of innate immunity and 
the direct induction of acute-phase proteins such as C-reactive protein (CRP), and sharp increases in 
serum CRP levels correlate with IL-6 levels after infection (Heinrich et al., 2003). This would have 
been interesting to measure using ferret sera that had not been heat-inactivated, perhaps using 
ELISA methodology, in order to determine whether or not there was a correlation with the results 
from the PBMCs, and it would have also provided another indicator of infection. CRP has previously 
been found to become elevated in plasma of mumps patients with orchitis (Niizuma et al., 2004). IL-
2 is produced by T lymphocytes and is heavily involved with T-cell proliferation, causing them to 
produce IFN-γ, among other cytokines. IL-10 has many suppressive activities and is reported to act as 
a negative regulator of IFN-γ and inhibit its synthesis by Th1 cells (Schroder et al., 2004) (Fiorentino 
et al., 1991), which would provide an explanation as to why in the ferret PBMCs, IFN-γ mRNA levels 
did not increase until the IL-10 mRNA levels decreased at day 7. If IL-2 is involved in stimulating 
induction of IFN-γ, this would suggest why it was detected earlier than IFN-γ. IFN-γ has also 
previously been demonstrated to be of importance at later stages of the immune response to 
coordinate a longer-term anti-viral state in the host (Cantin et al., 1999).  
The levels of IL-2, IL-6, IL-10 and IFN-γ proteins measured in basal media from HAE cells infected with 
MuV AFZ315 differed from the trends observed in the measured fold mRNA changes calculated from 
the ferret PBMCs. Increased levels of IL-6 at day 1 post infection correlates with its involvement in 
acute-phase immune activities, however, in the HAE cells more IFN-γ is present initially as opposed 
to IL-2 and IL-10. Once again though, IFN-γ and IL-10 do not reach peak levels at the same time 
which may be another demonstration of the negative regulation of IFN-γ by IL-10. Unfortunately 
there is only one data point available for each sample and time point due to lack of sample 
availability, so it would be of interest to repeat this experiment using more HAE cells in order to have 
a greater sample volume for testing in triplicate. There are many possible reasons as to why the 
trends observed for the HAE cells and PBMCs were different. The substances being measured were 
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different (mRNA and protein) and were done so by different means (real-time RT-PCR and ELISA) 
which could have an effect on the outcomes for comparison. The PBMCs came from an in vivo 
animal system where intranasal inoculation was used, and the HAE cells were washed thoroughly 
and inoculated directly onto the apical surface, and one system was ferret and the other human. 
Also, as the HAE cultures are lacking in types of immune cells such as Th1 and Th2 (Huang et al., 
2011) it is likely that the responses measured from the basal medium were basic cellular infection 
responses, whereas the PBMCs analysis revealed an actual immune response. It would be of interest 
in the future to carry out similar experiments, when more ferret reagents are available, in order to 
obtain a full cytokine profile for ferrets infected with MuV.  
The immune response data from these in vivo studies is highly indicative that although the ferrets 
did not become ill, they were infected with MuV. As no infectious virus or viral RNA was detected in 
any of the clinical samples (no shedding) or tissue homogenates, this raised the question of what 
happened to the virus and where did it go? Wild-type MuVs are known to spread in saliva or 
respiratory droplets, and oral swabs are the most common means of obtaining a sample from a 
mumps patient, therefore it was expected that the clinical MuV AFZ315 would be detected in oral 
fluid and/or nasal washes.  The fact that no attenuated vaccine virus was recovered was less of a 
concern as there is no reported connection between RIT 4385 and virus shedding, and the fact that 
this MuV is attenuated may account for low levels or lack of replication in tissues. After study A, the 
working hypothesis was that perhaps no virus was detected in tissues at day 28 because by this time 
point, the virus had been cleared from the animals’ system by the strong NAb response. The results 
from study C indicated that this was not the case, as no virus was recovered from tissues at 1, 4, 7, 
or 14 days post infection.  After obtaining these results, the hypothesis was that the lack of 
recoverable clinical MuV was due to a low titre of input virus and so the inoculum titre was 
increased in study D, by infecting ferrets with progeny AFZ315 from HAE cells which were found to 
be of a higher titre and highly genetically similar to the parent virus (section 3.5.4). The virus 
inoculum titre increase from 7 x 103 pfu/ferret to 1 x 105 pfu/ferret in study D did not aid virus 
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recovery in any of the tissue homogenates therefore it was concluded that a low inoculum titre was 
likely not to be the reason for this.  The results of these experiments were not in agreement with 
those from a previous study in which infectious MuV was recovered from nasal washings, turbinates 
and lung samples at days 3 and 4 post infection (Gordon et al., 1956). However, the virus used in the 
afore-mentioned investigation had been serially passaged through allantoic fluid of embryonated 
hen’s eggs 19 to 23 times prior to inoculation which may have caused selective adaptations in the 
virus.  
This conclusion resulted in the formation of a new hypothesis, this being that perhaps there was an 
issue with the detection capabilities and limits of the real-time RT-PCR assay. To address this, brain, 
kidney and spleen homogenates previously demonstrated to be negative for MuV were spiked with 
known quantities (pfu) of clinical MuV AFZ315 and compared with AFZ315 diluted in MEM only by 
real-time RT-PCR. The virus was successfully detected in all three of the spiked tissues with a 
sensitivity limit of 38 pfu per µL of RNA template. The MEM-diluted virus assay showed a higher 
sensitivity limit of 3.8 pfu per µL of RNA template, which may be due to the presence of compounds 
in the starting material of the spiked tissue samples known to be inhibitory in PCR reactions such as 
haemoglobin and lactoferrin (Al-Soud & Radstrom, 2001). The sensitivity limit for this PCR assay 
using ferret tissue homogenates was calculated to mean that for MuV RNA to be detected, the virus 
would need to be present in a quantity of approximately 6000 pfu per gram of ferret. This is a high 
quantity of virus, therefore the inoculum MuV would need to be concentrated in one or two tissues 
or be replicating efficiently to produce high titres of progeny virus in order to be detected by the 
method used here. With regards to the limit of detection of the RIT 4385 MuV, if it is considered that 
the lowest quantity of virus detected decreases by approximately 10-fold due to the presence of 
potential PCR inhibitors in tissue (as seen for clinical MuV), it can be assumed that the detection limit 
would be approximately 0.605 pfu per µL of RNA template making it more sensitive than for clinical 
MuV AFZ315.  
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The fact that no live MuV or viral RNA was detected may be as a result of host restriction factor(s) in 
the ferret. The virus may have been capable of only replicating at very low levels or inefficiently in 
tissues and organs. Virus restriction factors of the host organism are commonly related to the 
availability of a suitable receptor for binding and/or host anti-viral response. As ferret cells of the 
respiratory tract have been demonstrated to express similar SA patterns to those found in human 
cells (van Riel et al., 2007) (Jayaraman et al., 2012) it is unlikely that the receptor type or availability 
posed a problem. Studies on the SA content of ferret and human salivary or parotid glands are 
lacking, however  SA-containing mucous, a common barrier to viral and bacterial infection, has been 
shown to be present in the parotid glands of ferrets (Jacob & Poddar, 1978).  
The antiviral response of the animals may play a role in inhibiting MuV replication or restricting viral 
tropism. IL-2, IL-6, IL-10 and IFN-γ all activate several signalling pathways including the JAK-STAT 
cascade which the V protein of MuV is known to interfere with by targeting STATs for degradation 
(discussed in section 1.8.2), however there is a chance that this may affect only IFN α/β signalling 
and not that of IFN-γ, as has previously been reported to be the case for MV (Takeuchi et al., 2003). 
IFN-γ has been implicated in to act in a tissue-dependent manner during clearance of vaccinia and 
alpha-viruses (Kundig et al., 1993) (Binder & Griffin, 2001). It also upregulates several anti-viral genes 
including dsRNA-specific adenosine deaminase (ADAR) which may cause the translation of non-
functional proteins by an mRNA editing function (Patterson et al., 1995), and protein kinase dsRNA-
regulated (PKR) which can inhibit viral replication and activate NF-κB (Zamanian-Daryoush et al., 
2000). These may have a restrictive effect on MuV replication in ferret tissues. The MuV V protein 
may also not be fully functional in ferret cells and tissues, and could play a role in determining host 
range as has been described for the V protein of RSV (Bossert & Conzelmann, 2002) and NDV (Park 
et al., 2003).  
It is worth considering the possibility that the immune responses observed in the ferret sera and 
PBMCs were generated in response to the MuV viral antigen, the HN glycoprotein, and not 
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replicating virus. If this is the case, the insignificant neutralising antibody response from ferrets 
inoculated with heat-inactivated vaccine virus (study B) could be explained by the denaturation or 
irreversible conformational change of the antigen brought about by the high temperature treatment 
during the inactivation process. To test this theory, ferrets could be inoculated in the same way as 
described in this project with a virus vector expressing the HN protein of MuV.  
If the outcome of the virus recovery experiments in ferrets had been different and either live MuV or 
viral RNA had been successfully detected, a technique to detect viral proteins in tissue sections such 
as fluorescent in situ hybridisation could also have been carried out. This procedure has previously 
been used to successfully detect RSV proteins in infected cells of the lungs of cotton rats (Murphy et 
al., 1990). Any recovered MuV would have been titrated by plaque assay and sequenced to compare 
with the inoculum virus in order to determine if any changes at the nucleotide and amino acid level 
had been brought about by replication and adaptation to the host tissues.  
In conclusion, the in vivo data presented here provides evidence that ferrets are capable of 
producing mumps-specific neutralising antibodies after intranasal inoculation with clinical or 
attenuated vaccine MuVs, and that they appear to elicit a cytokine response to clinical MuV. These 
results alone are not conclusive as to whether or not the ferrets were infected with MuV, and 
experimental infection of ex-vivo ferret airway epithelial cells similar in set-up to the HAE cells used 
here would be useful to confirm whether or not ferret cells are capable of being infected with MuV. 
No live virus or viral RNA was recovered from any nasal washes, urine, faeces, PBMCs or tissues at 
any of the time points included. This indicates that the virus was not shedding from the animals and 
that it is unlikely that it was replicating in any ferret tissues. If virus is not being shed, transmission 
studies are not possible, and a lack of clinical symptoms and recovery of virus from samples make 
fundamental in vivo mumps research using the ferret model extremely difficult. This model would 
also be very limited in its uses for investigating attenuated vaccine viruses. The data raise more 
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questions than they answer, however do not provide evidence that the ferret is a suitable animal 
model for investigative MuV research.  
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CHAPTER 5 – CONCLUDING DISCUSSION 
Although mumps cases have been documented for hundreds of years, and vaccines have been 
available for over 60 years, specific virological data on MuV is somewhat lacking. Much of the 
knowledge available from the literature is inferred from research carried out on other 
paramyxoviruses, in particular the closely related hPIV5 which is often referred to as a prototypical 
rubulavirus and paramyxovirus. The lack of a sensitive cell culture model and an effective animal 
model are two reasons contributing to this lack of knowledge in the field of mumps research, and 
this PhD project was carried out in an attempt to tackle these issues.  
The project was divided into two concurrent parts. The first focussed on in vitro work to investigate 
the growth of MuV in various cell substrates, and the second addressed the assessment of ferrets as 
an in vivo model for mumps.  
Studies have been carried out in the past to assess the use of certain cell lines for MuV propagation, 
and a brief preliminary screen of eight cell lines has previously been carried out (Afzal et al., 2005). 
However this project is the largest screen that has been performed to investigate MuV growth and 
genetic stability in cell lines, including genetically engineered interferon-insensitive cells. Data on 
sialic acid receptor binding specificity of MuV was unavailable at the time of designing this PhD 
project and the SA studies described in this thesis are the first to provide data indicating that MuV 
may not exhibit any preferential binding. This is also the first investigation of mumps using an ex-vivo 
culture system which mimics the human respiratory epithelia (MucilAir™) and has demonstrated 
that HAE cells are capable of supporting efficient infection, replication and release of wild-type 
laboratory and attenuated MuV vaccine strains, and can be used for clinical MuV isolation producing 
genetically stable progeny virus with titres only slightly lower than Vero cells. Vero cells had 
previously been accused of producing genetically altered viruses during growth and serial passage 
however this had never been confirmed until now.  
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Ferrets had been experimentally infected prior to this PhD project (Gordon et al., 1956) with 
interesting results suggesting that they are susceptible to MuV infection and elicit an immune 
response, yet despite these findings, no other mumps studies using the ferret model have been 
documented. The in vivo data described here further validates the historical findings that ferrets 
generate a serum antibody response specific to MuV and also reports for the first time on the 
cytokine and IFN response in this animal model to MuV infection.  
The findings from both the in vitro and in vivo studies have provided new information in the area of 
mumps research and may further advance related research. For example, the cell lines identified as 
being suitable for propagating high titre, genetically stable representative wild-type MuV (Mu90) are 
widely available and easy to manipulate (Hep 2C, HGT-1 and MCF-7) so could be routinely used for 
growing stocks of virus in research laboratories and have potential to be used for cultivation of 
clinical isolates. These cells would also be useful for investigating MuV-host cell interactions by 
proteomics techniques such as stable isotope labelling of amino acids in cell culture (SILAC) coupled 
with mass spectrometry, or transcriptome analyses by human microarray and RNAseq. All of these 
techniques require the infection of a human cell line with the virus of interest as the annotated 
genome of the host cell must be fully available. It also makes the results of these types of 
experiments more meaningful as the data can be translated to provide information on the human 
infection. Now that the susceptibility of HAE cells to MuV infection has been confirmed, these types 
of cultures will be valuable for future mumps research and although they may not be as readily 
available as continuous cell lines such as Hep 2C, they are commercially available, produced under 
strict quality control, and have been demonstrated in this project to be the superior in vitro system 
for maintaining the genetic stability of MuV.   
As discussed in section 4.6, the ferret model appears not to be of value for studying virus 
pathogenesis, tropism, persistence and transmission of MuV in vivo. The guinea pig model may 
prove to be effective for these aspects of MuV infection as these animals have previously been 
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demonstrated to elicit a serum antibody response and infectious virus was recovered after 
intracerebral inoculation (Tokuda, 1957). From a technical point of view, guinea pigs are smaller, 
cheaper and also easier to handle than ferrets. Studies validating and elaborating on these findings 
are lacking and a systematic evaluation of the guinea pig as a mumps animal model should be 
carried out in the future in a similar manner to the experiments described in this thesis.  
The results obtained from infection of A549 cells constitutively expressing the V protein of hPIV5 or 
the NPro protein of BVDV (discussed in section 3.7) provided a proof of principle that expression of a 
molecule that will allow a virus to circumvent the host IFN response allows for enhanced virus 
replication. Transgenic mice expressing the human poliovirus receptor (Ren et al., 1990) have been 
successfully developed and used in polio research for many years, and in theory transgenic mice 
expressing a protein such as hPIV5-V or indeed MuV-V could be useful for MuV research. A 
transgenic mouse model expressing human STAT-2 has been developed and utilised for 
experimental hPIV5 infection (Kraus et al., 2008) and it would be interesting to infect mice like these 
or other IFN-knockout mice with MuV.  
The results generated during this PhD project including the “negative” findings, will be of interest to 
scientists in the field of paramyxovirus research and have made a significant contribution to mumps 
research. The data described for the assessment of ferrets as an in vivo MuV model have been 
submitted for publication. Therefore, this project has formed a distinct contribution to the 
knowledge of the subject and provides evidence of originality shown by the discovery of new facts 
and the exercise of independent critical power.  
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